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Abstract 
In Ghana, little is known about the nature and spread of carbapenemases in carbapenem-
resistant (CR) pathogens. The aims of the present study were to detect carbapenemase 
activity by using simple phenotypic tests, molecular typing to characterise the resistance 
genes and to determine the relatedness of the CR isolates collected from different 
hospitals in the country. 
  
A  total of 111 CR isolates were identified by disc diffusion susceptibility testing and the 
MIC E-test method. Phenotype-based methods including the modified Hodge test, 
boronic acid-disc synergy test, nitrocefin assays, plasmid analysis and sodium dodecyl 
sulphate polyacrylamide gel electrophoresis for the expression of the outer membrane 
protein were performed for each of the CR isolates. Amplified DNA products were 
examined for common ESBL encoding genes (blaTEM-1 and blaSHV -1) and 
carbapenemase resistance genes (blaK PC-1, blaIMP-1, blaNDM-1, blaV IM-1 and 
blaOX A-48). Enterobacterial repetitive intergenic consensus (ERIC) by PCR technique 
was used to establish the relatedness of isolates. 
 
Overall, a carbapenem-resistant prevalence of 2.9% (111 of 3840) was detected from 
the total of Gram-negative bacterial pathogens. In MIC E-test assays, 56.8% of CR 
isolates showed complete resistance to imipenem, meropenem and ertapenem at ≥32 
µ g/ml, of which 24.3% were found in Pseudomonas aeruginosa isolates and 18.9% in 
Acinetobacter baumannii isolates. In all, no K PC-1 and IMP-1 genes were detected. 
Carbapenemase genes identified were blaNDM-1 in Acinetobacter baumannii isolates, 
blaV IM-1 in Pseudomonas species and blaOX A-48 was only present in Klebsiella 
pneumoniae isolates. None of the carbapenemase-positive gene carriers harboured two 
xviii 
 
or more of carbapenemase resistance genes. Transfer experiments revealed the possible 
spread of the resistance genes from pathogens to commensal organisms by conjugation. 
Close relatedness with co-occurrence of oprD loss was detected among a small number 
of carbapenemase resistance gene carrying isolates of Acinetobacter baumannii. This is 
the first report of the detection and characterisation of carbapenemase resistance genes 
in Ghana.  
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Chapter one 
 
1. Introduction 
 
1.1 Background 
 
Over seventy years the antimicrobial era has been marked by successive discoveries of a 
wide range of antibiotics and the subsequent emergence of antibiotic resistance. 
Bacterial resistance continues to increase and, drug researchers and manufacturing 
industries are not producing new drugs to replace the existing antimicrobials against 
which resistance has developed. The effects on current infection rates cannot be simply 
estimated (Carlet et al. 2012, WHO 2014, Freeman et al. 2015).  
 
Howard and Scott (2005) reported that the economic impact related to antimicrobial 
resistance was expected to cost over $105 billion annually worldwide. In recent times, 
development of antimicrobial resistance is rapidly changing, and the impending public 
health challenges these may cause in many health sectors need worldwide coordinated 
interventions. Many deaths have occurred as a result of this in Europe and the European 
Centre for Disease Prevention and Control (ECDC) had estimated that 25,000 people 
may die each year from infections related to antimicrobial resistance (Carlet et al. 2012, 
Moyane, J ideani and Aiyegoro 2013). Global reports documenting the infection burden 
of common and diverse bacterial pathogens that have developed resistance to available 
antimicrobial agents is alarming. Spellberg et al. (2011) reported the annual costs of 
combating resistant bacterial infections to be between $21 billion and $34 billion in the 
USA alone. At the World Health Day held in the year 2011, two bodies; the World 
Health Organization (WHO) and the Infectious Diseases Society of America (IDSA) 
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predicted that antimicrobial resistance worldwide may have major consequences for 
human health unless concrete solutions are found (Spellberg et al. 2011, WHO 2015). 
The cost burden of bacterial resistance worldwide may be difficult to quantify currently 
according to the World Health Organization (WHO) due to limited information on drug 
resistance investigations carried out between 2013 and 2014 among member states. 
Only 17% of countries participated in Africa while in the other continents 62% to 100% 
responded (WHO 2015). This has prompted the WHO to adopt new strategies through 
education and to create awareness for its member states to know the extent of the 
problem of antimicrobial resistance at each country level. Indeed, the current emergence 
of carbapenem-resistant Enterobacteriaceae (CRE) is a source of worry to healthcare 
providers due to its limited treatment options, and has become a major public health 
challenge globally (Schwaber and Carmeli 2008, Public Health England 2015, WHO 
2015).  
 
1.2 Gram-negative bacteria and infections 
 
Infections acquired from clinically relevant Gram-negative bacilli include a wide variety 
of species. Urinary tract infections (Escherichia coli, Proteus species, Enterobacter 
species, Serratia marcescens), respiratory infections (Pseudomonas aeruginosa, 
Haemophilus species, Klebsiella species, Legionella pneumophila), and gastrointestinal 
infections (Salmonella typhi, Salmonella enteritidis, Shigella species, Helicobacter 
pylori) are the primary Gram-negative infections in most hospital settings (Peleg and 
Hooper 2010, Richet 2012). In recent times, a non-fermentative Gram-negative 
organism, Acinetobacter baumannii has been associated with hospital-acquired 
infections. Similarly, other less encountered Gram-negative bacteria such as 
Stenotrophomonas maltophilia and Aeromonas species have been increasingly reported 
3 
 
in many episodes of bacteraemia, meningitis, pneumonia, wound or surgical site 
problems in hospital intensive-care settings (Datta and Wattal 2010). Most of these 
Gram-negative bacteria are resistant to multiple drug agents and are increasingly 
becoming resistant to almost all available antimicrobial drugs worldwide (X u, Flavin 
and Flavin 2014).  
 
In Ghana, there are very few nationwide studies conducted on infections associated with 
antibiotic resistance. Most studies were carried out in a few hospitals and focussed on 
common pathogens such as Staphylococcus aureus and Salmonella typhi, rather than 
multi-resistant Gram-negative pathogens such as Pseudomonas and Acinetobacter 
species, commonly encountered in the developed countries (Newman et al. 2011, 
Donkor, Foster-Nyarko and Enweronu-Laryea 2013). In the United States, a survey 
based on National Healthcare Safety Network (NHSN) data showed that, 13% of 
Escherichia coli and Klebsiella, 17% of Pseudomonas aeruginosa and 74% of 
Acinetobacter baumannii in intensive-care units were multidrug-resistant (CDC 2008). 
Similarly, studies conducted in non-African countries in East Asia by K yungwon et al. 
(2011) on these same organisms further indicated significant increase in the K orean 
Nationwide Surveillance of Antimicrobial Resistance program (K yungwon et al. 2011). 
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1.2.1 Common antimicrobials for Gram-negative bacterial infections 
 
Development of several new and modified compounds active against drug-resistant 
Gram-positive organisms has been conducted in the last few years. In the case of 
resistant Gram-negative bacteria, few new antibiotics and no new classes of 
antimicrobials against resistant Gram-negative bacilli can be anticipated in the near 
future (WHO 2014). The use of suitable empirical antimicrobial treatment significantly 
improves patient outcomes and reduces their hospital stay in many instances by 
clinicians (Fraser et al. 2006). Most of the first line and low-cost drugs with broad-
spectrum activity such as co-trimoxazole, gentamicin, tetracycline, chloramphenicol, 
ampicillin, fluoroquinolones and some cephalosporins have been in use as effective 
therapeutic agents for the management of Gram negative bacterial infections since the 
1990s (K hadri and Alzohairy 2009, Habte-Gabr 2010). Carbapenems became the 
antimicrobial agents of choice for many serious bacterial infections, especially in 
hospitals, but most drugs, both β-lactams and other non β-lactam antimicrobials, have 
been inactive against multi-resistant Gram-negative bacteria (Moyane, J ideani and 
Aiyegoro 2013).  
 
1.3 Antimicrobial resistance in Gram-negative bacteria 
 
Imprudent use of antimicrobials has led to the development of resistance which has now 
reached a grave situation. Bacterial reactions to antimicrobials, in particular, may 
depend significantly on the concentration of antimicrobial drug present at any one time. 
Different types of mechanisms, such as acquisition of genes encoding enzymes (β-
lactamase types) that destroy the antibiotic, efflux pumps to remove the agents from the 
bacterial cell before reaching the target site, and alteration of binding sites that may take 
place before sufficient concentrations are reached to eliminate the entire poly-microbial 
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population. Gram-negative bacteria are no exception to these interactions (Walsh 2013). 
Gram-negative bacteria are often more resistant to antimicrobials, when compared with 
Gram-positive pathogens due to their outer membrane structure. The same outer 
membrane protects the bacteria from most dyes, antimicrobials and detergents that may 
damage either the internal membrane or the peptidoglycan in the cell wall. The outer 
membrane of these bacteria renders some protective resistance to lysozyme and 
penicillin attacks. However, in combination, lysozyme with ethylenediamine tetra-acetic 
acid (EDTA) and ampicillin antimicrobial, which serve as an alternative drug treatment 
for some pathogenic Gram-negative organisms, have been shown to breach the 
defensive outer membrane. There are other antimicrobials which can be used, including 
streptomycin, chloramphenicol and nalidixic acid (X u, Flavin and Flavin 2014). 
 
1.3.1 C linical significance and risk of E SBL s 
 
The discovery of Gram-negative resistance became apparent soon after the first 
semisynthetic penicillin, ampicillin, an agent found to be active against Gram-negative 
bacteria, was clinically introduced. Multidrug-resistant Enterobacteriaceae have been a 
growing concern worldwide (Pereira et al. 2011). In 1963, Temoneira-1 (TEM-1) was 
named after Temoneira, the affected patient, the first plasmid-encoded β-lactamase 
carrying Escherichia coli strain to have conferred resistance against the drug ampicillin 
(Datta and K ontomichalou 1965, A ltayb et al. 2014). Over the years, diverse resistance 
mechanisms have changed the distribution of plasmids and new mobile genetic features 
have been contributory in the horizontal transmission of resistance genes, with these 
multiple genes conferring resistance to many antimicrobials. Among the 
Enterobacteriaceae, TEM-1 and sulfhydryl variable-1 (SHV -1) β-lactamases were the 
most prevalent plasmid-mediated enzymes frequently found spreading in countries 
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worldwide (Medeiros 1997). In the 1970s, resistant Gram-negative bacteria had become 
more common in most hospital-acquired pathogens with TEM-1 and SHV -1 enzymes. 
Most of these bacteria carried multiple β-lactamases as well as other multidrug-resistant 
genes. In the early part of the 1980s, a number of new antimicrobials were clinically 
introduced in the health-care delivery systems, including the third-generation 
cephalosporins. Due to misuse of these agents, Germany in 1983 experienced the first 
extended-spectrum β-lactamase (ESBL) in a species of Klebsiella. ESBLs are resistance 
enzymes usually confer resistance in most Gram-negative bacterial pathogens as a result 
of more-selective pressure from the use of β-lactams: oxyimino-cephalosporins (such as 
cefotaxime, ceftriaxone, ceftazidime, or cefepime) and monobactams (aztreonam) but 
not carbapenems, which had undergone hydrolysis and further mutations (Bush 2013, 
Blair et al. 2015). The ESBL enzymes result from point mutation in the parent β-
lactamases, TEM-1 and SHV -1 by one to four amino acid changes which form the basis 
of resistance presumably due to evolutionary selective pressure from the use of β-
lactams, such as oxyimino-cephalosporins and aztreonam. To date, the number of 
known β-lactamases has increased, and there are now over 1000 that have been 
identified. The most recognizable among the mutants of SHV -1, named SHV -2, 
deactivated the extended-spectrum cephalosporin drugs and often carried many other 
resistance genes on its parent plasmid that conferred reduced susceptibility to other 
unrelated classes of antimicrobials (K nothe et al. 1983, A ltayb et al. 2014). 
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1.3.2 Other types of E SBL s  
 
Equally important ESBLs of clinical significance are the CTX -M and AmpC β-
lactamases families as indicated in table 1.1. The CTX -M family is classified under 
classes of β-lactamases as class A  ESBLs. For the past decade, CTX -M–type ESBL 
enzymes have become most prevalent in clinical isolates, mostly in Escherichia coli 
isolates in Asia, Europe and South America (Wang et al. 2013). 
 
Earlier, there were confusions as to where MEN-1 and Tolo-1 enzymes belong. CTX -
M-1 was subsequently found to be similar to the MEN-1 enzyme; while CTX -M-44 and 
CTX -M-45 were known to be the same as Toho-1 and Toho-2 respectively (Ma et al. 
1998, Bush 2013). Since CTX -M-1 recognition in clinical circles in the 1980s, over 130 
variants have been identified and genetically classified based on amino acid differences 
into 5 major divisions, CTX -M-1, -2, -8, -9, or -25 mostly identified in Escherichia coli 
and Klebsiella pneumoniae isolates from varying geographical locations (Rossolini, 
D’Andrea and Mugnaioli 2008, Rogers, Sidjabat and Paterson 2011). In 1999, a CTX -
M-15 variant was recovered from India; belonging to the CTX -M-1 group, it was shown 
to have dominance in the clinical setting and also shown to have worldwide distribution. 
Thus, more allelic variants were subsequently recovered from different Gram-negative 
bacterial isolates in both clinical and community settings and those yet to arrive are a 
threat to patients' conditions in the clinical environment (Cantón, González-Alba and 
Galán 2012, Wang et al. 2013). 
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T able 1.1 Beta lactamases classifications, E SBL  activity and representative 
enzymes 
Molecular class Functional group ESBL  activity
c
 Representative enzymes 
A 2a N PC1 
2b N TEM-1, SHV -1 
2be Y  CTX -M-14, -15 
2br N TEM-30, SHV -10 
2ber Y  TEM-50, TEM-121 
2c N PSE-4, CARB-3 
2ce N
e
 RTG-4 
2e Y  SFO-1, FEC-1, L2 
2f Y  K PC-2, SME-1
f
 
B 3a
g
 Y  IMP, V IM, NDM, L1 
3b N CphA 
C 1 N AmpC, ACT-1 
1e Y  GC1, CMY -37 
D 2d N OX A-1, OX A-10 
2de V  OX A-11, OX A-15 
2df Y  OX A-23, OX A-48 
Adapted and modified from (Bush 2013). 
c= Based on hydrolysis of cefotaxime, ceftazidime, or cefepime 
e= In spite of kcat values generally B1 s
-1
, resistance to cefepime and cefpirome is seen in 
producing organisms 
g= Includes subclasses B1 and B3 
Y = kcat >5 s
-1
, N= kcat <5 s
-1
, V = variable within the functional group. 
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AmpC β-lactamases are also of importance and the enzymes can be chromosome or 
plasmid-mediated. After sequencing of ampC gene from Escherichia coli K -12 strain, it 
was designated as class C according to Ambler's structural classification of β-lactamases 
(Table 1.1). Thus, differences in molecular structures between β-lactamases classes A  
and B actually determined ampC gene classification (J aurin and Grunstrom 1981). 
AmpC-like β-lactamases mainly from Enterobacter and Pseudomonas with ESBLs 
hydrolyse both penicillins and cephalosporins. Of clinical importance, plasmid-
mediated AmpC enzymes occurring in Gram-negative bacteria have detection problems 
with the phenotypic methods, therefore, dissemination associated with ESBLs pose 
serious risk of treatment failures (Rand et al. 2011). AmpC enzymes are inducible, 
unaffected by EDTA and clavulanic acid inhibitors, usually produced in low quantities 
and often suppress detection ability. The main mechanisms that initiate acquisition of 
plasmid-mediated ampC genes and over expression in bacterial strains are largely due to 
mutation at the AmpC attenuator and promotor regions (Getzlaff et al. 2011, Lakshmi et 
al. 2014). 
 
A  study by Cottell, Webber and Piddock (2012) earlier reported selective pressure of 
broad-spectrum cephalosporins such as cefotaxime and ceftazidime as the main cause of 
production for AmpC types of β-lactamases (Cottell, Webber and Piddock 2012). This 
suggestion has been entirely modified following a careful re-evaluation on a number of 
plasmid-mediated bacteria by the same group of investigators recently, that selective 
pressure of antimicrobials only increase the numbers of antimicrobial resistance 
isolates, and that production of AmpC β-lactamases largely depend on; suitability of 
plasmids, stability of bacterial strain interactions, complexity of the plasmids, ability to 
conjugate freely and survival of plasmids at different conditions (Cottell et al. 2014). 
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1.4 Carbapenem antimicrobials 
 
Carbapenems are bactericidal β-lactam antimicrobials with proven efficacy in severe 
infections caused by extended spectrum β-lactamase (ESBL) producing bacteria 
(Hawkey and L ivermore 2012). There are a few examples, namely imipenem, 
meropenem, doripenem, ertapenem, panipenem and biapenem, in use worldwide as a 
result of the rising resistance to cephalosporin antimicrobials in the Enterobacteriaceae 
group. Recent emerging mechanisms of resistance accumulate through the spread of 
carbapenem-destroying β-lactamases leaving narrow therapeutic options (Patel and 
Bonomo 2013). The search for carbapenem agents was initially from diverse sources. 
Among these carbapenem agents, selection for treatment depends on the pathogen 
present. 
 
1.4.1 Carbapenem mode of activity and structure-function relationship 
 
Carbapenems are potent members of the β-lactam family of antimicrobials that are 
structurally related to the penicillins. The term “carbapenem” explains the changes in 
that family from penicillin and cephalosporin antimicrobials: “carba-” signifies the 
replacement of a carbon atom for the sulfur at position 1, and “-penem” stands for the 
presence of a double bond between positions 2 and 3 (K napp and English 2001) as 
shown in Figure 1.1 where carbapenems have a carbon atom while the other β-lactams 
have a sulphur atom (red arrow). 
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Adapted from K napp and English (2001)  
F igure 1.1 T hree β-lactam agents depicting the functional groups 
 
Mode of action of carbapenems is initiated first by penetrating the bacterial cell wall 
and binding to enzymes known as penicillin-binding proteins (PBPs) (Mouton et al. 
2000, Zhanel et al. 2007). Earlier study reported that inhibition of PBPs 2 and 3 
generally occurs in Gram-negative bacillus-shaped bacteria to form spherical cells and 
filamentous organisms, respectively (Hayes and Orr 1983). The main inhibiting series 
of PBPs are 1a, 1b, 2, and 3; and the resultant lethal effect is the inactivation of an 
inhibitor of autolytic enzymes within the cell wall which leads to the killing of the 
bacteria (Sumita and Fukasawa 1995, Bonfiglio, Russo and Nicoletti 2002).  
 
Current understanding describes transpeptidase inhibition as the main enzyme target of 
carbapenems during bacterial cell wall synthesis. Through transpeptidation, a co-valent 
bond is formed by PBPs comprising of carboxypeptidase and transpeptidase enzymes 
which in effect prevent their peptide cross-linking activities during peptidoglycan 
biosynthesis. The lethal effects are thought to result in cell death by autolytic action 
within the bacterial cell (van Dam, Olrichs and Breukink 2009). According to Papp-
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Wallace et al. (2011), the mode of action of carbapenems remains uncertain. Much 
emphasis is placed on the rigid nature of the glycan backbone. V itality of the cell wall is 
affected when PBPs are repressed, the glycan backbone weakens due to autolysis and 
eventually the cell is destroyed by osmotic pressure in Gram-negative bacteria (Papp-
Wallace et al. 2011, Meletis 2016).  
 
Generally, carbapenems are preferred over other types of antimicrobials in treating 
invasive or life-threatening infections because of their concentration-independent killing 
effect on the infecting bacteria (Abbot et al. 2013, Watkins and Bonomo 2013). They 
are broad-spectrum and act against Gram-positive, Gram-negative bacteria and 
including anaerobes. Notably, a wider spectrum of activity is found among the cyclic 
amine types of carbapenems with pyrrolidine derivatives namely meropenem, 
doripenem, panipenem and ertapenem. Exceptionally, biapenem also in the cyclic amine 
group, panipenem has a marginal effectiveness against Gram-negative bacterial strains. 
 
Comparatively, among the carbapenems, doripenem is highly stable against hydrolysis 
of most β-lactamases such as ESBL  and AmpC-producing β-lactamases in the 
Enterobacteriaceae group (Marti et al. 2009, Chahine, Ferrill and Poulakos 2010), but at 
the same time is described to have lower MICs with respect to meropenem and 
imipenem for Acinetobacter baumannii and Pseudomonas aeruginosa (Mandell 2009, 
Bassetti, Ginocchio and Mikulska 2011). Evidence has shown that doripenem is least 
susceptible and much slower in carbapenemase hydrolysis (from 2 to 150 fold) than 
imipenem (Queenan et al. 2010). Ertapenem effectiveness against Pseudomonas 
aeruginosa is relatively limited when compared with meropenem or imipenem. Studies 
also confirmed that Acinetobacter baumannii has increased susceptibility to imipenem 
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or doripenem compared with that of meropenem (Oliver et al. 2004, Papp-Wallace et al. 
2011).  
 
Several reviews on carbapenems and its carbapenemase-producing genes in Gram-
negative bacteria have been reported. According to Papp-Wallace et al. (2011) and 
Bedenić et al. (2014), it has been established that prudent use of carbapenems, early 
recognition of infections and careful improvement in new treatment options for different 
classes of β-lactamases can significantly reduce the threat of spread in hospitals (Papp-
Wallace et al. 2011, Bedenić et al. 2014).  
 
1.4.2 Carbapenem usage and side effects 
 
Carbapenemases as a mechanism of resistance have been reviewed in the context of the 
effective use of carbapenems in combination therapy to enhance successes in patient 
outcomes (Lakshmi et al. (2014). Many enzymes are produced by bacteria that degrade 
β-lactam antimicrobials. Such enzymes are known as β-lactamases. However, bacteria 
find it difficult to effectively degrade carbapenem agents incorporated with β-lactamase 
inhibitors for in-vivo use. The first compound to be used was imipenem, given with 
cilastatin, which inhibits the renal metabolism of imipenem and prolongs its half-life 
(Birnbaum et al. 1985). Imipenem is noted for its dose-dependent gastrointestinal side 
effects as compared with the other carbapenems. Ertapenem is the carbapenem that has 
the lowest activity against Pseudomonas species and other non-fermentative Gram 
negative bacteria. Currently, different kinds of carbapenems are used in clinical practice 
as antipseudomonal agents; doripenem, imipenem and meropenem. The agents; 
ertapenem, imipenem and meropenem are poorly absorbed orally and require parenteral 
administration to be effective. Recently approved doripenem is of value among the 
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current available carbapenems for treating serious infections (K attan, V illegas and 
Quinn 2008, Watkins and Bonomo 2013).  
 
Carbapenems have trivial hepatic metabolism effects leading to hepatotoxicity with 
jaundice, although this is an uncommon medical condition for these agents (Thyrum et 
al. 1997, Zhanel et al. 2007). Most carbapenems are subject to degradation by the 
enzyme dehydropeptidase-1 (DHP-1) located in renal tubules and require co-
administration with a DHP-1 inhibitor such as cilastatin. The later types of carbapenem 
agents including doripenem and ertapenem require no β-lactamase inhibitor as they are 
made stable in their mode of activity against Gram-negative bacterial infections. These 
compounds vary in their binding to PBP, thereby giving unique differences of activity 
towards different types of organisms. This can be seen in those that inhibit PBP3 and 
the opportunistic pathogen, Pseudomonas aeruginosa, as a specific example. 
 
1.5 Development of carbapenem resistance 
 
Infection with CRE is emerging as an important challenge in health-care settings and a 
growing concern worldwide (Schwaber and Carmeli 2008, Nordmann, Naas and Poirel 
2011). Carbapenem agents are very effective antimicrobials and administered 
intravenously with little or no allergic cross reactions in hospitals (Cunha et al. 2008). 
Each carbapenem agent has its own function, making its selection specific and delicate 
in clinical practice for serious infections (Boeser 2008). The importance of the use of 
the carbapenems against Gram-negative pathogens cannot be overemphasized.  
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1.5.1 Intrinsic resistance of Gram-negative bacilli  
 
Development of resistance to carbapenems may be due to intrinsic or acquired 
resistance mechanisms or both. Large numbers of bacteria, both commensals and 
pathogens, naturally tend to be resistant to certain classes of antimicrobial agents. This 
insensitivity is termed intrinsic resistance, the occurrence of which limits and 
complicates drug selections for treatment. This can increase the risk for development of 
acquired resistance. For instance, Gram-negative organisms reduce the uptake of β- 
lactam drugs, by selectively altering their cell membrane porin channels. Reduction of 
outer membrane permeability in this manner prevents the β-lactams from reaching their 
targets.  
 
Forsberg et al. (2012) have shown transmission of different antimicrobial resistance 
genes from soil bacteria to clinical pathogens. Carriage of such genes was laterally 
exchanged to clinical pathogens and multiple mobilisation sequences including non-
coding regions were identified in short-read sequence data from many soil bacteria 
(Forsberg et al. 2012). For example, early metallo-β-lactamases (MBLs) studied and 
detected were chromosomal in nature from mainly opportunistic and environmental 
pathogenic bacteria including Stenotrophomonas maltophilia, Bacillus cereus and 
Aeromonas species (Franco et al. 2010). These bacteria are only opportunistically 
pathogenic, and Stenotrophomonas maltophilia is the only organism commonly 
associated with frequent hospital acquired infections. Others in the same category, often 
considered commensals, typically carry chromosomal metallo-β-lactamase enzymes, 
which are not transferrable, from the groups which had a serine-based hydrolytic 
mechanism of action (Queenan
 
and Bush 2007, Poirel, Potron and Nordmann 2012). In 
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the mid-1990s, chromosomal MBLs were detected in most carbapenem-resistant 
Pseudomonas aeruginosa and subsequently Acinetobacter species in clinical specimens. 
In recent times, MBL genetic materials are mobile in the Enterobacteriaceae family 
(Patel and Bonomo 2013, Walsh 2013). 
 
1.5.2 Acquired resistance of Gram-negative bacilli 
 
Bacteria have acquired multiple mechanisms of resistance including enzymatic 
inactivation, target site mutation and efflux pumps. Of these, the development and 
emergence of inactivating enzymes were established early following the discovery and 
clinical introduction of the β-lactam class of antibiotics. Over time, the β-lactam-
hydrolysing enzymes extended their spectra of activity beginning with penicillinases, 
followed by cephalosporinases, then to extended-spectrum β-lactamases (ESBLs) and 
most recently, to the metallo-β-lactamases (MBLs) and other carbapenemases. The 
MBLs have hugely impacted the utility of carbapenems (often considered as last resort 
drugs) which are used for the management of multi-resistant Gram-negative bacilli 
(Garcia 2013).  
 
Many of the acquired carbapenemases found in Enterobacteriaceae are plasmid-
mediated and have several ways of spreading amongst bacterial isolates. Apart from 
these enzymes, there are other important mechanisms conferring carbapenem-resistance 
that have been observed in recent times. First, the carbapenems least susceptible to 
hydrolysis (especially, imipenem and meropenem) can be destroyed in the presence of 
plasmid AmpCs in combination with ESBL enzymes associated with porin loss making 
Gram-negative bacteria insusceptible to carbapenem agents (Bedenić et al. 2014). A  
significant number of ESBL genes have the potential to transfer between organisms. In 
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contrast, those strains having their porins mutated or their expression modulated 
typically do not have potential for mobilisation but may proliferate locally within 
hospitals. This type of mechanism is recognisable in Klebsiella, Enterobacter species 
and Escherichia coli as well as other genera. Among the carbapenems, ertapenem is the 
worst affected; isolates may continue to be susceptible to other carbapenems. In most 
cases, reduced susceptibility to ertapenem depends largely on the degree of 
AmpC/ESBL presence and exact changes of the porins. The overexpression of efflux 
pumps and loss of OprD porin are the most common mechanism of carbapenem 
resistance in Pseudomonas aeruginosa, notably to imipenem. Other β-lactams may be 
affected by this mechanism. Pseudomonas aeruginosa efflux-pump overexpression 
occurs more regularly when meropenem is used when compared with imipenem. Both 
commensals and pathogenic bacteria have different mechanisms of using their efflux 
pumps to remove amphipathic or lipophilic substances in and out of the cells. These 
mechanisms have been recognised in other organisms such as Enterobacter aerogenes 
and Klebsiella species against imipenem agent (Walsh 2000).  
 
Generally, Gram-negative bacteria are more resistant to a large number of 
antimicrobials and other chemotherapeutic agents than Gram positive bacteria due to 
cell wall differences, external decreased membrane permeability, efflux pumps and the 
presence of various broad-spectrum-β-lactamases (e.g. ESBL and/or AmpC 
cephalosporinase). The resistance may be attributed to the presence of broad-specificity 
drug-efflux pumps (Wilke, Lovering and Strynadka 2005, Armand-Lefè vre et al. 2013) 
as illustrated in Figure 1.2, taking the opportunistic pathogen occurring in clinical 
strains of Pseudomonas aeruginosa, as an example. The structural proteins involved in 
β-lactam resistance are sub-divided; including β-lactamases, PBPs and efflux pump 
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systems. Those with solid arrows are the two repressors, BlaI and MexR representing 
the resistance operons, while BlaZ expressing β-lactamases. There are other structures, 
glycosyltransferase in class A  PBPs and BlaR in the cytoplasmic protease domain 
which remain less well understood and are represented by blue and green solid outlines, 
respectively. The diagram also depicts the collaboration of β-lactams and its 
subgroupings; BlaR as the β-lactam-dependent signalling agent, acylation of the PBPs 
(poor in PBP2x and 2a), ring hydrolysis by the β-lactamases, and proton antiport of the 
antimicrobials by the efflux pump groups. The recently determined structure of 
Streptococcus pneumoniae PBP1b is representing the closely-related resistance element 
PBP1a, and the MexB and OprM structures are used at this point as models. The 
structures are manually put together to co-ordinate AcrB and TolC as their respective 
homologues. The effector accountable for terminating MexR repression and the details 
of the exact interaction of MexA with MexB-OprM are not yet known. 
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Adapted from (Wilke, Lovering and Strynadke 2005) 
Figure 1.2 R esistance due to β-lactamase, PBP and efflux pump mechanisms in 
Pseudomonas aeruginosa 
Note: gm +/-, Gram-positive/negative; Mex, multidrug efflux; IM, inner membrane; OM, outer 
membrane; PG, peptidoglycan. CphA and CTX M9 are shown as representatives of the >40 
available metallo-β-lactamase and serine structures. 
 
One of the structures of drug-efflux pump systems extensively reviewed by Poole 
(2005) was MexAB-OprM. This is a three-component pump; inner resistance-
nodulation-division (RND) transporter ‘pump’ MexB, the outer membrane porin OprM, 
and the soluble periplasmic MexA which acts strongly on a large number of 
antimicrobials, including β-lactams and its β-lactamase inhibitors (clavulanic acid as an 
example). Understanding of this three-way efflux pump and its structural features were 
reviewed by Eswaran et al. (2004) and each component was investigated using 
Escherichia coli as an example; the orthologous inner membrane pump and outer 
membrane porin constituents AcrB and To1C have been resolved to 3.5 and 2.1Å  
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resolution respectively, while the structure of periplasmic component MexA from 
Pseudomonas aeruginosa has been solved to 3.5Å  resolution. The structural basis of the 
inner membrane pump, AcrB, has been determined in the presence of numerous 
hydrophobic small molecular compounds, which indicates a varied binding mode for 
each ligand, at least in this efflux pump element (Y u et al. 2003). The three proteins; β-
lactamase, PBP and efflux pump mechanisms interact to create a path to eliminate 
antimicrobial ligands. According to K aatz (2005) this has provided new ideas and 
understanding of target sites to drug development initiatives in future (K aatz 2005).  
 
Thirdly, non-carbapenemase specific mechanisms such as mixture of porin loss in 
addition with specific efflux pump systems have been reported in Acinetobacter 
isolates. Weak detection levels have been found for OX A carbapenemases, more than 
their absence (Doumith et al. 2009, Public Health England 2014). Carbapenemase 
inhibition of carbapenems are of enormous clinical concern, however, resistance may be 
low level, compromising detection and reading of results for most hospital laboratories 
potentially having the consequence of increased patient mortality (Akova et al. 2012). 
According to a report issued by Public Health England (2014) carbapepems are known 
substrates for all carbapenemases, and undetected cases in the health care setting may 
cause complications when dealing with serious infections involving these enzymes 
(Public Health England 2014). 
 
1.5.3 R isk factors for acquisition of CR E  infection 
 
There are a number of factors that predispose persons to infections by CRE and other 
multi-drug resistant (MDR) Gram-negatives including ESBL producers. Exposure to 
these resistant organisms can cause serious infections in patients with the following 
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reported risk factors: immune-suppression, advanced age, admission to ICU, 
mechanical ventilation, previous exposure to antimicrobials, organ or stem-cell 
transplantation, and prolonged hospital stay (Gasink et al. 2009, Arnold et al. 2011). 
Health-care associated infections caused by CRE, mainly Klebsiella pneumoniae, have 
been encountered most commonly in ventilator-associated pneumonia, bacteremia, 
urinary tract and surgical site infections. Generally, K PC-producing carbapenemases in 
the β-lactamase molecular class A  are rare, however, the variants are rapidly spreading, 
with K PC-2 and K PC-3 frequently reported in the UK  (Woodford et al. 2008). The gene 
is carried on a transposon which increases the risk of spreading in many hospital 
settings extensively worldwide (Y igit et al. 2001, Srinivasan and Patel 2008). In clinical 
situations, where K PC-producing bacteria are a major concern, early intervention has to 
be taken to prevent death by administering effective empiric antimicrobials when the 
patient is immunocompromised, undergoing organ transplants or during cancer 
treatment (Patel et al. 2008, Hara et al. 2013). 
 
There are reports which suggest that long-term care facilities play a crucial role in the 
spread of CRE. Neuner et al. (2011) reported readmission of 72% patients who were 
discharged with carbapenem-resistant Klebsiella pneumoniae bloodstream infections. 
While in another study, Ben-David et al. (2011) reported 42% in their initial hospital 
stay with records from post-acute care facilities in Israel. Growing evidence suggests 
early detection of CRE-colonized patients on admission to long-term acute care 
hospitals (LTACHs) may help to prevent institutional outbreaks and limit regional 
spread of this emerging public health threat. A  prospective study in Central V irginia by 
Lewis et al. (2013) concluded that CRE is more prevalent in regional acute care 
institutions than LTACHs (Lewis et al. 2013). 
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1.6 Gram-negative bacteria and carbapenemase resistance  
 
The carbapenem class of antimicrobials is able to kill most bacteria that produce β-
lactamase inhibitors, as their functional structure is an improvement over the other 
classes of β-lactam agents. Improper management of multidrug-resistant infections 
caused by Enterobacteriaceae producing extended spectrum β-lactamases (ESBLs) 
against carbapenems further leads to resistance in patients (Pitout and Laupland 2008).  
 
1.6.1 T he significance of carbapenemases 
Over the years, resistance to carbapenems has emerged and continues to proliferate 
among bacterial pathogens, particularly Klebsiella pneumoniae. A  new class of 
enzymes that affects many Gram-negative bacteria, known as Klebsiella pneumoniae 
carbapenemases (K PCs) is capable of rendering carbapenems ineffective. A  K PC-
producing Klebsiella pneumoniae isolate and its importance have been increasingly 
recognised in a wide range of Klebsiella pneumoniae ST258 due to the spread the 
organism exhibits worldwide (Arnold et al. 2011). The K PC enzyme inactivates 
carbapenam agents, last-resort treatments for serious infections which do not respond to 
other antimicrobial drugs (Y igit et al. 2001, Weisenberg et al. 2009). Most K PCs carry 
similar resistance profiles to most ESBLs, and reduced susceptibility to carbapenems; 
they do not, however, confer resistance but require an additional mechanism to be 
effective (Nicasio, K uti and Nicolau 2008). The enzyme type produced is no longer 
limited to Klebsiella pneumoniae isolates but also has the ability to disseminate to and 
transfer between various bacterial species on plasmids. The genetic element is often 
found in association with resistance determinants for other antimicrobials which give 
rise to multidrug- and pandrug-resistant isolates (Arnold et al. 2011, Walsh and 
Toleman 2012). 
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The K PC enzyme was first described in North Carolina and found in a Klebsiella 
pneumoniae isolate in 2001 (prevalent also in Israel, and Greece; outbreaks elsewhere in 
Europe. Some UK  cases imported via patient transfers) and remained the most 
important mechanism of resistance for the production of blaK PC, a carbapenemase 
gene. The gene is carried on a transposon (a piece of genetic material) which increases 
the risk of spreading in many hospital settings extensively worldwide (Y igit et al. 2001, 
Srinivasan and Patel 2008). The most recent data reported by the Centre for Disease 
Control and Prevention (CDC) revealed that CRE caused by the K PC enzyme have been 
described in 36 states of the USA. This is due to global spread of Klebsiella 
pneumoniae carbapenemase and has been accountable for a number of recounted 
outbreaks of carbapenem-resistant Enterobacteriaceae (CDC 2011). 
 
Klebsiella pneumoniae carbapenemase (K PC) and New Delhi metallo-β-lactamase 
(NDM) are among the common types of carbapenemase found in intensive care units 
(ICUs) which have high rates of transmission and excessive mortality when not 
detected. With the advent of New Delhi metallo-β-lactamase-1 (NDM-1) and other 
NDM variants from Gram-negative bacilli the effective use of carbapenems is 
diminishing. MBLs are different from other β-lactamases as they use zinc instead of the 
amino acid serine as the nucleophile at the active site. These MBLs are not inactivated 
by monobactam antimicrobials such as aztreonam. However, organisms identified in 
United States health-care facilities harbouring the NDM-1 enzyme were found to have 
expressed another resistance mechanism to monobactams (CDC 2010). 
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Other Gram-negative bacteria such as Escherichia coli, non-fermenting Pseudomonas 
and Acinetobacter species in recent times have acquired the resistant gene NDM-1 
which hydrolyses many carbapenem agents (Chen et al. 2011, Joucic et al. 2011). 
NDM-1 has a metallic ion as a cofactor and was first isolated from a Swedish patient of 
Indian origin after several hospitalisations in New Delhi, India (Livermore and 
Woodford 2000, Y ong et al. 2009). Currently, there are few alternatives to carbapenems 
for the treatment of hospital infections involving Gram-negative bacteria. In the United 
K ingdom, thirty-seven NDM-1 producers were investigated harbouring plasmids, 
clonally diverse from those found in South India, however, the NDM-1 types were 
readily transferrable across different types of bacteria which end up in strains which 
become resistant to multiple-antimicrobials (K umarasamy et al. 2010). Expression of 
carbapenemases including the NDM-1 in enteric bacteria has caused increased 
morbidity and mortality particularly in those who have travelled to the Indian 
subcontinent. Infections have occurred in many parts of the world including the USA, 
Canada, Europe, China, Israel, and are currently an emerging concern in South America 
(Woodford et al. 2008, Toye et al. 2009, Hara et al. 2013).  
 
There are other carbapenemase enzymes in existence, some are geographically 
associated and spread among the Enterobacteriaceae family including metallo enzymes 
IMP, V IM (scattered globally), non-metallo enzyme OX A-48 (widespread in Klebsiella 
pneumoniae in Turkey, the Middle-East and North Africa). Rarely encountered types 
are SME, IMI and SPM which also occur as acquired carbapenemase enzymes across 
the globe (Carrër et al. 2010, K umarasamy et al. 2010). 
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1.7 Molecular classification of carbapenemase enzymes 
 
A  large variety of carbapenemases have been identified in Enterobacteriaceae 
belonging to 3 classes of β-lactamases: the Ambler classes A , B and D β-lactamases 
(Table 1.2) adapted from Overturf (2010). These classes are of greatest clinical 
importance among nosocomial pathogens. Class A , C, and D β-lactamases all share a 
serine residue in the active site. The clinical role of a fourth class (Ambler class C) is 
unknown but possesses some extended activity towards carbapenems (J acoby and 
Munoz-Price 2005, Queenan and Bush 2007). 
 
1.7.1 C lass A  carbapenemases 
 
A  number of this class of enzymes have been identified; some are chromosomally 
encoded - NmcA (not metalloenzyme carbapenemase A), SME (Serratia marcescens 
enzyme), IMI-1 (Imipenem-hydrolysing β-lactamase), SFC-1 (Serratia fonticola 
carbapenemase-1), with the others being plasmid encoded - K PC (K PC-2 to K PC-13), 
IMI (IMI-1 to IMI-3), derivatives (GES-1 to GES-20) of GES (Guiana extended 
spectrum), but all actively hydrolyse carbapenems and are partially inhibited by 
clavulanic acid (Nordmann, Naas and Poirel 2011, Bedenić et al. 2014). Of these, the 
K PCs are the most prevalent and after a few years of its discovery, had spread 
worldwide and caused outbreaks in many Asian, North American and European 
countries as well as in Africa. K PC producers have evolved to be multidrug resistant to 
β-lactams thereby limiting therapeutic options for treating K PC-related infections in 
patients (Nordmann, Cuzon and Naas 2009). A  review of K PC genes by Perez and van 
Duin (2013) stated that there are currently 12 additional variants of blaK PC existing 
globally (Perez and van Duin 2013). A  study has shown that due to limited therapeutic 
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options, K PC resistant clones are disseminating internationally in several areas that 
have different multi-locus locations with additional β-lactamase content which differ by 
size, number, and structure of plasmids to compare producer isolates from different 
countries (Woodford et al. 2008). However, a single genetic element (transposon 
Tn4401) has been found in blaK PC genes (Cuzon et al. 2010, Nordmann, Naas and 
Poirel 2011). For instance, between 2009 and 2010, Canadian Nosocomial Infection 
Surveillance Program investigated 7 cases of K PC-3-positives involving Serratia 
marcescens (1), Escherichia coli (1), Klebsiella oxytoca (1) and Klebsiella pneumoniae 
(4) from a hospital and used MLST to identify these organisms. This study revealed 
ST512 as a single-locus variant from the original known ST258 Klebsiella pneumoniae 
isolates widespread in Greece. The indication was that there was interspecies and intra-
species were plasmid-mediated transfer belonging to the repFIIA replicon type. In 
another incidence, an elderly patient who visited Greece in 2012 contracted community 
acquired K PC-2-positive Klebsiella pneumoniae. This was isolated from the patient’s 
urine confirming it is widespread in Greece (Mataseje et al. 2012, Chan et al. 2013, 
J amal et al. 2013, Munoz-Price et al. 2013). 
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1.7.2 C lass B carbapenemases 
 
These enzymes are mainly in the class of β-lactamases having the ability to hydrolyse 
carbapenems but are susceptible to inhibition by EDTA, a chelator of Zn
2+
 and other 
divalent cations. The mechanism of hydrolysis depends on interaction of the β-lactam 
drugs with zinc ions in the active site of the enzyme. The most common metallo-β-
lactamase families include the NDM-1, IMP-type carbapenemases, V IM (V erona 
integron-encoded metallo-β-lactamase) GIM (German imipenemase), and SIM (Seoul 
imipenemase). The genes encoding these enzymes are often located within a variety of 
integron structures and incorporated in to the gene cassettes (Giakkoupi et al. 2003, 
Queenan and Bush 2007). 
 
By mid-2010, the NDM-1 gene may have been acquired by bacteria from the 
community and introduced to other countries including Europe and the United States 
through tourists travelling around the globe, while the same strains have been found in 
environmental samples in India (Walsh et al. 2011, K han and Nordmann 2012). At 
least, 8 variants have been described and identified in this group. NDM-genes are 
dominant in Klebsiella pneumoniae and Escherichia coli isolates but have also been 
found in association with Acinetobacter baumannii and Pseudomonas aeruginosa 
organisms (Pitout et al. 2008, Poirel et al. 2010, Bedenić et al. 2014). 
 
Currently, up to 18 varieties of IMP-type carbapenemases have been identified. This 
type was first recognized in the 1990s in J apan. The majority of these enzymes were 
investigated in Acinetobacter and Pseudomonas species as well as those in the 
Enterobacteriaceae family. The IMP genes have also been found in Brazil and Canada 
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after first reports from Europe in 1997. These gene types have spread slowly to other 
countries in the Far East and subsequently to the United States and Australia (Queenan 
and Bush 2007, Bush et al. 2011). 
 
V IM genes are rarely encountered in Enterobacteriaceae but occur most commonly in 
Pseudomonas aeruginosa and Pseudomonas putida. Another growing family of 
carbapenemases first isolated in V erona, Italy, in 1997, and exhibited predominantly 
integron-associated metallo-β-lactamases. The family consists of 14 members. The V IM 
and IMP families have some similarities in terms of which plasmids they are carried on 
and that they are integron-associated. The V IM family has amino acid sequence 
diversity of up to 10%, 15% for IMP, and 70% between the two families. Both 
hydrolyse all β-lactams except monobactams, and are susceptible to all β-lactam 
inhibitors (Marsik and Nambiar 2011). 
 
1.7.3 C lass D carbapenemases 
 
These enzymes are serine-ß-lactamases poorly inhibited by EDTA or clavulanic acid. 
These carbapenemases are of the oxacillinase (OX A) enzyme type, and have a weak 
activity against carbapenems. The enzymes are found primarily in non-fermenter 
organisms such, Acinetobacter baumannii, Pseudomonas aeruginosa and rarely in 
isolates of Enterobacteriaceae family in most countries including the United K ingdom 
and in the United States (Moquet et al. 2011, Poirel et al. 2011c). The OX A β-
lactamase with carbapenemase activity was first described by Paton et al. (1993), and 
the enzyme purified from a multidrug-resistant Acinetobacter baumannii isolated in 
1985 from a patient in Edinburgh, Scotland. Activity of OX A carbapenemases is 
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increased by upstream elements which control gene expression (Carrër et al. 2010). The 
major concern with OX A carbapenemases is their ability to rapidly mutate and expand 
their spectrum of activity. Studies by Mathers et al. (2013) reported frequent detection 
of class D among the Enterobacteriaceae family making this a threat and a major public 
health problem worldwide (Mathers et al. (2013). Currently, OX A-48 is the most 
common while non-nosocomial OX A-24 type has been found in environmental 
Acinetobacter species and the spread of OX A-23 type which occurs globally is more 
encountered in USA and Europe. The OX A-58 group had been described significantly 
over the globe in several outbreaks (Evan and Amyes 2014). OX A-48–type producers 
are among the most difficult carbapenemase producers to be identified due to their point 
mutant analogues with ESBLs; thus their true prevalence rates are difficult to estimate. 
Over the years, there have been 102 unique OX A sequences identified of which 9 are 
extended spectrum β-lactamases and at least 37 are considered to be carbapenemases 
(Queenan and Bush 2007, Nordmann, Naas and Poirel 2011). 
 
30 
 
T able 1.2 Carbapenemases by classification, activity and organisms 
 
Gene 
T ype 
C lassification by 
Ambler Class 
Activity Spectrum Organism(s) 
K PC A All β-lactams 
Enterobacteriaceae, P. 
aeruginosa 
SME A 
Carbapenems and aztreonam, 
but not 3rd/4th G 
cephalosporins 
S. marcescens 
NMC–A, 
IMI 
A  Same as for SME Enterobacter spp. 
GES A 
Imipenem and 3rd/4th 
cephalosporins 
P. aeruginosa and 
Enterobacteriaceae 
IMP, 
V IM, 
NDM 
B (metallo-β-
lactamases) 
A ll β-lactams; can test 
susceptible to aztreonam 
Pseudomonas spp. 
Acinetobacter spp. 
Enterobacteriaceae 
OX A D 
Weakly active against 
carbapenems 
A. baumanni, P. aeruginosa, 
and rare Enterobacteriaceae 
 
Note: K PC= Klebsiella pneumoniae carbapenemase, SME= Serratia marscescens enzyme, 
NMC-A= Non–metallo-enzyme carbapenemase, IMI= Imipenem-hydrolysing β-lactamase, 
GES= Guiana extended-spectrum β-lactamase, IMP= Imipenem-resistant Pseudomonas, 
V IM= V erona integron–encoded metallo-β-lactamase, NDM= New Delhi metallo-β-lactamase, 
OX A= Oxacillinase. 
 
 
1.8 L aboratory detection of carbapenem-resistant organisms 
 
The presence of a carbapenemase can be detected by a number of methods in clinical 
laboratories. These include automated systems or disc diffusion, minimum inhibitory 
concentrations (MICs), selective agar, modified Hodge test, synergy tests (e.g., E-tests 
or double disc tests) and molecular methods. The majority of the genes controlling 
carbapenemase production are transferrable by plasmids. The presence of 
carbapenemases signifies some relevance to clinicians; however, care has to be taken in 
the management of patients to carbapenem therapy which may change depending on the 
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mechanism of resistance existing at that time. Currently, detection of the enzymes is 
difficult because of the different mechanisms involved and unreliable techniques 
practised in some clinical laboratories (Perez and van Duin 2013). On the other hand, 
extended-spectrum β-lactamase-inhibitors, such as clavulanic acid, tazobactam, and 
sulbactam when used in combination with a carbapenem agent are also unreliable for 
phenotypically detecting carbapenemase production in bacterial isolates.  
 
1.8.1 Phenotype based methods 
 
The baseline test that first predicts carbapenemase enzyme production is disc diffusion 
or the use of automated systems. For disc diffusion, impregnated discs containing a 
standard amount of an antibiotic agent are placed on agar plate seeded with a bacterium 
to be tested. As the organism grows during overnight incubation, the antibiotic agent 
diffuses into the agar medium. Susceptibility of the test organism is proportional to the 
zone of inhibition produced by the antibiotic used. With the automated systems, 
instruments are used to analyse antibiotic susceptibility testing with standardised 
inoculum for the test strain and diluted in a specialised broth with a drop of 
antimicrobial susceptibility testing indicator added. The final inoculum turbidity is 
adjusted to 0.5 McFarland Standard. The inoculum is poured into a panel, closed in a 
secured place and the inoculated panel is then placed into, for example, instrument for 
V ITEK  or V ITEK  2 automated system. The panel is then read automatically by the 
instrument, the data generated is analysed with preliminary algorithms and compared to 
the controlled results as appropriate. Either one or both methods have shown variability 
in their ability relating to the underlying mechanism of carbapenem resistance. Several 
reports of carbapenemase detection using phenotypic based methods in Acinetobacter 
species, Pseudomonas species and Enterobacteriaceae have been documented (Liu et al. 
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2006, Miriagou et al. 2010). Reference MIC levels are more sensitive in determining 
resistant breakpoints for carbapenem susceptibility by broth microdilution and agar 
dilution, according to Patel, Rasheed and K itchel (2009), than E-test, disc diffusion, and 
many automated systems. For instance, a number of automated systems studied by 
Queenan and Bush (2007) identified up to 87% of K PC-producing Klebsiella 
pneumoniae study isolates as being susceptible to imipenem or meropenem.  
 
The determination of ertapenem MICs by automated testing tends to identify cases 
which are ertapenem-resistant, which in effect is recommended as a sensitive laboratory 
test of K PC production irrespective of the method employed (CDC 2010). Carbapenem 
susceptibility breakpoints against meropenem and imipenem keep on changing in recent 
times, due to lack of global consensus. For instance, previous MIC breakpoints 
EUCAST established were ≤2 µ g/ml and >8 µ g/ml as susceptible and resistant 
respectively (Abbott et al. 2013), compared with the CLSI breakpoints of susceptible at 
≤4 µ g/ml and resistant at ≥16 µ g/ml which may compromise results when testing on 
non-fermenting Acinetobacter species (CLSI 2013). Perez and van Duin (2013) 
established that detection with the new MIC lower breakpoints without using a 
phenotypic test such as the carbapenem-EDTA combination tests or modified Hodge 
test may result in lack of differentiation between various mechanisms of carbapenem 
resistance. For reliable results, European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) revised MIC 
breakpoints (Table 1.3) according to Hara et al. (2013) have been accepted and 
recommended for the detection of carbapenemase-producers.  
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T able 1.3 Breakpoint values (MIC , mg/L ) for carbapenems according to guidelines 
in E urope (E UCAST ) and the United States (CL SI) 
 
Note: EUCAST, European Committee on Antimicrobial Susceptibility Testing 
(www.eucast.org/clinical_breakpoints), version 2.0, 2012; CLSI, Clinical and Laboratory 
Standards Institute, M100-S22, 2012; S, sensitive; R, resistant.  
 
The use of chromogenic agar preparations have emerged for identification of MDR 
organisms from surveillance cultures such as CHROMagar K PC and CHROMagar™  
Acinetobacter (CHROMagar; Paris, France). Culture media are made selective by 
adding chromogenic substrates and agents that inhibit growth of other Gram-positive, 
Gram-negative and yeast isolates. The CHROMagar™  culture media were originally 
formulated for the screening of patients in the ICU and later redesigned so that 
Acinetobacter species appear as bright salmon red colonies. A  new formulation, with 
the addition of 'Klebsiella pneumoniae carbapenemase supplement' was able to pick out 
carbapenem-resistant Acinetobacter baumannii. Recent modifications to CHROMagar 
Acinetobacter have improved selective growth for organisms resistant to carbapenems 
(Gordon and Wareham 2009, Wareham and Gordon 2011). According to Arnold et al. 
 E UCAST  CL SI 
Carbapenem S R  S R  
Doripenem ≤1 ≥4 ≤1 ≥4 
Ertapenem ≤0.5 ≥1 ≤0.5 ≥2 
Imipenem ≤2 ≥8 ≤1 ≥4 
Meropenem ≤2 ≥8 ≤1 ≥4 
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(2011), CHROMagar K PC has a sensitivity of 100% and specificity of 98.4% compared 
with polymerase chain reaction (PCR). This technique is used for confirmatory 
identification of K PC production though is expensive in terms of cost and is mostly 
performed in research laboratories (Arnold et al. 2011). 
 
The modified Hodge test has been used extensively and is a phenotypic technique for 
detecting carbapenemase activity routinely used in clinical pathology laboratories. This 
test was recommended by the CLSI in 2009 (CLSI 2009), however, it is not specific for 
the detection of all carbapenemase enzymes, most significantly with isolates showing 
weak positive results and AmpC producers. Bonnin et al. (2012) performed modified 
Hodge tests on 19 carbapenemase-producing Acinetobacter baumannii isolates and 
found negative results for all tested NDM-producing isolates and only weak positive 
results for V IM-, IMP- and OX A-type producers (Bonnin et al. 2012). There are reports 
related to susceptibility testing in which the tests showed reduced susceptibility but give 
consistently negative results for the presence of carbapenemases. These may be due to 
greater genetic exchange among NDM-1 bacterial strains especially and using non-zinc-
supplemented Mueller-Hinton agar medium (Castanheira et al. 2011, Girlich, Poirel and 
Nordmann 2012). 
 
Double-disc synergy testing has several versions; carbapenem with -clavulanate, -
cloxacillin -EDTA or 2-mercaptoproionic acid and one which utilizes a double sided E-
test (BioMérieux, Solna, Sweden), imipenem versus imipenem with EDTA, and are 
used as a screening test for MBL producers. This method is efficient for detection of 
MBL carbapenemases with high resistance, but may be deficient for detecting MBL 
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producers with low resistance to imipenem according to Walsh et al. (2005). Other 
results have shown sensitivity with the imipenem-EDTA disc method, 95.7% for 
Acinetobacter species and 100% for Pseudomonas species (Queenan and Bush 2007, 
Overturf 2010). A  recent study by Nordmann, Naas and Poirel (2011) indicated there is 
no inhibition test available for detection of OX A-48/OX A-181 producers and observed 
that EDTA by itself has inhibitory action against some bacteria, due to permeability of 
the outer membrane, and can lead to false-positive results (Nordmann, Naas and Poirel 
2011). According to a recent report from Public Health England (2014), resistance to 
any of the carbapenem drugs may be confirmed using inhibitor based tests (Table 1.4). 
For the detection of carbapenemases in a community may largely depend on the 
availability of existing β-lactamase inhibitors (Public Health England 2014). 
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T able 1.4 Interpretation of inhibitor-based phenotypic synergy tests 
R esistance to  Synergy between  Carb 
a 
resistance 
mechanism  
Temo
C
 
(MIC 
≥64mg/L  
or no 
zone 
around 
30μg 
disc)  
Aztre
b
  Carb + 
EDTA / 
dipicolinic 
acid  
Carb + 
boronic acid  
Carb 
+ 
cloxacillin*  
Carb 
+ 
clavulanate
*  
 -  R   -   -+/   -+/   -+/  ESBL  or 
AmpC + 
porin loss  
++  S  +++   -   -   -  MBL 
(IMP, 
NDM, 
V IM)  
 -+/  R   -  +++   -   -+/  K PC  
+++  S   -   -   -   -  OX A-48  
Adapted from Public Health England (2014)  
 
Note: 
a
 Carba = carbapenem; 
b 
Aztre = aztreonam; 
c
 Temo = temocillin; R = resistant; S = 
susceptible; +/- = positive or negative; - = negative; + = positive. 
 
 
The newly developed Carba NP test, derived from the name “Carbapenemase 
Nordmann-Poirel”, is in use to detect carbapenemase producers in Enterobacteriaceae. 
The technique requires no expertise, is reproducible, inexpensive and may easily be 
adapted as an additional important test in any clinical laboratory. The test may help 
healthcare facilities to curb and implement rapid containment measures to limit the 
spread of carbapenemase producers in hospitals (Nordmann, Naas and Poirel 2011). 
Nordmann, Poirel and Dortet (2012) described the test as most efficient as compared 
with molecular-based methods. The Carba NP test is performed in wells and colour 
change from red to orange or yellow indicates the tested strains are producing 
carbapenemases. The Carba NP test rapidly and reliably identifies carbapenemase 
producers by changes in pH values using phenol red as the indicator. Colour develops 
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within 2 hours detecting strains that are imipenem resistant due to non-carbapenemase-
mediated mechanisms, such as combined mechanisms of resistance or from strains that 
are carbapenem susceptible but express a broad-spectrum β-lactamase without 
carbapenemase activity. Reports have shown that the test is 100% sensitive and specific 
for Enterobacteriaceae (Nordmann, Poirel and Dortet 2012) and 100% specific and 
94.4% sensitive for Pseudomonas species harbouring carbapenemases (Dortet, Poirel 
and Nordmann 2012a). In contrast, a study by Tijet et al. (2013) observed low 
performance of Carba NP test and false-negative results in OX A-48-like Pseudomonas 
aeruginosa and Enterobacteriaceae isolates with only 80% specificity (Tijet et al. 2013). 
Another study reports that Carba NP test, however, cannot differentiate among 
carbapenemase classes, particularly, weak carbapenemase activity in strains harbouring 
GES-type carbapenemases in high prevalence areas, Brazil and South Africa. An 
updated version designated “CarbAcineto NP test” for identifies all the types of 
carbapenemase in Acinetobacter species with high-level of sensitivity and specificity 
(Dortet et al., 2014, Hammoud, Moubareck and Sarkis 2014).  
 
1.8.2 Problems in phenotype based detection 
 
The recent changes in the breakpoints for carbapenems (CDC 2011) have further added 
to the complexity of dealing with multidrug-resistance in the Enterobacteriaceae family. 
Many laboratories in the USA conform to CLSI standards, approval must come first 
from this body before clinical laboratories can use the recommendations to detect 
carbapenemase producing isolates. On the other hand, most European, Asian and 
African countries use EUCAST or CLSI as their standards for their detection of 
carbapenemase producing isolates. Delays in breakpoint recommendations on 
automated kits and devices for use resulted in some laboratories not following strictly 
laid down rules, hence, undetected CRE with lower breakpoints silently disseminated 
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K PC-producing Klebsiella pneumoniae in a long-term facility for children and young 
adults (V iau et al. 2012).  
 
During the period of transition, there may be inconsistencies between laboratories 
regarding identification of ESBLs and CREs. Many different laboratory interpretations 
of MIC levels may have led to confusion among clinicians about when it is suitable to 
use an extended spectrum cephalosporin drug, a carbapenem, or neither of them. These 
determinants are also important for infection prevention and control practices. 
Pharmacists need to be responsive to these issues so that they can offer the best advice 
and other method in recommending appropriate antimicrobial choice. Pereira et al. 
(2011) offered suggestions on amended interdepartmental communication within 
hospital-care services during such transition periods to improve laboratory detection of 
ESBLs and CREs (Pereira et al. 2011). 
 
1.8.3 Genotype based techniques 
 
Molecular techniques have become an efficient tool for carbapenemase detection. 
Polymerase chain reaction (PCR) performed on colonies may give results within 4 to 6 
hours with excellent sensitivity and specificity and this may reduce the chance of 
spreading organisms in hospitals. Wang, Gu and Lu (2012) reported a real-time PCR 
assay with specificity and sensitivity at 100% as compared with 90% phenotypic K PC 
activity when assessed by modified Hodge test (MHT) and sequencing. More recently, 
multiplex PCR and microarray techniques for detection of several carbapenemase genes 
in one test have been produced. These are mostly focused on the detection of genes in 
Enterobacteriaceae including their subgroups of carbapenemases. The limit of these 
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modern tools lacks sequence similarity to genes already described (Queenan and Bush 
2007, Woodford et al. 2011, Abbott et al. 2013). Earlier studies largely focused their 
energies on K PC detection. With the emergence of equally important genes also 
spreading widely on plasmids, NDM, V IM and IMP in Class B group and recent 
underestimated Class D serine carbapenemase OX A-48 which is weakly detected by 
phenotypic methods have revolutionised for different molecular techniques. These are 
to improve the detection of unknown, dominant resistance genes and their variants to 
control sporadic dissemination into health-care facilities and community settings 
(Nordmann, Dortet and Poirel 2012). Notwithstanding the enormous contributions of 
molecular-based assays, they have their own drawbacks and frustrations to end-users 
mainly due to lack of trained personnel to properly man the equipment, labour-
intensive, time-consuming and cost of all consumables and reagents. As reported in two 
previous studies by Naas et al. (2011) and Nordmann, Naas and Poirel (2011) molecular 
assays that are employed should be made as inexpensive, specific, sensitive as possible 
for the detection of the desired gene and rapid to detect β-lactamase resistance genes to 
avoid ambiguities of results to improve care-receivers outcome (Naas et al. 2011, 
Nordmann, Naas and Poirel 2011). 
 
In relation to clinical laboratory practice, innovations of molecular techniques have been 
evaluated and are currently in use for the detection of carbapenemase producers. Check-
MDR CT102 DNA microarray, Check direct CPE assay and Hyplex-Super-Bug ID kit 
are on the market for diagnostic testing purposes. Excellent detection ability and 
reproducibility with these assays have been reported (Naas et al. 2011, K aase et al. 
2012, Nijhuis et al. 2013). Recent study report an intriguing finding in which a self-
generating plasmid harbours the OX A-48 gene in multiple transposons Tn1999 rapidly 
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and silently disseminating as one clone have been detected using molecular techniques 
(Bakthavatchalam, Anandan and V eeraraghavan 2016). 
 
Another important study by Sparbier et al. (2012) described the use of matrix-assisted 
laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) as a 
new tool detecting resistance patterns in bacteria from fresh positive blood cultures. The 
laser-based ionisation technique can detect changes in mass to charge ratios. 
Carbapenam resistant bacteria use β-lactamases to physically disrupt the structure of β-
lactam antimicrobials. The changes in the mass of the drugs make the resistant bacteria 
detectable by the MALDI-TOF MS technique, and return results within 4 to 5 hours. 
Secondary testing should be carried out to ascertain colonisation of resistant bacteria in 
the facility (Sparbier et al. 2012). MALDI-TOF MS is available in most research 
laboratories for confirmation of a host of bacterial resistance enzymes, recently 
including the OX A-48 carbapenemase activity with sensitivity and specificity of 98.9 
and 97.1% respectively (Sauget et al. 2014). However, cost and requirement of trained 
expert to man the instrument limits its use in routine laboratories for diagnostic 
purposes (Bakthavatchalam, Anandan and V eeraraghavan 2016). 
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1.9 E pidemiology of carbapenemase-producing organisms 
 
Across the globe, first reports of carbapenemases occurred in the 1980s. Its subsequent 
spread raised a number of concerns, and these have coincided with years in which no 
new antimicrobial agents against Gram-negatives have been developed. J apan reported 
the first carbapenemase from an Aeromonas hydrophila isolate in the 1980s. 
Sequentially, followed in London (1982) by Seoul imipenemase (SME-1) from Serratia 
marcescens, imipenemases (IMI-1) in California (1984) and NMC-A in France (1990), 
both from Enterobacter cloacae (Garcia 2013). 
 
Carbapenem resistance involves one or more of several diverse mechanisms of actions 
in multi-resistant Gram-negative bacteria. The most frequently encountered β-lactamase 
enzymes are the acquired carbapenemases in the Ambler class A  group of which 
Klebsiella pneumoniae carbapenemases (K PCs) predominate worldwide (Woodford, 
Turton and Livermore 2011, Public Health England 2015). An alarm call on the spread 
of carbapenem-resistance has been in existence since K PC was identified in 1996 in the 
United States. Clinical characteristics of K PC carrying organisms vary with local 
differences and conditions. Countries such as Israel, Greece and Colombia have 
outbreaks of K PC through their existing local situations and others mainly by 
importation for instance, in Canada, Australia and New Zealand (Munoz-Price et al. 
2013, The et al. 2015). Following worldwide spread of Klebsiella pneumoniae ST258 
type strain, and throughout the USA in particular, multilocus sequence typing (MLST), 
a specific molecular tool was used to find out the global epidemiology linkages and help 
understanding the dissemination of K PC genes. There are fresh fears and challenges on-
going and under discussion by researchers as to how to curb the spread of carbapenem 
resistance across the globe for epidemiological reasons. Detection has been difficult due 
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to differences in their genetic makeup within and across countries. Researchers have 
observed divergent resistant patterns from CREs in Europe, the United States and South 
America. The unusual resistance factors have been monitored through a surveillance 
programme, named the Intensive Care Antimicrobial Resistance Epidemiology 
(ICARE) by the CDC from 2000 onwards. Earlier CRE infections, particularly K PC, 
were confined to hospitals in New Y ork. Between 2000 and 2010, the infection rate had 
increased from 1% to 12% in 42 States respectively (K uehn 2013) with a 50% 
associated mortality rate (Freifeld et al. 2011, Nordmann, Naas and Poirel 2011). 
Thirty-nine states of the USA, including Puerto Rico, were hit by the threat of K PC 
positive organisms within the next few years. Strict control measures were instituted, 
such as short-stay in acute-care settings, made the CRE infections infrequent and 
contained the rate below 5% as compared with 8% in long-term acute-care hospitals 
monitored by the CDC Network (CDC 2013). The occurrence resulted in many other 
K PC-positive Klebsiella pneumoniae isolates to be categorised while the majority have 
been found in Pseudomonas aeruginosa (Robledo, Aquino and V azquez 2011), 
Pseudomonas putida and others in the Enterobacteriaceae family (Bennett et al. 2009). 
 
Studies have shown that the spread of K PC-positive organisms in some parts of the 
USA was not related to travel. Most infections seemed to occur in hospitals, with the 
majority of the outbreaks contracted in long-term care facilities (LTCFs) for care 
receivers with severe medical conditions who needed longer stays for their clinical 
management (Endimiani et al. 2009, CDC 2013). Patel et al. (2008) reported 38% 
infection-specific mortality and 48% in hospital mortality for patients infected with 
carbapenem-resistant Klebsiella pneumoniae isolates, contrasting with 12% and 20% 
for carbapenem-susceptible Klebsiella pneumoniae respectively (Patel et al. 2008). The 
clinical impact of K PC-positive bacteria occurs within 48 hours of admission, with 
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isolates identified from samples such as blood, wound swabs, urine and sputum. 
Patients with a history of frequent exposure in a health-care facility may easily trigger 
community-acquired infections (Gasink et al. 2009, CDC 2013). The guidance as to the 
detection and control of these isolates have been expanded with appropriate 
recommendations as a public health measure in 2012 by CDC on regional bases all over 
USA (Snitkin et al. 2012, CDC 2013). 
 
Currently, 39 countries in the European Union including France and the United 
K ingdom have come together to fight the burden of CREs in their respective countries. 
The study is being coordinated by the European Centre for Disease Prevention and 
Control in Stockholm to keep epidemiological data of patients who test positive for such 
bacteria in their health-care institutions (Glasner et al. 2013, McK enna 2013). Between 
the years 2003 and 2007, the UK  experienced the first recorded K PC gene with a K PC-
4 variant in an Enterobacter species from a blood sample and the first case of a known 
Klebsiella pneumoniae producing K PC-positive isolate, all from Scotland (L ivermore et 
al. 2008, Woodford, et al. 2008). There were scattered increases in numbers as the 
K PC-positive isolates continued to be identified by the UK  national public reference 
laboratory in 2008 (4 hospitals 5 isolated) and in 2009 (12 hospitals 13 isolated) with 
Klebsiella pneumoniae ST258 the most frequent strain to be captured by MLST (10 out 
of 12). The source was traced to Greece, Cyprus or Israel, with patients having travelled 
to those countries in the time prior to admission. Between 2010 and the first six months 
of 2012, the epidemiological pattern rapidly changed in terms of numbers identified, 
231 K PC-positive strains in 2010, 368 in 2011 and 293 for the first six months in 2012 
were referred for further confirmation at the national reference laboratory (Livermore 
2012, Public Health England 2015). 
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Rapid spread of CREs across Europe was observed in late 2005 when an identified K PC 
isolate in Israel was later found to be genetically related to a type strain in New Y ork. 
France acquired its first K PC-2-positive Klebsiella pneumoniae in 2005 from a patient 
who had had 3 months admission in a New Y ork City (NY , USA) hospital. The strain 
type was isolated from blood and urine cultures. From 2009 to 2012, there have been 
several CREs investigated. In a recent study, five cases out of 20 were confirmed and 
linked their sources to countries such as K uwait, China, Italy and Israel. Community 
acquired strains were found to be rare and most of the documented cases in France were 
from persons colonisation with the strains (Naas et al. 2005, Munoz-Price et al. 2013). 
 
Carbapenemases became a public health concern in 2007 when a total of 1,275 CRE 
infections were identified across their health care centres. K PC-positive organisms 
found its way in to other countries including Italy, Colombia and the United K ingdom 
(Schwaber et al. 2011, Cantón et al. 2012, Patel and Bonomo 2013). In early 2008, 
Sweden was the next country to identify multidrug-resistant K PC-positive isolates, this 
time with a different metallo-β-lactamase enzyme. More cases of this type of enzyme 
were seen within three years in the USA and in the UK . Other Enterobacteriaceae, such 
as Escherichia coli were harbouring NDM, exhibiting more resistant traits than K PC-
positive Klebsiella isolates (Y ong et al. 2009). There were no clear-cut patterns of 
dissemination for carbapenemase positive Klebsiella bacteria including those with 
NDM-1 genes into hospitals. For instance, following a Colorado episode, the CDC used 
whole-genome sequencing, a technology utilised for the first time to resolve outbreaks 
in the hospital. Researchers were in doubt as to exactly how NDM was escalating 
among the population. Studies later revealed that bacteria carrying the NDM enzyme 
found its way outside the boundary of hospital settings into community water and 
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sewage environments with some epidemiological link to parts of Southern Asia 
(K umarasamy et al. 2010, Patel and Bonomo 2013). 
 
In Italy, the enzyme type described in Israel ST258 isolates located in transposon Tn 
4401 was detected in K PC-positive isolate (K PC-3 gene type) (Giani et al. 2009). Over 
the years, 7 different patients with wound infection in V erona hospital at the surgical 
ICU had their isolates closely related to K PC-3-positive Klebsiella pneumoniae ST258 
(Mazzariol et al. 2012). The situation was more disturbing when in 2011, the same 
strain type carrying colistin-resistance was found in Palermo general hospital in 
different acute wards and elsewhere from isolates (Acinetobacter baumannii and 
Pseudomonas aeruginosa) in other countries (Mammina et al. 2012, Aboulmagd and 
Alsultan 2014). Spain also confirmed a K PC-3 variant among 8 suspected cases through 
colonisation in a hospital in Madrid from a Spanish man in his mid-sixties in 2009, and 
7 of the isolates were ST384 while the other one was carrying ST388 type (Curiao et al. 
2010). A  later outbreak which occurred in late 2009, this time a variant closely related 
to the K PC-2 gene type had been found in three Citrobacter freundii. The earlier 
isolates, none were attributed to travels outside the country (Gomez-Gil et al. 2010). 
However, in close neighbour Portugal, a K PC-2-positive Escherichia coli isolate was 
recovered from river water although there were no reports of medical cases in 
connection of K PC-positive isolates in recent times from their hospitals (Poirel et al. 
2012). 
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Poland has a history of high prevalence of CREs carrying K PC genes. A  K PC-positive 
case was confirmed in Warsaw. Later, a number of cases were confirmed by the 
national reference laboratory in five Warsaw hospitals towards the end of 2008, with 
more identified from 2009 to 2012 (not published). Most common sources of infections 
were either through stool or urine and ST258 type of strains were high among the 
isolates countrywide (Baraniak et al. 2011, ECDPC 2011). In Greece K PC-positive 
Klebsiella pneumoniae isolates were confirmed in Sweden and France in 2007 
(Tagmark et al. 2007, Cuzon et al. 2008). An outbreak of K PC-2-positive Klebsiella 
pneumoniae was reported afterwards in a tertiary hospital in Heraklion (Maltezou et al. 
2009), and two years later the type strain had spread into all tertiary hospitals including 
most acute-care services countrywide (Zarkotou et al. 2011, Gaibani et al. 2014). 
 
Currently, K PC-positive organisms are frequently encountered in Greece and are not 
only found in the ICU, patients on surgical and medical wards have been victims of 
such infections. Outbreaks in long-term care facilities have been described, Escherichia 
coli carrying K PC-2-positive gene contributed to 40% infections outside ICUs 
(Mavroidi et al. 2012). However, there has been no evidence of horizontal transmission 
into the community. On the other hand, several confirmed cases of colonisation of K PC-
positive Klebsiella pneumoniae from Greece have been reported in other countries most 
of them following international travel (V an der Bij and Pitout 2012). There have been 
several other carbapenemase enzymes established in most K PC-positive isolates in 
Greece. A  surveillance study involving 40 hospitals had 5% V IM-1 or V IM-4 genes and 
the whole study team all reported 378 K PC-positive isolates in their findings. Other 
studies have revealed much higher numbers in V IM isolates or the presence of both 
V IM and K PC in most isolates. Of all the epidemic cases, Greece had recorded most 
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K PC-positive isolates having other genes linkages, and ST258 type included with the 
genetic make-up closely related (Giakkoupi et al. 2011, Lascols et al. 2013). 
 
Israel is one such country with a successful story of controlling CRE infections after 
strain ST258 was suspected to have been imported from the USA in 2005 and 
eventually spread over all Israeli health-care facilities (Navon-V enezia et al. 2009). 
Most contributing risk factors at that period included poor infection control set-up, 
previous use of antimicrobial and ICU stay. Until middle of 2008, outbreak of K PC-
positive Enterobacteriaceae had been controlled considerably, with incidence reduced 
by 79% in the country and bacteraemia taking up 50% as the attributable mortality rate 
of all clinical infections (Schwaber et al. 2008, Borer et al. 2009). Acquiring CRE 
infections from the community was not encountered, however, in long-term care 
facilities (LTCFs) the carriage were well established in a study carried out by Cantón et 
al. (2012) due to frequent transfer of patients from acute-care facility to the latter for 
further management. One of the measures taken to control the spread was compulsory 
search of CREs from rectal samples in high risk patients (Ben-David et al. 2011, Cantón 
et al. 2012).  
 
The most hit areas of the Asian continent by the CRE isolates were India, Hong K ong, 
Taiwan, South K orea, and central, north-west, eastern and south-west parts of China. In 
India in particular, K PC-positive isolates were observed during a phase-3 clinical trial 
of tigecycline drug between 2002 and 2006 from three organisms; Klebsiella 
pneumoniae, Proteus mirabilis and Escherichia coli (J ones et al. 2009). By the end of 
2010, an active surveillance study identified 9 more organisms harbouring the blaK PC 
gene in which 8 Klebsiella pneumoniae isolates were with 7 K PC-2 and 1 K PC-3, and 1 
Escherichia coli isolate with K PC-2. Interestingly, one of Klebsiella pneumoniae 
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isolates was co-harbouring K PC-2 with OX A-1, NDM-1, TEM-1, CTX -M-15 and 
SHV -12 β-lactamases, and RmtB known to be transferring aminoglycoside resistance 
(K umarasamy and K alyanasundaram 2012). The SENTRY  programme carried out 
(between 2006 and 2007), identified OX A-181 as the gene recognisable in Indian 
health-care facilities (Castanheira et al. 2011). Earlier K PC-positive organisms seemed 
to be rare until French researchers reported K PC-positive Escherichia coli suspected to 
have been imported from India by a patient who had been colonised (Patron et al. 
2012).  
 
The most common carbapenemase gene in China is K PC-2 type found in a number of 
Klebsiella species. Zhejiang province recorded K PC-positive Klebsiella pneumoniae in 
China in the year 2004 from a mid-seventy year old ICU patient (Wei et al. 2007), and 
then significant numbers of K PC-positive Enterobacteriaceae were later identified in the 
eastern part of China. As many as 95 isolates of Klebsiella pneumoniae that showed 
susceptibility to carbapenem agents were later found to be carrying K PC-2 genes, 
closely related to ST258 type (Qi et al. 2012). The Shanghai region detected K PC-3 
genes, one each in Citrobacter freundii and Escherichia coli respectively and infections 
were mainly from urine and sputum specimens. In many instances, the K PC-3 gene is 
more common in Enterobacter cloacae and Klebsiella pneumoniae isolates found 
abroad (L i et al. 2011). China had no effective infection control strategy in place and 
most patients received broad-spectrum antimicrobials including carbapenems in ICU 
wards where many patients had indwelling medical procedures complicating 
management. The most alarming situation was the detection of K PC-positive 
Enterobacter cloacae and Citrobacter freundii in hospital sewage, raising awareness of 
possible pollution of water bodies and reservoirs (Zhang, Lu and Zong 2012) while Ge 
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et al. (2011) studied and reported eminent community acquired infections with K PC-2-
postive isolates in China.  
 
Endemicity of K PC genes had been identified in these regions of Latin America, 
specifically, across Colombia among the Enterobacteriaceae family. Reported cases of 
K PC-positive isolates of K PC-2 type were found in Klebsiella pneumoniae isolates 
from two patients in 2005 (V illegas et al. 2006, Mojica et al. 2012), and both had no 
travels outside the country. Later in 2006, the country became the first to experience a 
K PC gene in Pseudomonas aeruginosa (V illegas et al. 2007). After two years, a K PC-
3-producing Klebsiella pneumoniae outbreak occurred in which 20 died out of 32 
patients. Fourteen of the death tolls were due to infections, with one patient travelling 
from Israel, a country with several outbreaks of K PC-3 genes (Lopez et al. 2011). A  
number of K PC genetic lineages were identified in Colombia; namely Pseudomonas 
aeruginosa ST235, ST308, ST1006 and 1060, while in Klebsiella pneumoniae, ST258 
and ST51233 were identified (Cuzon et al. 2013, Munoz-Price et al. 2013). Subsequent 
reports on molecular investigations revealed extensive dissemination of K PC genes 
spreading across 3 regions out of 7 metropolitan areas studied in 2009 (Mojica et al. 
2012, Maya et al. 2013). Argentina also had its K PC-2-positive Klebsiella pneumoniae 
identified in 2006.  
 
By the end of 2010 following SENTRY  studies carried out for 2 years, substantial 
increases in K PC-positive isolates in Argentina and Brazil were recorded (Gales et al. 
2012). In another surveillance study conducted in 7 cities, 65 out of 514 Pseudomonas 
aeruginosa isolates were carrying K PC genes, and most had genetic relatedness to 
ST654, different from the ST258 Klebsiella pneumoniae type which suddenly spread up 
to mid-2009 in Argentina (Pasteran et al. 2012, Ramìrez et al. 2013). A  K PC-positive 
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enzyme in Brazil was recorded in 2006, a variant K PC-2-positive from 4 Klebsiella 
pneumoniae isolates in an intensive care unit with no trace of overseas travels (Monteiro 
et al. 2009). Subsequent expanded studies carried out across the country including 
waste water from hospital environment, revealed clone type-ST437 was common 
among K PC-2-harbouring Klebsiella pneumoniae isolates (Chagas et al. 2011). Brazil 
and other parts of the region had most species of Pseudomonas harbouring K PC-2 genes 
from hospital sittings. V enezuela and Chile, in particular, had no evidence of 
endemicity, however, several outbreaks of K PC-positive carriers from the 
Enterobacteriaceae group were latterly recorded (Maya et al. 2013). 
 
Many countries have not instituted active surveillance studies specifically monitoring 
the K PC threat since its inception around the globe, the majority of which are in the 
African continent. Countries in Africa, including Morocco, K enya and South Africa 
have reported NDM-1 as the most dominant carbapenemase gene (Poirel et al. 2011a, 
Poirel et al. 2011b). However, South Africa was the first to have reported a K PC-2-
positive organism in 2012 (Brink et al. 2012). Strict infection control measures and 
regular surveillance programmes instituted by countries such as Australia and New 
Zealand have recorded prevalences as low as 1% of K PC harbouring genes in hospital 
acquired Enterobacteriaceae infections. The control measures were implemented after 
increased numbers of care-servicers were accepted to be treated from the Bali bombing 
episode in 2002 and the 2004 tsunami disaster which occurred in the Indian Ocean 
(CDC 2013, Munoz-Price et al. 2013).  
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1.10 T reatment options for CRE  infections  
 
Antimicrobial treatment of CRE infections has been challenged by the emergence of 
more complex resistance phenotypes as well as economic and regulatory pressures. 
Agents such as polymyxins and tigecycline have recently seen resurgence in their 
clinical usage (particularly colistin) in the management of multidrug-resistant Gram-
negative infections, particularly CRE including carbapenem-resistant Acinetobacter 
baumannii in most hospitals (Hagihara et al. 2014). 
 
The polymyxins are active agents and attain sufficient serum levels in the treatment of 
serious bloodstream and CRE infections. The agents produce additive or synergistic 
effects on humans against multidrug-resistant organisms including Acinetobacter 
baumannii isolates when combined with another antimicrobial agents such as 
tigecycline. In a study conducted by Lee et al. (2009), 16 patients with recurrent 
infections caused by K PC-producing Klebsiella pneumoniae evaluated that three out of 
twelve managed with polymyxin monotherapy experienced polymyxin resistance in 
their treatment. None of the four cases which were treated with polymyxin in combined 
therapy with tigecycline detected resistance to either antimicrobial agent (Lee et al. 
2009, Marchaim et al. 2011). Out of several outcomes of monotherapies, polymyxin B 
monotherapy exhibited inferiority as against combination therapy in the management of 
patients (Petrosillo, Ioannidou and Falagas 2008). In an outbreak of K PC-2 infections in 
Greece, 22% resulted in polymyxin failure after treatment (Maltezou et al. 2009). 
 
Tigecycline, a glycylcycline, is active in vitro against most carbapenem-resistant 
Escherichia coli. The drug is licensed for most complicated intra-abdominal, skin and 
soft tissue infections. Interestingly, a study reports success in various infections caused 
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by carbapenemase producers (Arnold et al. 2011). A  later review of 10 studies including 
33 patients with serious infections caused by multidrug resistant-Enterobacteriaceae, 
K elesidis et al. (2008) reported 70% favourable outcomes with tigecycline treatment of 
cases, while 49% were only for intra-abdominal infections. Recurrence of infections 
was detected, prompting the management of the drug for a longer period in order to 
attain favourable results, due to delayed clearance of the CRE strain from the body 
which several studies had reported (K elesidis et al. 2008). However, tigecycline use 
alone remains a concern in blood, urine, respiratory or other serious infections, and 
there have been several reports of development of resistance due to low concentration 
level (Falagas, K arageorgopoulos and Nordmann 2011, Patel and Bonomo 2013). 
 
Combination therapy with tigecycline proved successful in many instances with positive 
clinical outcomes in the majority of infections involving K PC bacteria (K elesidis et al. 
2008). During an outbreak of K PC-2 infections in Greece, 88% of the patients were 
effectively treated with combination therapy involving tigecycline (Maltezou et al. 
2009, Arnold et al. 2011). In a study involving over 1,000 patients with severe illnesses 
and a high prevalence of multidrug-resistant organisms, tigecycline showed a significant 
success and a positive tolerability profile when the drug was used (Bodmann et al. 
2012, Hara et al. 2013). 
 
Aminoglycosides, notably gentamicin, amikacin and tobramycin have different in vitro 
activities. Treatments of CRE infections may depend on the susceptible organism as 
studies have shown gentamicin activity against gentamicin-susceptible strains in urinary 
tract infections have positive outcomes. Of the aminoglycosides, amikacin appears to be 
the more active against CREs when compared with gentamicin or tobramycin (Abbott et 
al. 2013). While in another study, amikacin and tobramycin showed remarkably low 
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susceptibility to infections caused by MDR Gram-negative bacteria. This may be due to 
gentamicin modifying enzymes which have been carried by these MDR organisms. The 
use of aminoglycosides as monotherapy against carbapenemase-producing Klebsiella 
pneumoniae infections are considered ineffective, and therefore not recommended for 
clinical management of patients (Satlin et al. 2011, Hara et al. 2013). 
 
Fosfomycin, a bactericidal antibiotic that inhibits bacterial cell wall biogenesis has seen 
its use renewed globally in response to the recent threat of antimicrobial resistance 
including carbapenem-resistant Klebsiella pneumoniae isolates (Falagas et al. 2008, 
Neuner et al. 2012). The drug is effectively used to treat urinary tract infections and has 
low rates of resistance. However, poor outcomes may occur when treating complicated 
Pseudomonas aeruginosa as a urinary pathogen. Many patients that developed 
treatment failure were immunosuppressed or had urethral stents due to the use of 
fosfomycin as monotherapy in kidney transplant cases.  
 
Combination therapies have shown remarkable outcomes in dealing with MDR and 
CRE infections. The most commonly used combinations are colistin, polymyxin B or 
tigecycline combined with a carbapenem. In a retrospective study by Qureshi et al. 
(2012) on patients with bacteremia, the monotherapy, either  tigecycline or colistin-
polymyxin B alone had 58% mortality rate as compared with 13% for the tigecycline or 
colistin-polymyxin B combined with a carbapenem on a 28-day assessment, and this 
was observed in infections caused by K PC-producing Klebsiella pneumoniae isolates 
(Qureshi et al. 2012). Lee and Burgess (2012) also studied several antimicrobials for 
treatment of patients and recommended combination therapy (polymyxin plus 
tigecycline, polymyxin plus carbapenem, polymyxin plus aminoglycoside) as the best 
option compared with monotherapy (tigecycline or colistin-polymyxin B) in 
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complicated infections involving MDR and CRE (Lee and Burgess 2012). In future, 
treatments for infections caused by carbapenemase producers may involve new β-
lactamase inhibitors such as methylidene penems; avibactam, MK -7655; the maleic acid 
derivative ME1071; ('neoglycoside') plazomicin, a novel aminoglycoside; the 
polymyxin derivatives NAB739 and NAB7061; and the siderophore monosulfactam, 
BAL30072 combined with cephalosporins and novel classes of antimicrobial agents 
effective against these pathogens (Hawkey and Livermore 2012, Patel and Bonomo 
2013). Continual studies as regards to combination therapy trials need to be intensified 
until more efficient and acceptable combined therapy is accepted and recommended for 
the management of CRE infections. 
 
1.11 Prevention of CR E  infections  
 
The non-availability of antimicrobials for the management of CRE infections should be 
given first line importance and newer drugs effective against carbapenemase producers 
should be developed at the earliest opportunity (Nordmann, Naas and Poirel 2011). 
Worldwide, the detection of carbapenemase producers in a clinical laboratory is based 
first on susceptibility testing results obtained by disc diffusion or by automated systems 
(Miriagou et al. 2010). The difficulty of the clinical laboratory to detect these enzyme 
producers early is the fact that some organisms that harbour blaK PC, have MICs that 
are elevated but still within the susceptible range for carbapenems due to complex 
mechanisms exhibited by carbapenem-resistant bacteria. 
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To curtail the spread, CDC (2013) proffers guidelines for areas where CRE are not 
endemic (acute care facilities) and these should firstly review microbiology records for 
the preceding 6-12 months to determine whether CRE have been recovered at the 
facility. Secondly, if the review finds previously unrecognized CRE, perform a point 
prevalence culture survey in high-risk units to look for other cases of CRE, and thirdly 
perform active surveillance cultures of patients with epidemiologic links to persons 
from whom CRE have been recovered. In areas where CRE are endemic, an increased 
likelihood exists for importation of CRE, and facilities should consider additional 
strategies to reduce rates of CRE. 
 
In areas of low to middle income status such as in most African countries, including 
Ghana, active surveillance had not be given primary importance because of scarce 
resources in terms of competent staffing to carry out screening, poorly equipped 
laboratories and material shortages. Therefore, strict compliance with hand hygiene has 
to be made mandatory, contact precautions, screening patients with no link to known 
CRE patients in high-risk areas, and rectal swab taken to the laboratory for 
identification of CRE may go a long way to minimise the spread of outbreak of CRE 
infections. According to Hara et al. (2013) several studies have shown remarkable 
success in many health care settings implementing portions of these guidelines. Usage 
of drugs such carbapenems, fluoroquinolones, aminoglycosides and others 
inappropriately is associated with increased emergence of resistance, CRE included 
(ECDC 2011). Therefore, careful use in the ICUs of such antimicrobials may require 
tailored guidance and be supported by laboratory evidence. 
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1.12 Problems and clinical relevance of carbapenemase production 
 
Globally, antimicrobial resistance in the family Enterobacteriaceae is classified as the 
leading cause of nosocomial infections in patients with multiple invasive devices or in 
the immunocompromised (Marchaim et al. 2008). Movement of carbapenemase 
encoding genes through mobile genetic elements has emerged and become a second step 
of resistance in horizontal transfer of plasmids between different species of bacteria 
(Diene and Rolain 2014). High levels of CRE in ICUs were reported in a study carried 
out in Europe, Klebsiella pneumoniae and Escherichia coli organisms were found to be 
endemic and multi-resistant with carbapenemase genes. Serious cases involving 
transplantations, long stay in the ICUs are at a high risk of acquiring these organisms 
(van Duijn, Dautzenberg and Oostdijk 2011, van-Duijn et al. 2013). 
 
Currently, the main reason for the spread of CRE infections and antimicrobial-resistance 
genes is the dissemination of plasmids into community populations through stool or 
wound contacts by injuries as one of the mode of transmissions (Schwaber and Carmeli 
2014). There is the need, therefore, for aggressive detection, surveillance and control 
strategies to capture information to help researchers examine the multifactorial nature of 
antimicrobial resistance among Gram-negative bacteria (Spellberg et al. 2008). As in 
the UK  today, other countries in Europe, Asia, the Far East and the Americas, CRE has 
become a serious threat, and the control of healthcare associated infections has become 
a priority for healthcare managers (Watkins and Bonomo 2013). Carbapenem resistance 
is uncommon in the community, however, reports have indicated the existence of spread 
of CRE into the environment in India (Walsh et al. 2011), and such an alarming effect 
cannot be overemphasised. Recent figures from the CDC (2013) indicated that the 
prevalence of CRE has initially increased from 1% to 4% and subsequently to 18% in 
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long-term acute-care hospitals according to the database of national surveillance. 
Electronic systems for sharing information between hospitals and nursing homes 
regarding patients with CRE are needed in order to curtail their spread. The threat calls 
for rapid detection methods, high-calibre personnel and well-equipped laboratory setups 
to strengthen surveillance studies since the practice of microbiology is still a complex 
field that requires experience and logic. Thus, highly trained microbiologists are needed 
to interpret results using systems of electronic laboratory reporting to correlate with 
instant updates of epidemiological data from investigating centres (CDC 2013).  
 
The routine practice of “culture and susceptibility” as a matter of rule should be 
augmented with quicker methodologies. Typical culture and sensitivity testing take 
several days to produce results, allowing transmission of undetected CRE and delaying 
effective antimicrobial therapy. Frequent changes of MIC breakpoints of resistance for 
carbapenems though relevant to patient care without performing phenotype based test 
may cause improper differentiation between various mechanisms of carbapenem 
resistance (Endimiani et al. 2010). Ability to monitor the emergence of resistance, using 
both phenotypic and genotypic methods depending on the availability of resources, and 
expertise to perform the tests and interpret results for clinicians is crucial. There is the 
need for governments to equip clinical laboratories to carry out genetic finger printing 
of bacteria so that they are used subsequently to detect, trace, or track cases of CRE 
outbreaks, their sources and how to control their spread. 
 
With the exception of South Africa (Brink et al. 2012), a number of studies have also 
been carried out mostly in north African countries Egypt (K aase et al. 2011, Abdelaziz 
et al. 2012), Morocco (Hays et al. 2012) and L ibya (El Salabi et al. 2012) which have 
revealed significant number of threats of carbapenemase resistance genes in their 
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hospitals. Other countries have extended the search of spread into the community; 
recently Senegal (Moquet et al. 2011), K enya (Poirel et al. 2011b) and Nigeria (Y usuf 
et al. 2013) have recorded significant number of emerging CRE isolates from hospitals 
to the community settings. Most countries in Africa are not carrying out extensive work 
to ascertain the presence of CREs. This is due to a number of factors including 
economic problems, political instability, and inconsistent or poor availability of 
resources to carry out rapid clinical laboratory identifications and perform cheaper 
surveillance studies. The imminent threat of untreatable infections from CREs have 
been highlighted by researchers worldwide, as evidenced by the emerging inter-hospital 
spread that occurred in Israel (Samra et al. 2007), and later many countries in Europe, 
Australia, China, India, the Middle East, and South America (Queenan and Bush 2007, 
Overturf 2010, Nordmann, Naas and Poirel 2011, Patel and Bonomo 2013, Walsh 
2013).  
 
1.13 Future solutions to curb global CRE  threat 
 
The growing threat to public health includes the rapid spread of CRE into the 
community. Organisms in the Enterobacteriaceae family are the common cause of 
community infections, and in recent times the occurrence of CRE also have been 
evidenced to spread from their main niche among hospital exposed patients into the 
community among otherwise healthy persons through faecal carriage (J acob et al. 
2013). Multidrug-resistant Gram-negative bacteria such as Acinetobacter and 
Pseudomonas species, less encountered in hospitals are the main organisms. However, 
these organisms have the potential to spread resistance to other bacterial isolates and 
into the community (Nicolas-Chanoine et al. 2013, Sievert et al. 2013). The threat must 
be answered by strict adherence to infection control strategies and policy guidelines 
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designed for individual countries (Walsh et al. 2011, Nordmann, Poirel and Dortet 
2012). Performing more efficient identification of carbapenemase producers in the 
clinical microbiology laboratory is an important first step and provides key evidence for 
the control of CRE infections. The early identification of carbapenemase-producing 
isolates both in clinical infections and at the carrier-state should be mandatory to 
prevent the development of untreatable infections. The right to obtain a prescription at 
the first sign of a trivial infection propels the threats of resistance globally. Therefore, 
international campaigns to educate health-care providers, patients and lay persons may 
be warranted to limit the over-use and abuse of antibiotics in humans and agriculture. 
 
Development of novel antimicrobials remains the prime objective for CRE control, a 
look at critical interventions aimed at preventing the transmission and infections with 
these organisms are of great significance. In waiting for more effective treatment 
options, healthcare settings can use prudent antimicrobial stewardship and effective 
infection control methods to decrease the impact of these organisms where this 
emergence of carbapenem resistance is known to be uncommon. Heightening the 
awareness of the public health threat by governments, policy makers, and or taking 
political decisions based on active surveillance testing for CRE may have some impact 
and support health caregivers to curb the resistance. 
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1.14 J ustification of the study in Ghana 
 
Multidrug resistance globally has reached an alarming stage and WHO has described it 
as the one of the three most serious problems confronting human health. Bacterial 
resistance has been a major public health concern, therefore, surveillance studies of 
antibacterial resistance should be in place and coordinated to minimise gaps in 
information gathering to combat the phenomenon. Notably, lack of focus by member 
countries instituting early implementation and the development of a global programme 
for surveillance of antimicrobial resistance may greatly affect patient outcomes in the 
future and cause universal suffering in human health (WHO 2014).  
 
Currently, there are limited and less effective antimicrobials circulating against 
carbapenemase-producing bacteria which are more difficult to treat. In a recent infection 
report released in the United K ingdom a surveillance study clearly revealed that, colistin 
was the only drug which remained effective against over 90% of carbapenem-resistant 
Gram-negative bacteria associated with diverse mechanisms of resistance (Patel and 
Bonomo 2011, Public Health England 2015). With the most sophisticated monitoring 
systems, frequent surveillance studies and proper documentation systems at the 
doorsteps of developed countries such as in the United K ingdom, France, Germany and 
other resourced countries, South Africa and Egypt are not comparable to the least 
endowed country like Ghana to monitor and tackle enhanced surveillance of 
carbapenem-resistant Gram-negative bacteria in its regional hospitals. Ghana already 
has a problem conducting large scale surveillance studies and in carrying out efficient 
laboratory management systems as regards to data collection, use of laboratory based 
equipment and availability of detection reagents to identify any antimicrobial resistance 
including CR isolates. Study parameters used in many developed countries to evaluate 
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bacterial resistance are not the same in Ghana, therefore, may pose serious challenges in 
the early detection of CR organisms for clinical management of patients. For instance, 
OX A-48 producing strains require more efficient techniques for detection in clinical 
laboratories. To date, no variant-types of carbapenemase-producing genes have been 
investigated or studied for epidemiological records in Ghana.  
 
The demand for effective anti-microbial agents remains high due to escalating microbial 
resistance. High incidence of treatment failures, morbidity and mortality in many 
infectious diseases are strongly correlated with antimicrobial resistance. For instance, 
the overuse of β-lactam drugs has caused a considerable increase in the incidence of 
infections caused by ESBL-producing organisms with subsequent adverse effects on 
clinical outcomes (K im et al. 2002). Ghana is no exception to threats of global 
antimicrobial resistance. The two most important Teaching Hospitals, K omfo Anokye 
(K ATH) and K orle-Bu (K BTH) have carried out extensive studies on antimicrobial 
resistance in the country. Studies carried out by Newman et al. (2011) evaluated the 
extent of multi-drug bacterial resistance for a number of pathogens but did not evaluate 
the use of carbapenem agents for the detection of carbapenem-resistance in multi-drug 
resistant Gram-negative bacteria. The results were alarming due to improper monitoring 
and misuse of antimicrobials by many people without prescriptions (Newman et al. 
2011). 
 
Most hospitals in Ghana have limited facilities and resources to properly confirm the 
presence of ESBLs and the recently occurring K PC-type genes in clinical isolates. 
Standard testing regimens used elsewhere cannot be performed routinely because of the 
difficulty in detecting the underlying mechanisms of resistance based on phenotypic 
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identification of the organisms. Harmony and K enneth (2003) reported that extremely 
broad antimicrobial use of carbapenem drugs pose substantial risks. Patients treated 
with carbapenem antimicrobials may no longer be subsequently treated for the same 
infection using cephalosporin antimicrobials (Harmony and K enneth 2003). However, 
in most countries, including Ghana, carbapenems remain one of the few therapeutic 
options for treatment of serious infections including ESBL-producing organisms after 
they have been detected. In a study by Queenan and Bush (2007) the current 
epidemiology of metallo-β-lactamase production generally follows certain patterns of 
increasing occurrences that are country specific unless this is carefully monitored 
(Queenan and Bush 2007). The epidemiology of carbapenem-resistant organisms 
remains largely unknown in Ghana. Cases of CR organisms have been observed 
routinely by most microbiological laboratories in Ghana but no serious documentation 
has been kept. People, therefore, stand the chance of acquiring and bringing this 
emerging resistance into the country as many travel worldwide for various reasons 
including medical interventions. The spread of CR organisms was attributed to the risk 
of travel to the most affected countries in the Indian sub-continent for some form of 
surgical and medical investigations. At present, most hospital laboratories in Ghana lack 
the necessary diagnostic tools for CR detections; therefore, ensuring effective treatment 
of patients cannot be guaranteed.  
 
In many parts of the world, studies have acknowledged that the location of K PC genes 
is on highly mobile genetic elements thereby contributing to their rapid spread with 
frequent co-transfer of multiple antimicrobial resistance factors. The infection strata 
may happen in acute care facilities where critically ill patients are exposed to invasive 
devices (e.g., ventilators or central venous catheters). Carbapenem-resistant organisms 
in these settings may become an important challenge and increase the likelihood of 
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importation of such infections into ICUs. In effect, K PC dissemination in hospitals 
causes serious outbreaks in ICUs (Brink et al. 2012). The carbapenemase enzymes 
produced render the carbapenems ineffective, contributing to mortality rates of 40%-
50% in hospital settings (Queenan and Bush 2007, Schwaber et al. 2008, van Duijn et 
al. 2011, CDC 2013, Watkins and Bonomo 2013). According to Thaden et al. (2014) 
the current rate of mortality and poor outcome of patients in parts of United States 
community hospitals may fall between 48% and 71% for CRE infections. A  number of 
CR studies have been investigated in African countries, namely South Africa (Brink et 
al. 2012), K enya (Poirel et al. 2011b), Senegal (K empf et al. 2012), Morocco (Poirel et 
al. 2011a), Nigeria (Y usuf et al. 2013, Ogbolu, and Webber 2014) and Egypt (Abdallah 
et al. 2015) with common carbapenemase variant types detected. However, there have 
been screenings but not extensive studies in hospitals to establish high levels of CRE 
detections in Ghana. 
 
As a matter of policy, general housekeeping and infection control guidelines have been 
instituted all over hospitals in Ghana. However, curbing the spread of carbapenem 
resistance in Gram-negative bacterial infections needs serious interventions. Strategies 
have to be adopted by stakeholders to enhance surveillance studies among the regional 
and tertiary hospitals. The Ministry of Health (MOH) of Ghana is expected to spearhead 
this study with necessary logistical supplies, training of laboratory personnel, data 
collectors for regular analysis and feedback of results to develop a greater understanding 
of the epidemiology of carbapenem resistance in the country. Regional and national 
analysis of results may allow identification of patients prone to acquiring CR organisms, 
evaluation of changes in the epidemiology of carbapenemase-producing bacteria and 
monitoring of any interventions adopted to curb the spread of carbapenem resistance. 
District hospitals in the country should be monitored. Those with facilities to perform 
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reliable microbiological laboratory tests should be allowed to send suspected CR 
isolates to designated regional laboratory centres to access and manage the local data as 
well as providing the prospects for district-level results analysis. As part of the 
projected WHO programme report, enhanced surveillance studies need to be carried out 
in many countries (WHO 2014). Ghana’s MOH should engage experts in the field of 
antimicrobial resistance in collaboration with the Noguchi Memorial Institute for 
Medical Research (NMIMR), University of Ghana, who have the mandate and 
responsibility to monitor the insurgence of carbapenem resistance. The situation of CR 
bacteria across the globe is disturbing. Ghana needs the collection and analysis of these 
CR data to be informed and fine-tuned its strategies year by year for the laboratory 
detection and management of patients. Epidemiological data of CR organisms may 
finally depend on the outcome of this study for the country. 
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1.15 Hypothesis 
 
Carbepenem-resistant organisms are widely distributed among Gram-negative bacilli 
and the nature of the resistance loci vary significantly among these clinical isolates from 
selected hospitals in Ghana. 
 
1.16 Main objective  
 
The overall objective of the study is to investigate carbapenem resistance in Gram 
negative bacteria in Ghana using phenotype based detection and genotypic 
characterisation methods. 
 
1.16.1 Specific objectives 
ñ To identify the spectrum of Gram-negative bacteria resistant to carbapenems 
from clinical specimens. 
ñ To determine the incidence and distribution of carbapenem resistance by 
phenotype based techniques. 
ñ To characterise the presence of plasmid-mediated carbapenemase resistance 
genes.  
ñ To determine the genetic diversity of the carbapenem-resistant isolates using 
ERIC-PCR technique. 
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Chapter two 
 
2. Materials and methods 
 
2.1 Materials 
 
A ll the kits and reagents used for this study were prepared according to the 
manufacturer’s recommendations and guidelines except where stated otherwise, and 
where some materials demanded re-constitution before use, this done according to the 
manufacturer’s recommendations and guidelines. 
 
2.2 E thical Approval 
Ethical approval for this study was obtained from the ethical committee of the School 
Biomedical & Allied Health Sciences, College of Health Sciences, University of Ghana 
(Ethics Identification Number: SAHS-ET/SAHS/PSM/ML/05/AA/26A/2012-2013). 
Sheffield Hallam University, Research Degree Sub-Committee confirmed the PhD 
registration (SHU: GT/RDSC 27
th
 J une 2014) on the research topic while Risk 
Assessment Unit of the Biomolecular science Research Centre, Sheffield Hallam 
University approved the use of Hazard group 2 organisms for this study. 
 
2.3 Sample sites 
A prospective study was carried out in four selected hospital laboratories in Ghana. 
Carbapenem-resistant (CR) isolates were recovered from September 2012 to September 
2014 from patients who were diagnosed with various infections in four tertiary care 
hospitals located in four distinct regions in Ghana (K orle Bu Teaching hospital in the 
Greater Accra Region, Effia-Nkwanta hospital in the Western Region, AngloGold 
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Mines hospital in the Ashanti Region and Ho Regional hospital in the V olta Region) as 
indicated in Figure 2.1.  
 
 
 
 
 
 
F igure 2.1 Map of Ghana depicting sample sites 
 
Note: "The Star sign" indicating four regional hospitals namely; K BTH, GA/R= K orle Bu 
Teaching Hospital, Greater Accra Region, ENRH, W/R= Effia-Nkwanta Regional Hospital, 
Western Region, AGAMH, A/R= AngloGold Ashanti Mines Hospital, Ashanti Region, HRH, 
V /R= Ho Regional Hospital, V olta Region 
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2.3.1 K orle Bu T eaching Hospital 
K orle Bu Teaching hospital (K BTH) is a referral hospital with a 2,000 bed capacity. 
The facility receives 1,500 daily visits of people and admits almost 250 patients each 
day (Annual Report of K BTH 2012). The Teaching Hospital, ranked third in Africa in 
terms of competent medical staff and resources continues to introduce specialised 
services. Within Africa, this referral hospital is among the few that perform DNA 
investigations and was the first to carry out kidney transplantation in the West African 
sub-region (Annual Report of K BTH 2012). Their clinical laboratories are manned by 
qualified and competent Biomedical Scientists.  
 
2.3.2 E ffia-Nkwanta hospital 
The main regional hospital of the Western region of Ghana is situated at the capital, 
twin city, Sekondi-Takoradi. The municipality has a population of over 440,000 
inhabitants which the hospital serves including the surrounding villages. According to 
the Ghana Health Service annual report (2005) the hospital has a greater than 400 bed 
capacity and serves as a referral point for many clinical conditions which need specialist 
interventions. The refurbished laboratory named Public Health Reference Laboratory 
(PHRL) is currently in use to cover public health issues in the region and other regional 
hospitals in the country. Currently, the Ghana Health Service has finalised the use of the 
hospital as an associate Teaching Hospital to the School of Medical Sciences (SMS), 
University of Cape Coast (UCC). The affiliation may allow more intakes of medical 
students to be enrolled due to the low bed capacity at the Cape Coast Regional Hospital 
(UCC 2015).  
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2.3.3 AngloGold Mines hospital 
The AngloGold Mines hospital has a bed capacity of over 100 and is the referral facility 
in the municipality. However, other referral patients are admitted from the West and 
Central Districts, Adansi North and South Districts, and Amansie East. In the Ashanti 
region, the hospital is the second largest facility catering for over 40% of non-workers 
in the AngloGold Mining Company in and surrounding the Obuasi municipalities. On 
average, 15,000 patients are managed monthly by the hospital care providers 
(AngloGold 2007, http://www.spyghana.com/anglogold-medical-facility-obuasi-
formally-commissioned-obuasi/).  
 
2.3.4 Ho R egional hospital 
The Ho Regional hospital has 150 beds serving an estimated population of over 260,000 
inhabitants according to the 2000 census estimation. Ho municipal is the administrative 
capital of the V olta region surrounded by 24 other districts. The municipality shares 
borders in the west with Ho West District, to the south with Agotime-Ziope, to the north 
with Hohoe Metropolis and the Republic of Togo in the east. In 2012, Regional 
Hospital status was upgraded to a Teaching Hospital due to the establishment of the 
University of Health and Allied Sciences (UHAS) in the region (Ghana Health Service 
2006, Health News 2012).  
 
2.4 Bacterial isolates 
A total collection of three thousand eight hundred and forty (3,840) Gram negative 
bacilli isolates were screened among the Enterobacteriaceae family and non-fermenting 
organisms belonging to different species; Pseudomonas, Acinetobacter, Klebsiella, 
Enterobacter, Providencia, Shigella, Cronobacter, Sphingomonas species and 
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Escherichia coli. Clinical specimens from different infection sites such as wound, urine, 
sputum, ear, aspirate, stool, cerebrospinal fluid, catheter tip, eye and high vaginal swab 
were obtained from the four selected hospitals in Ghana. These CR isolates were 
multidrug resistant to different classes of antimicrobials tested including carbapenems. 
A  collection totalling one hundred and eleven (111) isolates which showed multidrug 
resistant (MDR) including intermediate or complete resistance to carbapenems 
(imipenem, meropenem and doripenem), identified by antimicrobial susceptibility 
testing were identified for this study (see Appendices 1 and 2).  
 
2.5 Microbiological assays 
 
2.5.1 Identification of bacterial isolates 
A ll the 111 CR pathogens from various clinical specimens were identified to the genus 
levels by conventional methods. Quality control strain Escherichia coli ATCC 25922, a 
known susceptible strain to carbapenems, and Klebsiella pneumoniae carbapenemase 
positive NCTC 13438 were included in the identification. Stock cultures of the isolates 
were cultured onto MacConkey agar (Oxoid Ltd, UK ) plates for 18-24 hours prior to 
identification and confirmation to species levels was determined by the use of V itek 2 
automated Compact system (BioMérieux, France). Inoculum of the isolate was adjusted 
to 0.5 McFarland standard, and then poured into a panel covered in a secured place. The 
inoculated panel was then read automatically by the device. The results generated were 
analysed with preliminary algorithms and compared with the control data as appropriate 
giving either excellent or good identification. 
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2.5.2 Antimicrobial resistance testing 
A ll the MDR isolates were re-tested using three carbapenem discs (Oxoid Ltd, 
Basingstoke, UK ); imipenem, meropenem and doripenem by the British Society for 
Antimicrobial Chemotherapy (BSAC) disc diffusion method (Andrews 2004) on 
Mueller-Hinton agar (MHA), (Biotec Ltd, UK ). Impregnated discs containing a 
standard amount (10 µ g) of each of the carbapenems were placed on agar plates seeded 
with the bacteria to be tested. As the organism grows during overnight incubation, the 
carbapenem agent diffuses into the agar medium. Susceptibility of the test organism is 
proportional to the zone of inhibition produced by the antibiotic used. According to 
Clinical and Laboratory Standards Institute (CLSI) breakpoints (CLSI 2012), an isolate 
is considered resistant or susceptible to the three carbapenems used if the zone sizes 
ranged from ≤15 to ≥23 mm (imipenem or meropenem) and ≤19 to ≥24 mm 
(doripenem) respectively. A  reference strain of Escherichia coli ATCC 25922 was 
included as a negative control organism. For isolates with diameters ≤15 mm, minimum 
inhibitory concentrations (MICs) were determined using the E-test method (CLSI 2012, 
EUCAST 2012), and resistance was defined as isolates with MIC against the same 
carbapenems of ≥4 µ g/ml according to CLSI breakpoints. Additionally, E-test strips 
(BioMérieux, France) for imipenem, meropenem and ertapenem showing MIC values 
greater or within 2 to 4, 2 to 4, and 2μg/ml levels respectively were considered 
carbapenemase producers which were confirmed by the modified Hodge test. 
 
2.5.3 Determination of minimum inhibitory concentration by the E -test method 
For isolates with diameters ≤15 mm inhibition to any of the carbapenems, MICs were 
determined using E-test strips of 3 carbapenems (imipenem, meropenem, ertapenem) 
each gradient ranging from 0.002 to 32 µ g/ml, and a cefpodoxime gradient from 0.016 
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to 256 µ g/l for detection of ESBLs. Diffusion method on agar plates designed by the 
British society for antimicrobial chemotherapy (BSAC) followed (Andrews 2004). 
Prepared inoculum suspension in 0.85% NaCl of the test organism adjusted to 0.5 
McFarland turbidity standard was swabbed onto the MHA plate. Impregnated E-test 
strips of the 3 carbapenems and cefpodoxime were placed on agar plates already 
inoculated with the bacterium to be tested and incubated at 35ºC in air for 16-18 hours. 
The MIC results were read following the incubation. Resistance was defined as isolates 
with MICs against the same carbapenems of ≥4 µ g/l (except ertapenem of 2 µ g/ml) 
according to CLSI revised breakpoint recommendations (Table 1.3). Based on the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines 
(EUCAST 2012), organisms that were found to show resistance to imipenem and 
meropenem (MIC ≥4 μg/ml respectively), and ertapenem (MIC ≥2 μg/ml); according to 
the Clinical and Laboratory Standards Institute (CLSI 2012) were to be confirmed using 
the modified Hodge test. Cefpodoxime (BioMérieux, France) MICs by E-test method 
were carried out of which ≥1 µ g/ml was considered as ESBL  positive. 
 
2.6. Phenotypic based methods for carbapenem-resistant organisms 
 
The following techniques, modified Hodge test (MHT) and boronic-acid disc synergy 
test (BADST) were carried out as additional phenotype based techniques in this study.  
 
2.6.1 Modified Hodge test 
This method was performed for the detection of Class A  carbapenemase previously 
described by Anderson et al. (2007). Briefly, the indicator organism Escherichia coli 
ATCC 25922 was prepared by obtaining an overnight culture which was adjusted to 0.5 
McFarland turbidity standard followed by a 10 fold dilution in saline. This broth was 
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then used to inoculate the surface of plates of Mueller-Hinton agar (Biotec Ltd, UK ) by 
swabbing. Meropenem (10μg) was placed at the centre. Three to five colonies of the test 
organisms were used to inoculate the plate in a line straight from the edge of disc to the 
end of the plate and incubated overnight at 35-37ºC for 16-24 hours. The plate was read 
and interpreted as positive test when a clover-leaf like indentation of the Escherichia 
coli ATCC 25922 grew along the test organism growth streak within the disc diffusion 
zone. 
 
2.6.2 Boronic acid-disc synergy test 
Boronate derivatives have structural resemblance of β-lactams have long been used in 
searching the function of β-lactamase enzymes, particularly class C enzymes. However, 
in 2008, inhibitory effects of boronic acid and its derivatives such as 3-
aminophenylboronic acid (APBA) and phenylboronic acid (PBA) have been confirmed 
to detect K PC production and other members of the class A  carbapenemases with better 
sensitivity and specificity when meropenem disc supplemented with PBA. Cut-off value 
of ≥5 mm zone diameter difference with and without PBA was accepted (Doi et al. 
2009). A  cut-off value of ≥7 mm when meropenem disc is used, with and without 400 
μg of PBA, was effective for detecting K PC-producing Klebsiella pneumoniae isolates 
and differentiating them from plasmid-borne AmpC-producing Escherichia coli and 
Klebsiella pneumoniae (Tsakris et al. 2011, Hrabák, Chudáčkova and Papagiannitsis 
2014). 
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A  modified boronic acid-disc synergy test (BADST) described by Doi et al. (2009) was 
performed on Mueller-Hinton agar (Biotec Ltd, UK ). Carbapenem discs containing 
10μg each of imipenem, meropenem and ertapenem were supplemented with 20 μl of 
20 mg/ml 3-aminophenyl-boronic acid (APB) and dissolved in dimethyl sulphoxide 
(DMSO; Sigma-Aldrich Company Ltd Dorset, UK ) to yield a 400 μg/ml final 
concentration. A  suspension of the test organism was prepared according the same 
protocol described above then used to swab the surface of a MHA plate. The 
supplemented discs of imipenem, meropenem and ertapenem containing 400 μg/ml each 
and un-supplemented discs of each antimicrobial respectively were placed far apart on 
the plate and incubated at 35-37ºC in air for 16-18 hours. A  positive test for K PC 
enzyme production was recorded when the measured diameter of the growth-inhibitory 
zone around each carbapenem disc with boronic acid was ≥5 mm more than that around 
the disc containing the carbapenem alone. 
 
2.6.3 Sensitivity and specificity calculation for modified Hodge test and boronic 
acid-disc synergy test 
Determination of sensitivity (SE) and specificity (SP) were calculated based on the 
formulas described by Pasteran et al. (2010) to evaluate the reliability of MHT and 
BADST compared with PCR-based results for carbapenemase resistance genes. SE 
formula = a/(a + c) x 100, where a represents the number of carbapenemase-producing 
isolates correctly identified and c represents the number of true carbapenemase-
producing isolates incorrectly identified as non-producers. SP formula = d/(b + d) x 100, 
where d  represents the number of CR isolates correctly identified by MHT screen as 
non-carbapenemase producers and b being the number of CR isolates incorrectly 
identified as carbapenemase-producing isolates. The formulas a/(a + b) and d/(c + d) 
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may be used to calculate positive predictive figure (PPF) and negative predictive figure 
(NPF), respectively.  
 
2.6.4 Nitrocefin assay for β-lactamase enzyme identification 
Beta-lactamase enzymes are the main components of resistance to β-lactam 
antimicrobials for most Gram-negative organisms. In recent times, nitrocefin 
interactions with ESBLs offer valuable evidence in assessing β-lactam compounds 
(Papanicolaou and Medeiros 1990, Dai et al. 2012). 
 
2.6.4.1 Principle of nitrocefin assay 
Nitrocefin in solution at neutral pH is expected to produce two absorption levels. One 
absorption peak is spectrophotometrically read at 217 nm when linked to 7-acyl group 
and another peak level at 386 nm. Subsequent to exposure to β-lactamase, the level 
considerably reduces at 386 nm, and a new level formed appears at 482 nm which 
relates to degraded nitrocefin. This difference in shift can be measured over time and 
allows estimation of activity of a given β-lactamase enzyme based on the rate at which 
it degrades nitrocefin, a coloured cephalosporin whose visible absorption spectrum (and 
hence colour) changes upon hydrolysis of the β-lactam ring. 
 
2.6.4.2 Preparation of β-lactamase extracts  
A ll 111 CR organisms were grown in 10 ml Mueller-Hinton broth at 37ºC in a shaking 
incubator for 16-18 hours. The technique described by Dai et al. (2012) was used and 
modified. The overnight broth culture was centrifuged at 4,000 rpm for 10 minutes to 
recover the cell deposit. The pellet was washed once with sodium phosphate buffer (100 
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mM with pH of 7.0). The supernatant was removed and the wet weight of the pellet was 
determined. The pellet was re-suspended in sodium phosphate buffer using a minimum 
of 5 µ l of buffer per microgram of sample. The cell suspension was sonicated (Sonic & 
Materials, Inc., USA, model: V CX  750) for 5 minutes on ice (4×15 s at 30-s intervals) 
and centrifuged at 6,400 rpm at 4ºC for 20 minutes to obtain cell-free extract for 
nitrocefin assay. Disruption by sonication was to release β-lactamase enzyme into the 
cell-free suspension from periplasmic region of the cells. The β-lactamase extracts were 
stored at -20°C or colder until assay testing. Frozen samples were thawed at room temp 
(20-25ºC) or in a refrigerator before use.  
 
2.6.4.3 Microplate assay for determination of β-lactamase concentration 
In each well, 10 µ l of collected extract was added to a 96-well plate. Total volume was 
adjusted to 50 µ l per well with βL Assay Buffer (100 mM Sodium phosphate, pH 7.0). 
Reaction mixture was prepared according to the manufacturer's instructions. In each 
well, a total reaction mix of 50 µ l was prepared comprising βL Assay Buffer 48µ l and 
2µ l of nitrocefin solution. Reaction mix was added to the extract in each well and was 
then thoroughly mixed and the absorbance of the solution was measured at 390 and 486 
nm every minute for a 15 minute period using a plate reader (Tecan Infinite
®
 200 PRO 
Männedorf, Switzerland). Positive controls were prepared in βL Assay Buffer and 10 µ l 
of diluted positive control pipetted into the desired well. Double distilled water was 
included as a negative control. The volume was adjusted to 50 µ l with βL Assay Buffer. 
For the blank, 10 µ L  sodium phosphate buffer was used and adjusted in the same way as 
the positive control. The mixture was then incubated at 30°C for 1 hour.  
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2.7 Genotypic characterisation of carbapenemase-producers 
All the 111 CR isolates were investigated for the presence of carbapenemase-producing 
genes with primers from the five most common genes namely; New Delhi metallo-beta-
lactamase-1 (NDM-1), Klebsiella pneumoniae carbapenemase-1 (K PC-1), V erona 
integron-encoded metallo-β-lactamase-1 (V IM-1), Oxacillinase-48 (OX A-48) and 
Imipenem-resistant Pseudomonas-1 (IMP-1) in this study.  
 
2.7.1 Genomic DNA extraction of CR  organisms 
DNA isolation procedures were carried out in accordance with guidelines set by Millar 
et al. (2002) in order to minimise contamination for false-positive results. Bacterial 
suspension of 1 ml was grown overnight at 37°C. The extraction procedure was 
conducted using a QiaAmp mini K it (Qiagen, Hilden, Germany) for Gram negative 
bacteria according to Qiagen guidelines. The eluted chromosomal DNA (in 2 x 2 ml 
sterilised Eppendorf tubes) was stored at -20°C.  
 
2.7.2 Preparation of primer sets 
Each of the five primers of carbapenemase-producing genes (IMP-1, V IM-1, OX A-48, 
NDM-1 and K PC-1) was diluted from 100 μg/μl stock solution and stored at -20
o
C by 
adding the desired volume of nuclease-free PCR water. To make a working solution, the 
stock solution was diluted in ratio 1:10 with nuclease-free PCR water with each primer 
sets (Table 2.1) according to the manufacturer’s instructions. Exclusion of CTX -M 
primers was due to unavailability of reference control strain during the study.  
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T able 2.1 Primer sets for amplification of carbapenemase and extended spectrum 
β-lactamase genes 
Gene Primer sequence (5’→ 3’) 
 
Amplicons 
size (bp) 
R eference 
blaIMP Forward - GGAATAGAGTGGCTTAAY TCTC 
Reverse – GGTTTAAY AAAACAACCACC 
232 (Poirel et al. 
2011d) 
blaV IM Forward - GATGGTGTTTGGTCGCATA 
Reverse - CGAATGCGCAGCACCAG 
 
390 (Poirel et al. 
2011d) 
blaOX A-
48 
Forward - GCGTGGTTAAGGATGAACAC 
Reverse – CATCAAGTTCAACCCAACCG 
438 (Poirel et al. 
2011d) 
blaNDM Forward - GGTTTGGCGATCTGGTTTTC 
Reverse – CGGAATGGCTCATCACGATC 
621 (Poirel et al. 
2011d) 
blaK PC Forward - CGTCTAGTTCTGCTGTCTTG 
Reverse – CTTGTCATCCTTGTTAGGCG 
798 (Poirel et al. 
2011d) 
blaTEM Forward - TCAACATTTTGTCGTCG 
Reverse – CTGACAGTTACCAATGCTTA 
860 (Schlesinger 
et al. 2005) 
blaSHV  Forward - TTTATCGGCCY TCACTCAAGG 
Reverse – GCTGCGGGCCGGATAACG 
930 (Schlesinger 
et al. 2005) 
 
Note: IMP, imipenem-resistant Pseudomonas; V IM, V erona integron-encoded metallo-β-
lactamase; OX A-48, oxacillinase-48; NDM, New Delhi metallo-β-lactamase; K PC, Klebsiella 
pneumoniae carbapenemase; TEM-1, Temoniera-1; SHV -1, sulphydry1 variable-1 
 
2.7.3 PCR  reaction mix preparation 
The PCR reaction mix was prepared aseptically using PyroMark Master Mix K it 
(Qiagen, Hilden, Germany) following the manufacturer's instructions with 2 μl of DNA 
extract in a final reaction volume of 25 μl as indicated in Table 2.2 was prepared.  
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T able 2.2 Composition of PCR reaction mix 
R eagent V olume per PCR  
reaction (μl) 
F inal concentration 
PCR master mix (QIAGEN) buffer, 
2x 
12.5 1x 
Forward primer (MWG) working 
solution, 10 pmol 
0.5 0.2 pmol 
Reverse primer (MWG) working 
solution, 10 pmol 
0.5 0.2 pmol 
CorralLoad (QIAGEN), 10x 2.5 1x 
DNA template,1-5ng/µ l 2.0 0.4 ng 
Nuclease free water (QIAGEN) 9.5 made up appropriately to 
the total volume 
T otal volume 25.0  
 
 
2.7.4 PCR  amplification conditions 
Primer sets used were obtained from Eurofins MWG Ebersberg, Germany (Table 2.2). 
The cycling conditions carbapenemase genes were: initial denaturation at 95ºC for 3 
minutes, followed by 40 cycles of denaturation at 95ºC for 1 minute, annealing at 58ºC 
for 30 seconds, and elongation at 72ºC for 1 minute 30 seconds, followed by a final 
elongation step at 72ºC for 10 minutes in a thermal cycler (MJ  Research PTC-150 
MiniCycler™ , USA). The PCR cycles were run between 2 and 3 hours.  
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2.7.5 PCR  products for electrophoresis 
Gels were prepared using 2% agarose (Invitrogen, Carlsbad, USA) in 1 x Tris-Acetate-
EDTA buffer. Before solidification of prepared gels, 2.5 μl of ethidium bromide was 
added. A ll PCR products were analysed by electrophoresis in 1 x TAE buffer prepared 
from 10 x TAE buffer per litre (48.8 g Tris base, 11.4 ml Glacial acetic acid, 3.7 g 
EDTA disodium salt). 
 
2.7.6 L oading and electrophoresis of amplified PCR  products 
The presence of coralload dye required no other loading dye for the amplified PCR 
products. Therefore, each well was loaded with 6 μl of test samples. A  molecular 
marker 1 kb DNA ladder (Invitrogen, Carlsbad, USA) was used as an external reference 
for size comparison. Each electrophoretic set was run at 100 volts per centimetre for 1 
hour.  
 
2.7.7 V isualisation of bands on agarose gel 
The amplified bands in the gel were visualized by a trans-illuminator (UV  light) to 
confirm the PCR products.  
 
2.7.8 Purification of PCR  products for sequencing 
Reagents needing to be prepared from the QIAquick PCR purification kit (Qiagen, 
Hilden, Germany) were prepared according to the manufacturer’s instructions. The 
purified PCR products were stored at -20°C prior for sequencing. 
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2.7.9 Sequencing of purified PCR  products 
Purified PCR products for sequencing by Eurofins Genomics, Ebersberg were followed 
according to the protocol instructions. Forward primer of each appropriate 
carbapenemase gene (2 µ l) was added to 7.5 µ l of purified PCR DNA product and 
nuclease-free water respectively to make up a total volume of 17 µ l for sequencing. The 
purified 26 positive carbapenemase producers including positive control strains were 
prepared and sent to Eurofins Genomics, Ebersberg, Germany for sequencing.  
 
2.7.10 Determination of extended spectrum β-lactamase genes in total DNA extracts  
Primers were identified from Schlesinger et al. (2005) study to amplify regions of the 
extended spectrum β-lactamase genes (blaTEM and blaSHV ) (Table 2.2). Amplification 
conditions in a thermal cycler (MJ  Research PTC-150 MiniCycler™ , USA) with initial 
denaturation 15 minutes at 95
o
C and 35 cycles of 1 minute at 94
o
C, 1 minute at an 
annealing temperature of 47
o
C and 50
o
C designed for each primer set for TEM and 
SHV  respectively, and 1 min at 55
o
C, followed by 10 minutes at 72
o
C for the final 
extension. The amplification cycles were run for 2 to 3 hours. A ll other set ups were 
followed as indicated in the above sections; 2.7.1, 2.7.2, 2.7.3 and 2.7.5 to 2.7.7.  
 
2.7.11 Outer membrane protein analysis of CR  isolates 
A  recent study by Sugawara and Nikaido (2012) claimed that the major proteins in the 
outer membrane of Acinetobacter baumannii, non-fermenter isolate which belongs to 
the low-permeability trimeric porin group, but have been found to equate to Escherichia 
coli OmpF/OmpC, and also shares close homology to Pseudomonas aeruginosa OprF 
and Escherichia coli OmpA (Sugawara and Nikaido 2012). Therefore, in-house MBL-
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positive (V IM positive) and wild-type Pseudomonas aeruginosa control strains from 
Sheffield Hallam University (SHU) collection were included and used for the study 
analysis of OMPs. Two methods, with some modifications, were employed separately 
for organisms in the Enterobacteriaceae family and Acinetobacter species (Mizuno and 
K ageyama 1978), and for Pseudomonas species (Sambrook and Russell 2001) due to 
structural differences. 
 
2.7.11.1 Separation of outer membranes of E scherichia coli, Acinetobacter species 
and other organisms 
Bacterial cultures were grown to stationary phase (6 hours) aerobically at 37°C in 
Mueller-Hinton broth (Biotec Ltd, UK ). A liquots (0.1 ml) of the overnight culture were 
added to 20 mls of Mueller-Hinton broth in a 50 ml conical centrifuge tube (to allow for 
appropriate aeration). The cultures were then grown to an optical density of 0.6 at 600 
nm (late exponential phase growth). The bacterial culture was then harvested by 
centrifugation at 4000 g (1600 rpm) for 15 minutes using Eppendorf 5804R with the 6 x 
125 g rotor (Thermo Scientific). The pellet was subsequently re-suspended in 9ml of 
phosphate-buffered saline (PBS), 100 µ g lysozyme per ml was added, and the solution 
was left for 20 minutes, or until the culture had a more translucent appearance. The 
culture was then disrupted at 4ºC by sonication through five cycles of 30 seconds, 
followed by 30 seconds without sonication. The remaining solution was then subjected 
to two successive centrifugation steps (10 minutes at 2,500 g or 1,000 rpm) to remove 
whole cells, or large cell debris, with the supernatant being kept in each case. The 
supernatant was then centrifuged at 27,500 g (11,000 rpm) for 90 minutes to pellet the 
cell membranes. The pellet was then re-suspended in 1.7% (w/v) sodium-lauryl-
sarcosinate by repeated pipetting within the 20-30 minutes at room temperature. Outer 
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membrane vesicles were then harvested by centrifugation at 27,500 g for 90 minutes. 
The pellet was re-suspended in 1.5 ml double-distilled filter-sterilised water and was 
centrifuged at 27,500 g for 60 minutes to remove the sodium-lauryl-sarcosinate. The 
pellet was re-suspended in 50 µ l of double-distilled filter-sterilised water and stored at -
20°C until required (Sambrook and Russell 2001).  
 
2.7.11.2 Outer membranes separation from Pseudomonas species 
Cultures were grown in 20 ml of Mueller-Hinton broth (Biotec Ltd, UK ) to attain 
optical density of 0.6 at 600 nm (late exponential phase growth) before use. The 
bacterial broth was centrifuged at 1600 rpm (Eppendorf 5804R centrifuge, Thermo 
Scientific) for 15 minutes to harvest the deposit. The pellet was re-suspended in the 
following order; 4.5 ml of 20% (2M) Sucrose, 5.0 ml (0.1M Tris HCL pH7.8 at 25°C, 
0.4 ml 1% Na-EDTA (pH7.0) and 0.9 ml of 0.5% (0.07M) lysozyme. The content was 
left for 20 minutes, then warmed to 30°C and kept for 60 minutes. After 30 minutes 
within the 60 minutes, deoxyribonuclease 3 µ g/ml was added. The suspension was 
centrifuged to remove the cell debris at 13,000 rpm for 15 minutes at 30°C. The 
supernatant collected was centrifuged in Sorvall Lynx 6000 centrifuge (Thermo 
Scientific, rotor T29-8 x 50) at 29,000 rpm for 60 minutes. To the pellet obtained, 4 ml 
of 5mM MgCl2 was added then centrifuge at 15,000 rpm for 20 minutes. The pellet was 
re-suspended in 1.5 ml of double distilled (DD) and filtered-sterilized water to remove 
the MgCl2. After another centrifugation, the pellet was suspended in 50 µ l of DD 
filtered-sterilized water and stored at -20°C until required (Mizuno and K ageyama 
1978).  
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2.7.11.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE ) 
Resolving gels were made at a 12% concentration of acrylamide: bisacrylamide (37:5:1) 
(Bio-Rad, UK ) by mixing 4.8 mL of 40% acrylamide, 4 ml of 2 M Tris-HCl (pH8.8), 
6.9 ml of distilled water, 160 µ l of 10% SDS, 160 µ l of 10% ammonium persulphate 
(APS). Polymerisation of acrylamide was prepared by adding 16 µ l N,N,N’,N’-
tetramethylethylenediamine (TEMED) (Bio-Rad), the gel solution was cast between 
two glass plates in the apparatus and then layered with isopropanol equilibrated with 
saturated aqueous sodium chloride. Once gel polymerisation was complete, the 
saturated isopropanol was removed and the area at the top of the gel was dried with 
filter paper. The stacking gels were made containing 6% acrylamide concentration by 
mixing 1.5 ml of 40% of acrylamide, 2.5 ml of 0.5 M Tris-HCl (pH 6.8), 5.8 ml of 
distilled water, 100 µ l of 10% SDS, 100 µ l of 10% APS. Acrylamide polymerisation 
was initiated by adding 10 µ l TEMED, the gel solution was overlaid on the resolving 
gel, and 15-well comb was pushed into the gel to create sample wells. After complete 
polymerisation, the gel apparatus was assembled in the appropriate tank and covered in 
1 x SDS-PAGE running buffer made from 10 x Tris-glycine-SDS buffer in 500 ml of 
deionised water at pH 8.3; Tris base 15.0 g, Glycine 72.0 g, SDS 5.0 g. The crude outer 
membrane protein samples were mixed with SDS-PAGE loading buffer at a 6:1 ratio, 
boiled for 5-10 minutes, and loaded into the wells created in the gel. Electrophoresis 
was set at 130 volts per centimetre until the blue colour in the loading dye in the sample 
buffer had reached the end of the gel (approximately 45 to 60 minutes). Outer 
membrane proteins were visualized by staining the gel for 1 hour with Coomassie 
brilliant blue R solution, and then destained with destain solution overnight and 2 other 
changes of destain solution over 2 to 3 hours until the gel was clear. Outer membrane 
protein bands were compared with standard pre-stained protein ladder (Thermo-
Scientific, Leicestershire, UK ). 
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2.8 Plasmid analysis of carbapenem-resistant organisms 
 
2.8.1 Plasmid DNA extractions 
A ll CR isolates were grown in 5 ml each in MHB for overnight. For the overnight broth, 
50 µ l was used to inoculate fresh MHB and incubated at 37
o
C in a shaker incubator for 
16-18 hours. The plasmid DNA was extracted from the bacterial suspension using 
QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The eluted plasmid DNA was stored at -20 ˚C until required.  
 
2.8.2 Purified plasmid DNA and concentration analysis 
A  NanoDrop®  ND-1000 spectrophotometer (NanoDrop, Wilmington, USA) was used 
to measure the concentration of purified nucleic acid at a spectrum range from 220 to 
750 nm. The manufacturer’s protocol instructions were followed and used to measure 
purified plasmid DNA extracted from CR isolates. The spectrophotometer instrument 
works on a patented sample-retention methodology which relies solely on surface 
tension to hold up the sample in place. A  volume of 1 μl of a DNA extracted sample 
was aliquoted onto the end of a receiving fibre (fibre-optic cable). A  source fibre 
(second cable) was to bring into contact with the liquid DNA sample in between the gap 
causing liquid to be read at the fibre optic ends. The controlled gap for both paths was 
between 0.2 mm and 1 mm. The presence of the sample resulted in the passage of light 
from a pulsed X enon flash lamp through the sample, and subsequent analysis of the 
light intensity by a spectrometer. The absorbance ratio falling at 260 nm and 280 nm 
was used to assess the DNA purity in the sample, and a ratio ~1.8 was considered as 
pure in state. 
.
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2.8.3 Detection of common β-lactamases and carbapenemase genes in plasmid 
DNA extracts  
A ll CR isolates including the numbers which were positive by PCR for carbapenemase 
genes from total DNA extracts were amplified for the corresponding genes in their 
plasmid DNA extracts. The primers, reaction mix, PCR cycle conditions, gel 
preparation and visualisation of PCR bands were set as described in sections 2.7.2 to 
2.7.7 and 2.7.10 from total DNA amplification procedures. 
 
2.8.4 Plasmid transfer experiment 
To explore the carbapenemase genes located on transferable plasmids, a method 
described by K hajuria et al. (2014) was performed. The resistance pattern was based on 
inhibition against specific cephalosporins (cefotaxime and cefpodoxime) and 
carbapenems (imipenem, meropenem and doripenem). Carbapenem-resistant isolates 
used in this study were used as donor cells while Escherichia coli Top10 competent 
cells (Life Technologies, Carlsbad, USA) as the recipient organism (susceptible to 
cephalosporins and carbapenems tested). Conjugations were performed by mixing 1 ml 
of the donor cells to 10 ml of the recipient cells at log-phase in Mueller-Hinton broth 
(Biotec Ltd, UK ) and incubated in a mild shaking incubator at 35ºC for 16-18 hours. 
The transconjugants were selected on Mueller-Hinton agar (Biotec Ltd, UK ) with 
selection based on growth on agar plates in the presence of cefotaxime (2 µ g/ml) and 
sodium azide (100 µ g/ml) incubated for 48 hours. Donor and recipient cells were killed 
by sodium azide and cefotaxime agents respectively while the resultant survival 
colonies were considered as the transconjugants (resistant to both agents), sub-cultured 
and stored at -80ºC. The identity of the transconjugants was confirmed by indole 
positive test and decreased susceptibility to a panel of β-lactams including carbapenems.  
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2.8.5 Plasmid curing and restriction enzyme digestion experiment 
The plasmid curing technique was by physical method of incubation at 45°C described 
by Di Martino et al. (1997). The method was used to investigate the 26 PCR-positive 
carbapenemase isolates for curing. The isolates were inoculated in 5 ml of Mueller-
Hinton broth (Biotec Ltd, UK ) each in duplicate. One broth culture was incubated at 
37°C while the other at a higher temperature of 45°C overnight for plasmid curing. The 
curing was confirmed by loss of plasmid and antimicrobial susceptibility testing using 
antibiotics to which isolates were resistant. Digestion reactions was carried out in 50 µ l 
reaction volumes with 20 µ l or 1 µ g of each plasmid DNA extract by simple boiling a 
suspension of the cured isolates in double-distilled water for 15 minutes then mixed 
with 20 µ l of EcoRI and HindIII restriction enzymes (Invitrogen) in digest buffer and 
incubated in a water bath at 37ºC for digestion to take place for 4 hours according to the 
protocol of instructions. The content was analysed by electrophoresis on a 1% agarose 
gel prepared with 1 x TAE buffer (40mM 56 Tris base, 20mM acetic acid, 1mM EDTA) 
at 100 volts per centimetre for 2 hours. 
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2.9 Molecular typing of carbapenem-resistant isolates by E R IC-PCR  
A total number of CR isolates (111) was subjected to enterobacterial repetitive 
intergenic consensus-PCR (ERIC-PCR) amplification using total DNA extractions with 
the following primers: ERIC1R (5
’
-ATGTAAGCTCCTGGGGATTCAC-3’) and ERIC2 
F (5’-AAGTAAGTGACTGGGGTGAGCG-3’). Preparation of primer set and PCR 
reaction mix composition (Table 2.2) were followed as indicated in sections 2.7.2 and 
2.7.3 respectively. PyroMark Master Mix K it (Qiagen, Hilden, Germany) was used with 
2 μl of DNA extract each in 25 μl final reaction volume. Based on using the standard 
ERIC-PCR annealing temperature at 52°C for majority of microbial pathogens, no 
amplified band was visible on agarose gel electrophoresis, rather upon several trials at 
different temperatures, 45°C annealing temperature proved to be useful for band size 
estimates and genotype analysis in this study. Amplification conditions were as follows: 
denatured for 15 minutes at 95°C and then subjected to 45 cycles of denaturation for 30 
seconds at 94°C, annealing for 45 seconds at 45°C, extension for 7 minutes at 72°C, and 
a final extension for 10 minutes at 72°C. 
 
2.9.1 E lectrophoresis and computer analysis of gene sequence and E R IC-PCR  data 
The amplified products were prepared and electrophoresed as described in sections 
2.7.5 and 2.7.6. Gene Ruler 1 kb DNA Ladder Plus (Invitrogen, Carlsbad, USA) was 
used as a molecular marker standard. The presence of coralload dye in the reaction 
mixture required no loading dye again for the amplified PCR products. Each well was 
loaded with 10 μl of test samples including the molecular marker standard and 
electrophoretic set was run at 100 volts per centimetre for 45 minutes. Gel images were 
digitally photographed and documented.  
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2.9.2 Sequence data and analysis of phylogenetic trees 
The phylogenetic data were evaluated using the Neighbor-Joining method (Saitou and 
Nei 1987). The evolutionary history and taxa analysis were taken from 500 replicates to 
prepare the bootstrap consensus tree (Felsenstein 1985). Less than 50% of the replicates 
collapse and conform to divisions of the corresponding branches. The evolutionary 
distances were measured using the maximum composite likelihood technique (Tamura, 
Nei and K umar 2004) and these are calculated in units of the number of base 
substitutions per position. The analysis was based on 14 nucleotide sequenced data. 
Codon sites were included, first + second + third and noncoding areas. A ll ambiguous 
sites were removed for each sequence pair. There were 490 sites in the final analysis. 
Phylogenetic data were conducted in Molecular Evolutionary Genetics Analysis version 
6.0 (MEGA6) (Tamura et al. 2013). 
 
2.9.3 E R IC-PCR genetic relatedness analysis 
With the complexity of diverse band sizes, the formation of clustering analysis could 
not have been assessed by extrapolation alone. For more discriminating interpretations 
of gel electrophoretic images by ERIC-PCR products, specifically written software 
designed by the GelCompar II evaluation software (Applied Maths, K ortrijk, Belgium) 
was sourced through the website (http://www.applied-maths.com/download/software) 
before a full featured license granted for a month (2/10/2015 until 1/11/2015) to 
generate computer-assisted images for the dendrogram data analysis for this study. 
Clustering information of different CR Gram-negative bacteria with control strains were 
determined by random enterobacterial repetitive intergenic consensus-PCR (ERICPCR) 
fingerprint patterns using Gel Compar II image analysis software and Unweighted 
Pair Group Method with Arithmetic Mean (UPGMA) cluster method. 
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Chapter three 
 
3. Phenotypic and genotypic characterisation of carbapenem-
resistant isolates 
 
3.1 Background and Aims 
 
Carbapenemase producing bacteria have limited treatment options and are difficult to 
manage by clinicians in health care facilities due to the presence of ESBLs, hydrolysis 
of β-lactams, including carbapenem antimicrobials, by β-lactamase enzymes, use of 
inactive transpeptidases, and expulsion of the antibiotic through efflux pumps (Walsh et 
al. 2005, Wilke, Lovering and Strynadka 2005, Temkin et al. 2014). In recent times, 
carbapenemase producing genes have gained worldwide recognition as they can spread 
across different strains and species. The enzymes have been characterised as various 
classes of carbapenemases including the most common types: the New Delhi metallo-β-
lactamases (NDM), verona integron-encoded metallo-β-lactamases (V IM), oxacillinase-
48 (OX A-48), imipenem-resistant Pseudomonas-1 (IMP-1) and Klebsiella pneumoniae 
carbapenemases (K PCs) with determinant encoding genes expressed as; blaNDM, 
blaV IM, blaOX A-48, blaIMP, and blaK PC, respectively (Nordmann, Naas, Poirel 
2011).  
 
Recently, a few African countries have extensively investigated carbapenemase 
producers among the Enterobacteriaceae group to find out the prevailing types and 
distribution in their locations such as in South Africa (Coetzee and Brink 2011), K enya 
(Poirel et al. 2011b), Morocco (Hays et al. 2012), Tanzania (Mushi et al. 2014), Nigeria 
(Ogbolu and Webber 2014) and Uganda (Okoche et al. 2015). More importantly, in 
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terms of resistance to carbapenems, in sub-Saharan regions there is limited data 
available to ascertain the extent of the spread of carbapenemase gene carriers. Current 
studies show there is a lack of interest, poor implementation of surveillance studies and 
an unsystematic approach to carry out research studies on carbapemase-producing 
bacteria in this part of the sub-region (Manenzhe et al. 2014). Recently, a nationwide 
laboratory based antimicrobial resistance study carried out in Ghanaian health care 
facilities by Opintan et al. (2015) reported no data on the prevalence and distribution of 
CRE, despite the fact that there are increased numbers of multidrug-resistant organisms 
in the country (Opintan et al. 2015). Previous studies attested to the high incidence of 
multidrug resistance among common pathogens attributed to the unregulated use of 
antimicrobials and improper diagnosis of patients' infections in most developing 
countries (Newman et al. 2011), Nigeria (Ogbolu et al. 2011) and Rwanda (Ntirenganya 
et al. 2015). 
 
Outbreaks of CRE infections are considered a serious threat to patient care and tracing 
the source of transmission in hospitals from infected patients is a cumbersome task to 
undertake in any facility. A  study by Sahin et al. (2015) recommended early detection 
of CRE organisms from colonised patients as an important step in curbing infections 
and its spread. Clinical manifestations of CRE organisms are similar to infections 
caused by susceptible pathogens, however, detection methods are more critical in 
reducing their dissemination within hospitals. The problem arises when interpreting the 
susceptibility testing results of an organism that has demonstrated resistance to a 
carbapenem via disc diffusion methodology while proving susceptible once its MIC is 
determined by alternative methods. This may complicate interpretation in a clinical 
laboratory with consequences for public health. Therefore, for meaningful detection, 
more comprehensive methods are needed to detect either carbapenemase gene producers 
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or carbapenemase non-PCR positives to avoid any ambiguities in reporting results to 
clinicians (Sahin et al. 2015).  The aim of this study was to apply various techniques to 
identify carbapenem-resistant Gram-negative organisms and their resistance genes from 
the hospital environment.  
 
The objectives were to: 
ñ Identify carbapenem-resistant bacteria using various phenotype based techniques 
ñ Determine the prevalence and distribution of carbapenemase producers from 
various clinical specimens 
ñ Investigate the presence of ESBL  by cefpodoxime E-test and nitrocefin assay 
ñ Detect carbapenemase-producing isolates using PCR-based assay 
ñ Determine the presence of outer membrane proteins of carbapenemase non-PCR 
positives and carbapenemase gene producers by SDS-PAGE 
ñ Determine the phylogenetic relationships of isolates PCR-positive for 
carbapenemase genes 
 
3.2 Method summary 
Suspected CR isolates were collected between the months of September 2012 through 
September 2014 from four selected regional hospitals in Ghana. Identification of 
bacterial strains was by both conventional and automated systems (V itek 2) to obtain a 
species level of identification of organisms. Disc diffusion assays and MIC 
determination using E-test strips for imipenem, meropenem and ertapenem were 
performed. The presence of ESBL enzyme was determined by combined disc assay 
using cefpodoxime with or without clavulanic acid and a nitrocefin assay. Outer 
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membrane protein analysis was performed using SDS-PAGE where extractions of 
Pseudomonas isolates were differently treated from those in the Enterobacteriaceae 
group and Acinetobacter baumannii isolates because of the specific efflux pump 
systems exhibited in the cell wall structure in order to visualise the different porin levels 
within each bacterial cell.  
 
A  modified Hodge test and boronic-acid disc synergy test were also carried out as 
additional phenotype-based methods on strains showing reduced susceptibility and 
complete inhibition to carbapenems. Total DNA was extracted directly from all CR 
isolates for molecular characterisation of carbapenemase genes with five common 
primers by PCR-based assay and sequenced purified positive carbapenemase gene 
producers to determine phylogenetic relationships with controlled strains compared to 
established strains from the GenBank database. Full description is in Chapter two of this 
study. 
 
3.3 R esults 
3.3.1 CR  isolates demographics and characteristics 
The study identified 111 non-duplicated CR isolates from 55 male and 56 female 
patients with ages between 3 days and 91 years (Appendix 1). Of the 111 isolates, 51 
were Pseudomonas aeruginosa, 31 Acinetobacter baumannii, 12 Escherichia coli, 7 
Pseudomonas putida, 3 each for Klebsiella pneumoniae and Enterobacter cloacae, and 
one each for Cronobacter sakazakii, Providencia stuartii, Shigella sonnei and 
Sphingomonas paucimobilis, respectively from ten different sample collection sites 
(Tables 3.1 and 3.2).  
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3.3.2 R esistance pattern of CR  isolates 
The study revealed the lowest frequency of resistance to imipenem (58%), followed by 
meropenem (66.7%) and doripenem (75%) by the disc diffusion method with 
corresponding minimum inhibitory concentrations evaluated using the E-test method 
(BioMérieux, France). In the MIC investigations, doripenem was replaced by 
ertapenem, due to its good selectivity for community-acquired pathogens, notably 
Pseudomonas aeruginosa mutants, and also detect cross-resistance better with 
meropenem and imipenem than doripenem. Providencia stuartii was the only CR 
isolate which showed 100% susceptibility to meropenem while Klebsiella pneumoniae, 
Enterobacter cloacae, Cronobacter sakazakii, Shigella sonnei and Sphingomonas 
paucimobilis isolates were 100% resistant to imipenem, meropenem and doripenem, 
respectively. The highest measurable MIC levels were observed in 56.8% of CR isolates 
at ≥32 μg/ml by the E-test method of which 24.3% and 18.9% were detected in 
Pseudomonas aeruginosa and Acinetobacter baumannii isolates, respectively. 
Susceptibility testing results in table 3.3 were based on ≥23 mm as susceptible, 20-22 
mm as intermediate and ≤19 mm as resistant for all carbapenems. However, figure 3.1 
shows E-test thresholds of ≥32 µ g/ml for resistance to the 3 carbapenems (imipenem, 
meropenem, ertapenem), levels ranging from ≥16 to ≤4 µ g/ml were resistant to 1 or 2 of 
the carbapenems, and levels at <4 µ g/ml showed intermediate resistance to either 1 or 2 
of carbapenems tested. Details of these resistant isolates are shown in Table 3.3 and 
Figure 3.1. 
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T able 3.1 Distribution pattern of carbapenem-resistant organisms by age groups, sex and source of specimens 
Numbers indicate the total number of CR isolates in each category 
 
 P. 
aeruginosa 
A. 
baumannii 
E . coli P. putida E n. cloacae K. 
pneumoniae 
C. 
sakazakii 
P. stuartii S. 
sonnei 
S. 
paucimobilis 
Age 
(years)     
          
  0-9 15 9 3 2 1 0 0 0 0 0 
10-19 4 4 1 0 1 0 0 0 0 0 
20-29 4 5 2 3 0 0 1 0 0 1 
30-39 7 5 2 0 1 1 0 0 0 0 
40-49 2 0 2 1 0 1 0 1 0 0 
50-59 7 1 2 0 0 0 0 0 0 0 
60-69 3 2 0 1 0 1 0 0 1 0 
70-79 7 3 0 0 0 0 0 0 0 0 
80-89 2 1 0 0 0 0 0 0 0 0 
90-99 0 1 0 0 0 0 0 0 0 0 
Sex           
Female 17 21 9 3                   2 2 1 1 0 0 
Male 34 10 3 4 1 1 0 0 1 1 
Specimen            
Wound 
(47)  
24 13 5 1 1 1 1 1 0 0 
Urine (31) 16 14 6 2 2 1 0 0 0 1 
Sputum (7) 4 1 0 1 0 1 0 0 0 0 
Ear (4) 1 0 0 3 0 0 0 0 0 0 
Aspirate 
(5) 
2 3 0 0 0 0 0 0 0 0 
CSF (2) 2 0 0 0 0 0 0 0 0 0 
Stool (1) 0 0 0 0 0 0 0 0 1 0 
Catheter 
tip (1) 
1 0 0 0 0 0 0 0 0 0 
HV S (1) 0 0 1 0 0 0 0 0 0 0 
Eye (1) 1 0 0 0 0 0 0 0 0 0 
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T able 3.2 Distribution pattern of carbapenem-resistant organisms from selected hospitals in Ghana 
 
 
a 
Total number of CR isolates obtained from the hospital;  
 
Note: K BTH, GA/R= K orle Bu Teaching Hospital, Greater Accra Region; ENRH, W/R= Effia-Nkwanta Regional Hospital, Western Region; AGAMH, 
A/R= AngloGold Ashanti Mines Hospital, Ashanti Region; HRH, V /R= Ho Regional Hospital, V olta Region 
 
 
   
P. 
aeruginosa 
 
A. 
baumannii 
 
E . coli 
 
P. putida 
 
E n. 
cloacae 
 
K. 
pneumoniae 
 
C. 
sakazakii 
 
P. stuartii 
 
S. 
sonnei 
 
S. 
paucimobilis 
Hospital   
KBTH, 
GA/R 
(93)
a
 
45 (48.4%) 28 (30.1%) 10 
(10.8%) 
4 (4.3%) 2 (2.2%) 1 (1.1%) 1 (1.1%) 1 (1.1%) 0 
(0.0%) 
1 (1.1%) 
ENRH, 
W/R (6) 
2 (33.3%) 3 (50.0%) 0(0.0%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 0 
(0.0%) 
0 (0.0%) 
AGAMH, 
A/R (7) 
4 (57.1%) 0 (0.0%) 1 (14.3%) 1 (14.3%) 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 0 
(0.0%) 
0 (0.0%) 
HRH, 
V/R (5) 
0 (0.0%) 0 (0.0%) 1 (20.0%) 2 (40.0%) 1 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 
(20.0%) 
0 (0.0%) 
Total 
number               
111(%) 
51 (46)    31 (28)    12 (11)     7 (6.3)      3 (2.7)      3 (2.7)      1 (0.9)      1 (0.9)     1 (0.9)     1 (0.9)      
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T able 3.3 R esistance pattern of carbapenem-resistant isolates against carbapenems  
Bacterial species Antimicrobial agents 
Number of CR  
isolates 
Imipenem %  for 
each group of CR  
isolates 
Meropenem %  for 
each group of CR  
isolates 
Doripenem %  for 
each group of CR  
isolates 
S I R  S I R  S I R  
51 P. aeruginosa        11.8 5.9 82.3 0.0 0.0 100.0 2.0 0.0 98.0 
31 A. baumannii          00.0 9.7 90.3 0.0 0.0 100.0 0.0 0.0 100.0 
12 E . coli                      16.7 25.0 58.3 0.0 33.3 66.7 0.0 25.0 75.0 
7 P. putida                14.3 0.0 85.7 0.0 0.0 100.0 0.0 0.0 100.0 
3 K. pneumoniae          0.0 0.0 100.0 0.0 0.0 100.0 0.0 0.0 100.0 
3 E n. cloacae              0.0 0.0 100.0 0.0 0.0 100.0 0.0 0.0 100.0 
1 C. sakazakii 0.0 0.0 100.0 0.0 0.0 100.0 0.0 0.0 100.0 
1 P. stuartii               0.0 0.0 100.0 100.0 0.0 0.0 0.0 0.0 100.0 
1 S. sonnei                 0.0 0.0 100.0 0.0 0.0 100.0 0.0 0.0 100.0 
1 S. paucimobilis    0.0 0.0 100.0 0.0 0.0 100.0 0.0 0.0 100.0 
 
Note: CR= carbapenem-resistant, S= susceptible, I= intermediate, R= resistant  
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Figure 3.1 Carbapenem-resistant isolates and E -test MIC  against carbapenems 
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3.3.3 E SBL  determination by cefpodoxime and nitrocefin assay  
Cefpodoxime with and without clavulanic acid was used to screen for ESBL as 
described in Chapter 2 (Section 2.5.2). Of all the CR isolates, none showed ESBL  
activity with the test when the results were interpreted according to Livermore and 
Woodford (2004) established guidelines for cefpodoxime ESBL determination. A  
difference of ≥ 5 mm in ratio for either cefpodoxime combination with clavulanic acid 
compared to the same disc when tested alone (Livermore and Woodford 2004). 
Readings measured in millimetres were between zero and three for all the CR isolates 
including Klebsiella pneumoniae (NCTC 13438) carbapenemase-positive (K PC-
positive) and Escherichia coli (ATCC 25922) as positive and negative control strains, 
respectively (see Appendix 2). These results indicated that cefpodoxime disc and 
clavulanic acid were not good indicators for determining ESBL activity in CR isolates. 
In contrast, MIC determination using the E-test method was more discriminating 
ranging from 8 to ≥256 µ g/ml to cefpodoxime for ESBL  detection (see Appendix 2). 
 
The nitrocefin assay for detection of β-lactamase activity was conducted as described in 
Section 2.5.3. The assay was also considered non-specific since colour intensity of β-
lactamase activity was determined from the sample within 2 to 22 minutes. A ll CR 
isolates were measured against a blank sample and negative and positive β-lactamase 
controls to determine a cut-off point based on the background β-lactamase activity. A 
sample that showed a measurable colour development at the same condition and time 
with the positive control was considered as positive β-lactamase test. The nitrocefin 
assay was controlled with K PC-positive (NCTC 13438) strain as a positive control 
which yielded measurable quantity of β-lactamase activity comparable to all the CR 
isolates studied. In all, β-lactamase activity for the 26 carbapenemase producers was 
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from 84% to 174% compared with the negative control. The presence of β-lactamase 
activity in the test extracts showing more than 46% is considered positive for nitrocefin 
assay. Details of these results are shown in Table 3.4.  
 
3.3.4 Prevalence of carbapenemase detection based on phenotypic tests 
 
From this study, phenotypic identification for carbapenamase activity was revealed in 
21 of 111 CR isolates (18.9%) by the modified Hodge test (MHT) method and 3/111 
(2.7%) by boronic acid-disc synergy test (BADST) screen. A  total of 21.6% exhibited 
carbapenemase production by both methods. None of the CR isolates were positive for 
both MHT and BADST phenotypic test. The three Enterobacter cloacae isolates were 
the only isolates which showed positivity from the BADST screen. Details of the 
carbapenemase activity among the CR isolates are shown (Table 3.5, Figures 3.2 and 
3.3). 
  
                           L eft                                                                           R ight 
Figure 3.2 Positive and negative modified Hodge test on Mueller-Hinton agar plate  
Left: M= meropenem disc, P= positive modified Hodge test (arrowed clover-leaf like 
indentations), C= negative Escherichia coli ATCC 25922 control strain 
Right: M= meropenem disc; A, B, C & D= carbapenem-resistant organisms showing no clover-
leaf like indentations 
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T able 3.4 Detection of β-lactamase activity using nitrocefin assay 
 
Sample Number 
Average A 390/486 2 - 22 
min linear range 
R atio against K pc-
positive control 
R elative %  
activity in 
comparison 
to K pc-
positive 
control 
1 0.510499998 0.817834931 81.78349 
2 0.575563631 0.922068648 92.20686* 
3 0.539854537 0.864861705 86.48617 
4 0.548899997 0.879352778 87.93528 
5 0.555518177 0.889955284 88.99553* 
6 0.570063629 0.913257494 91.32575* 
7 0.567218174 0.908698997 90.8699* 
8 0.553281817 0.886372572 88.63726 
9 0.570809093 0.914451748 91.44517 
10 0.591654539 0.947846721 94.78467 
11 0.598890901 0.95943957 95.94396 
12 0.527181815 0.844559658 84.45597* 
13 0.625409083 1.001922422 100.1922 
14 0.613027275 0.982086427 98.20864 
15 0.555863635 0.890508716 89.05087 
16 0.54130908 0.867191922 86.71919 
17 0.564954536 0.905072587 90.50726 
18 0.57553637 0.922024975 92.2025 
19 0.562490908 0.901125788 90.11258* 
20 0.579454547 0.928302 92.8302 
21 0.611599998 0.979799891 97.97999 
22 0.559299995 0.896013858 89.60139 
23 0.613327265 0.982567019 98.2567 
24 0.520481809 0.833826064 83.38261 
25 0.620736355 0.994436584 99.44366 
26 0.568572727 0.910869028 91.0869 
27 0.572400001 0.917000426 91.70004* 
28 0.584799994 0.936865553 93.68656 
29 0.543463637 0.87064358 87.06436 
30 0.592763635 0.949623524 94.96235 
31 0.533481815 0.854652429 85.46524 
32 0.585745459 0.938380214 93.83802 
33 0.56287273 0.901737477 90.17375 
34 0.617990911 0.990038308 99.00383 
35 0.520345444 0.833607605 83.36076 
36 0.574809096 0.920859862 92.08599 
37 0.534554547 0.856370975 85.6371 
38 0.601818177 0.964129146 96.41291 
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Sample Number 
Average A 490 2 - 22 
min linear range 
R atio against K pc-
positive control 
R elative %  
activity in 
comparison 
to K pc-
positive 
control 
39 0.562563631 0.901242292 90.12423* 
40 0.609718182 0.97678517 97.67852 
41 0.629872723 1.009073295 100.9073 
42 0.597136367 0.95662876 95.66288* 
43 0.594772724 0.952842138 95.28421* 
44 0.571963635 0.916301356 91.63014 
45 0.548518186 0.878741107 87.87411 
46 0.572172723 0.91663632 91.66363* 
47 0.571427275 0.915442092 91.54421* 
48 0.573954544 0.919490846 91.94908 
49 0.599745458 0.960808594 96.08086 
50 0.750145452 1.201753489 120.1753* 
51 0.844909083 1.353567413 135.3567 
52 0.74403636 1.191966558 119.1967 
53 0.775781821 1.242823653 124.2824 
54 0.665109087 1.065522912 106.5523 
55 0.55108182 0.882848118 88.28481 
56 0.739799998 1.18517979 118.518 
57 0.968872726 1.552160553 155.2161 
58 0.736945445 1.180606718 118.0607 
59 0.848936368 1.360019234 136.0019 
60 0.726718176 1.164222355 116.4222* 
61 0.727609093 1.165649627 116.565 
62 0.744336361 1.192447168 119.2447* 
63 0.766090908 1.227298545 122.7299 
64 0.798309093 1.278912958 127.8913* 
65 0.769827274 1.233284306 123.3284 
66 0.77927273 1.248416184 124.8416 
67 0.729054543 1.167965278 116.7965 
68 0.68872727 1.103359887 110.336 
69 0.694172724 1.112083651 111.2084 
70 0.970218182 1.55431601 155.4316 
71 0.612518175 0.981270836 98.12708 
72 0.770909087 1.2350174 123.5017* 
73 0.764745458 1.225143097 122.5143 
74 0.768218187 1.230706504 123.0707* 
75 0.734899998 1.177329856 117.733 
76 0.652163641 1.044783954 104.4784* 
77 0.826881826 1.324687256 132.4687 
78 0.582818183 0.933690638 93.36906 
Continuation from page 101 
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Sample Number 
Average A 490 2 - 22 
min linear range 
 
R atio against K pc-
positive control 
 
R elative %  
activity in 
comparison 
to K pc-
positive 
control 
79 0.769536365 1.232818262 123.2818 
80 0.683127273 1.094388538 109.4389 
81 1.092072731 1.749530324 174.953 
82 0.876345461 1.403929349 140.3929 
83 1.004709081 1.609571372 160.9571 
84 0.760381818 1.218152427 121.8152* 
85 0.674281819 1.08021788 108.0218 
86 0.760672737 1.218618488 121.8618 
87 0.951972718 1.525086278 152.5086 
88 0.889636365 1.42522174 142.5222 
89 0.670027272 1.073401979 107.3402* 
90 0.765445449 1.226264503 122.6265 
91 0.768681824 1.231449264 123.1449 
92 0.97350909 1.559588134 155.9588 
93 0.940027269 1.505949344 150.5949 
94 0.632163633 1.012743395 101.2743 
95 0.88874546 1.423794485 142.3794 
96 0.673409099 1.078819758 107.882 
97 1.040681806 1.66720066 166.7201 
98 0.778554542 1.247265628 124.7266* 
99 0.802754543 1.28603469 128.6035 
100 0.976545448 1.564452463 156.4452* 
101 0.796218195 1.275563281 127.5563 
102 0.771590916 1.236109708 123.611* 
103 0.772954545 1.23829428 123.8294 
104 0.919490923 1.473049556 147.305 
105 0.738954549 1.183825359 118.3825* 
106 0.809799991 1.29732169 129.7322 
107 0.806545453 1.29210783 129.2108 
108 1.086909094 1.741258036 174.1258* 
109 0.896536361 1.436275722 143.6276 
110 0.810845446 1.298996536 129.8997 
111 0.752799993 1.206006137 120.6006 
+ve control (K pc) 0.62420909 0.999512656 99.9513* 
-ve control (Ec) 0.00110000 0.461100000 46.1100 
= carrier of carbapenemase genes by PCR technique* 
Note: +ve control (K pc)= Klebsiella pneumoniae carbapenemase (NCTC 13438) positive 
control strain, -ve control (Ec)= Escherichia coli (ATCC 25922) negative control strain. All CR 
isolates indicating more than 46% were considered nitrocefin positive as this was the value 
recorded for the negative control. 
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Figure 3.3 T wo boronic acid-disc synergy tests on Mueller-Hinton agar plate 
Note: P= positive boronic-acid disc synergy test {A= meropenem disc + boronic acid (31mm), 
B= meropenem disc alone (24mm)} ; N= negative boronic-acid disc synergy test {C= 
meropenem disc + boronic acid (6mm), D= meropenem disc alone (6mm) 
 
 
3.3.5 Phenotypic and genotypic correlation of carbapenem-resistant isolates 
Of the 21 MHT positive isolates none were detected by BADST screen as positive. Out 
of these, 11.7% (13/111) were Acinetobacter baumannii CR isolates of which 7.2% 
were carbapenemase positive, followed by 4.5% for Pseudomonas aeruginosa and 1.8% 
for Klebsiella pneumoniae isolates. Surprisingly, there were only two Klebsiella 
pneumoniae positive OX A-48 producers (1.8%) and one positive NDM-1 Acinetobacter 
baumannii isolate (0.9%) detected by PCR-based assay. Carbapenemase resistance 
genes, V IM-1, K PC-1 and IMP-1 were undetected by MHT as carbapenemase-
producing isolates. A  correlation was observed between MHT positivity and PCR assay 
for OX A-48 gene positivity. The only remaining CR Klebsiella pneumoniae isolate 
showed negative result for MHT, BADST as well as K PC resistance gene in this study. 
There was no correlation between BADST positivity and PCR-based results (Table 3.5).  
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3.3.6 Distribution and prevalence of carbapenemase-producing genes 
Based on the PCR assay, 26/111 (23.4%) of genomic DNA extracts were carriers of 
PCR-positive carbapenemase genes of which 14.4% were blaNDM-1, 7.2%  blaV IM-1 
and 1.8% for blaOX A-48 genes. The highest prevalence was from Acinetobacter 
baumannii (9 NDM-1 positives) and Pseudomonas aeruginosa (2 NDM-1 and 7 V IM-
1), followed by Escherichia coli (3 NDM-1), Klebsiella pneumoniae (2 OX A-48), one 
V IM-1 for Pseudomonas putida isolate, and one each NDM-1 for Providencia stuartii 
and Shigella sonnei, respectively. No carbapenemase encoding genes were found in 
Enterobacter cloacae, Cronobacter sakazakii and Sphingomonas paucimobilis.  
 
In this study, females harboured more NDM-1 genes (Acinetobacter baumannii isolates) 
in ages between (3 days and 9 years) than the male counterparts in scattered age groups. 
However, more positive V IM-1 genes were detected in Pseudomonas aeruginosa 
isolates than any other strains from males between the ages of 50 and 59 years. None of 
the positive V IM-1 Pseudomonas aeruginosa isolates were detected from the female 
counterparts in all the year groups. Details of carbapenemase activity by phenotype-
based assays, distribution and prevalence of carbapenemase resistance genes are shown 
in Tables 3.5, 3.6 while Figures 3.4 and 3.5 depict carbapenemase resistance gene 
distribution in the four hospitals, age groups, both sexes and source of specimens among 
the CR isolates. Clearly, phenotype-based tests were less efficient in detecting 
carbapenemase activity considering the percentage sensitivity and specificity values 
when compared with the PCR-based assay results obtained in this study (Figure 3.5). 
The percentage values were calculated using Pasteran et al. (2010) calculation formulas 
described in Chapter 2, section 2.6.3.  
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T able 3.5 Distribution of presumptive carbapenemase producers in phenotypic 
and genotypic assays among carbapenem-resistant isolates 
Bacterial isolate Phenotypic test T ype of gene 
Organism CR  
total 
MHT  BADST  K PC-1 NDM-1 V IM-1 OX A-
48 
IMP-1 
P. 
aeruginosa 
51 5 - - 2 7 - - 
A. 
baumannii      
31 13 - - 9 - - - 
E . coli                    12 - - - 3 - - - 
P. putida              7 - - - - 1 - - 
K. 
pneumoniae       
3 3 - - - - 2 - 
E n. cloacae             3 - 3 - - - - - 
C. sakazakii           1 - - - - - - - 
P. stuartii                 1 - - - 1 - - - 
S. sonnei                1 - - - 1 - - - 
S. 
paucimobilis     
1 - - - - - - - 
T otal 111 21 3 - 16 8 2 - 
 
Note: - = not found  
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T able 3.6 Prevalence of carbapenemase resistance genes and the tested assays 
 
Carbapenem-resistant isolate (n)
a
 
 
Number (%) by: 
 
MHT (n=21) 
 
b
BADST (n=3) 
 
PCR amplification 
assay Carbapenemase genes (26)  SE SP SE SP 
NDM-1 (16) (6.3)
c 
(78.9) (0) (0) 16 (100) 
V IM-1 (8) (0) (79.6) (0) (0) 8 (100) 
OX A-48 (2) (100)
d 
(82.6) (0) (0) 2 (100) 
IMP-1 (0) (0) (0) (0) (0) 0 (0) 
K PC-1 (0) (0) (0) (0) (0) 0 (0) 
 
a 
Total number of CR isolates (111) 
b 
None was detected by PCR assay 
c 
Only MHT positive (n=1) was detected by PCR assay 
d
 A ll MHT positives (n=2) were detected by PCR assay 
 
Note: MHT= modified Hodge test, BADST= boronic acid-disc synergy test, n= number, 
SE= sensitivity, SP= specificity 
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F igure 3.4 Distribution of carbapenemase resistance genes among hospitals and type of specimens  
Note: n= total number, K BTH, GA/R= K orle Bu Teaching Hospital, Greater Accra Region; ENRH, W/R= Effia-Nkwanta Regional Hospital, Western 
Region; AGAMH, A/R= AngloGold Ashanti Mines Hospital, Ashanti Region; HRH, V /R= Ho Regional Hospital, V olta Region 
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F igure 3.5 Distribution of carbapenemase-positive genes in both sexes, among age groups and carbapenem-resistant isolates  
 
Note: Despite the differences in CR isolates, source of specimens and demographic information obtained from the four hospitals studied, one of the 
carbapenemase resistance genotypes was detected in each hospital in this study (Figures 3.4. and 3.5) 
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3.3.7 Analysis of outer membrane proteins by SDS-PAGE  
All CR extracted samples were performed as described in Chapter 2, sections 2.7.11.1 
and 2.7.11.2. The isolated fractions were subjected to SDS-PAGE investigations 
(Section 2.7.11.3) to observe the differences of protein profiles. In all, the levels of 
outer membrane proteins were varied because of diverse CR isolates studied. A  study 
conducted on the OMPs of Pseudomonas aeruginosa strain by Hancock and Brinkman 
(2002) was adapted and used (Table 3.7) for the analysis of this study.  
 
T able 3.7 Important outer membrane proteins of Pseudomonas aeruginosa strain 
 
Gene Protein function and name Number of 
AAs 
K nown 
porin (class)
a
 
OprC  Putative copper transport porin OprC 723 GP 
OprD Basic amino acid, basic peptide and imipenem 
porin OprD; also named Porin D, Protein D2 
443 SP, P 
OprF  Major porin and structural porin OprF; Porin F 350 P 
OprG Outer-membrane protein OprG 232  
OprH PhoP/Q and low Mg
2+
-inducible outer-
membrane protein H1 
200 GP 
OprI Outer-membrane lipoprotein OprI 83 EP 
OprJ  Multidrug efflux protein OprJ  479 EP 
OprM Major intrinsic multiple antibiotic resistance 
efflux protein OprM 
485 EP 
(Adapted from Hancock and Brinkman 2002) 
a
P, general porin; SP, specific porin; GP, putative gated porin; EP, OprM family member of 
efflux and protein secretion porins  
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In support of Hancock and Brinkman (2002), a recent study by Sugawara and Nikaido 
(2012) explicitly described that the major proteins in the outer membrane of 
Acinetobacter baumannii (not in the high-permeability trimeric porin group) relates to 
Escherichia coli OmpF/OmpC and shares close homology with Pseudomonas 
aeruginosa OprF and Escherichia coli OmpA (Sugawara and Nikaido 2012). In this 
study, in-house Pseudomonas aeruginosa control strains from the Sheffield Hallam 
University (SHU) collection, MBL-positive (SHU: 2048, V IM positive) and wild-type 
MBL-negative (SHU: 2054, V IM negative) isolates were used alongside the 111 
isolates identified to analyse various expression of porins, specifically OprD and OprF 
in all the CR isolates on SDS-PAGE (Tables 3.8, 3.9 and 3.10).  
 
Of the control strains, the wild type showed absence of porin band (~44 kDa) on SDS-
PAGE (Figure 3.6) and was compared with the CR isolates on SDS-PAGE which 
expressed different OMP levels (Figure 3.7 and Appendix 3). The important OMPs for 
Pseudomonas aeruginosa isolate including imipenem-resistance determinant porin 
OprD in addition to OprM/J , OprF and OprH/G are shown in Table 3.8. Of the 51 CR 
Pseudomonas aeruginosa isolates, 48 (94.1%) reduction or loss of OprD was observed, 
including the V IM-1 carbapenemase positive-producers while 3 with moderate to high-
level of porin expression were observed. For the 31 Acinetobacter baumannii isolates, 
30 (96.8%) showed significantly diminished OmpA or OprF porin expression (Table 
3.9), which is similar to the OprF of Pseudomonas aeruginosa isolate. Similar analysis 
of OMPs in the Enterobacteriaceae group (Table 3.10) confirmed that the two OX A-48 
positive Klebsiella pneumoniae isolates were deficient of a major 35-kDa OmpC, the 3 
Enterobacter aerogenes and 10 Escherichia coli isolates lacked a major 37-kDa OmpF, 
and the 2 Escherichia coli isolates had decreased expression of a major 37-kDa OmpF, 
which is also highly similar to Pseudomonas aeruginosa OprF. For all the CR isolates, 
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a detailed analysis of major porins in relation to carbapenem MIC levels is shown in the 
Appendix 4. 
 
 
F igure 3.6 Outer membrane proteins of control strains and selected carbapenem-
resistant isolates on SDS-PAGE   
Note: M= protein marker in kDa; C1= Control SHU 2048 V IM positive Pseudomonas 
aeruginosa strain; C2= Control SHU 2054 MBL negative Pseudomonas aeruginosa strain; 68-
87 & 105= selected samples; OprM/J  (48/49kDa)= major intrinsic multidrug efflux proteins; 
OprD (44kDa)= specific for β-lactam imipenem resistance; OprF  (35kDa)=  major porin for 
structural stabilisation of peptidoglycan; OprH/G (22/23kDa)= polycationic antimicrobial 
uptake and putatively in iron uptake. Band corresponding to OprD in C2 strain is showing a 
reduced or loss of expression 
 
 
113 
 
T able 3.8 Analysis of outer membrane proteins among Pseudomonas isolates on 
SDS-PAGE  
Isolate 
code 
Name of isolate Common outer membrane proteins of 
importance 
OprM/J  OprD OprF  OprG/H 
1 P. aeruginosa + +++ ++ + 
3 P. aeruginosa - + - - 
6* P. aeruginosa - + - - 
7* P. aeruginosa - - - - 
10 P. aeruginosa - - - - 
12* P. putida - - - - 
13 P. aeruginosa - - - - 
14 P. aeruginosa - - + - 
15 P. aeruginosa - + + + 
16 P. aeruginosa - + ++ + 
17 P. aeruginosa - - - - 
21 P. aeruginosa - - + - 
24 P. aeruginosa - - + - 
25 P. aeruginosa - - + - 
26 P. aeruginosa - - - - 
28 P. aeruginosa - + +++ + 
31 P. aeruginosa - + - - 
32 P. aeruginosa - - + - 
37 P. aeruginosa - + - + 
39* P. aeruginosa - - - - 
40 P. aeruginosa - + + - 
41 P. aeruginosa - + - - 
44 P. putida - - - - 
47* P. aeruginosa - - - - 
48 P. aeruginosa - - + - 
52 P. aeruginosa - - - - 
54 P. aeruginosa - - - - 
57 P. aeruginosa - - - - 
58 P. aeruginosa - - - - 
59 P. aeruginosa + ++ ++ - 
60* P. aeruginosa - + - - 
61 P. aeruginosa - - - - 
62* P. aeruginosa - + - - 
63 P. aeruginosa - - - - 
65 P. aeruginosa - - - - 
66 P. aeruginosa - - - - 
70 P. aeruginosa - + - + 
71 P. aeruginosa - + - + 
74* P. aeruginosa - - ++ + 
78 P. putida + - - - 
79 P. aeruginosa + - ++ - 
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Isolate 
code 
Name of isolate Common outer membrane proteins of 
importance 
OprM/J  OprD OprF  OprG/H 
80 P. aeruginosa - - - - 
81 P. aeruginosa +++ - +++ + 
83 P. putida + ++ - - 
84* P. aeruginosa - - - - 
86 P. aeruginosa + - +++ + 
87 P. aeruginosa - - ++ - 
88 P. putida + - - - 
90 P. putida - - - - 
92 P. putida - - - - 
96 P. aeruginosa - - - - 
99 P. aeruginosa ++ ++ +++ +++ 
100* P. aeruginosa - - + - 
101 P. aeruginosa - - - - 
104 P. aeruginosa - + - - 
109 P. aeruginosa - + - - 
110 P. aeruginosa + + +++ - 
111 P. aeruginosa + + +++ - 
* Carrier of carbapenemase genes by PCR assay 
Note: +++= high level of protein, ++= moderate level of protein, += low/reduced level of 
protein, -= no amount of protein 
 
 
 
 
 
 
 
 
 
Continuation from page 113 
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T able 3.9 Analysis of outer membrane proteins among isolates of Acinetobacter 
baumannii on SDS-PAGE  
Isolate 
code 
Name of isolate Common outer membrane proteins of 
importance 
OprM/J  OprD OprF
a
 OprG/H 
4 A. baumannii - - - - 
8 A. baumannii - - - - 
20 A. baumannii - - - - 
22 A. baumannii - - - - 
27* A. baumannii - - - - 
29 A. baumannii - - - - 
30 A. baumannii - - - - 
34 A. baumannii - - - - 
36 A. baumannii - - - - 
38 A. baumannii - - - - 
42* A. baumannii - + - - 
43* A. baumannii - - - - 
45 A. baumannii - - - - 
46* A. buamannii - - - - 
49 A. baumannii - - - - 
50* A. baumannii - - - - 
51 A. baumannii - - - - 
56 A. baumannii +++ ++ ++ - 
64* A. baumannii - - - - 
69 A. baumannii + - - - 
72* A. baumannii - - - - 
73 A. baumannii - - - - 
75 A. baumannii - - - - 
77 A. baumannii - - - - 
82 A. baumannii - + - - 
94 A. baumannii - - - - 
102* A. baumannii - - - - 
103 A. baumannii - + - - 
106 A. baumannii - + - + 
107 A. baumannii - - - - 
108* A. baumannii - + - + 
Carrier of carbapenemase genes by PCR assay* 
a
 OprF in Pseudomonas isolate is synonymous to OmpA in Acinetobacter baumannii  
Note: +++= high level of protein, ++= moderate level of protein, += low/reduced level of 
protein, -= no amount of protein 
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T able 3.10 Analysis of outer membrane proteins among the E nterobacteriaceae 
isolates on SDS-PAGE  
Isolate 
code 
Name of isolate Common outer membrane proteins of 
importance 
OprM/J  OprD OprF
a
 OprG/H 
2* E. coli +++ + - - 
5* E. coli + + - - 
9 C. sakazakii - - - - 
11 S. paucimobilis - - - - 
18 E. coli - - - - 
19* K.  pneumoniae - - - - 
23 E. coli - - - - 
33 En. cloacae - - - - 
35 E. coli - - - - 
53 E. coli - - - - 
10 K. pneumoniae - - - - 
67 E. coli - - - - 
68 E. coli ++ +++ - + 
76* P. stuartii ++ - - + 
85 E. coli ++ +++ - + 
89* S. sonnei - - - - 
91 En. cloacae - - + - 
93 E. coli - - + - 
95 En. cloacae + + + + 
97 E. coli - - - - 
98* K.  pneumoniae - - - - 
105* E. coli ++ +++ - + 
Carrier of carbapenemase genes by PCR assay* 
 
 
a 
OprF in Pseudomonas isolate is synonymous to OmpC/F  
Note: +++= high level of protein, ++= moderate level of protein, += low/reduced level of 
protein, -= no amount of protein 
 
3.3.8 Sequenced data and phylogenetic analysis of carbapenemase positive genes  
The sequence data obtained from Eurofins Genomics (Ebersberg, Germany) of the three 
different carbapenemase genes (OX A-48, V IM-1 and NDM-1) identified in this study, 
including controls, were searched for their corresponding nucleotide homologies using 
BLAST available at the National Centre for Biotechnology Information (NCBI) website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequences were evaluated against known 
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sequences which yielded >97% identity with previously characterised CR bacteria in the 
GenBank database.  
 
3.3.9 Phylogenetic relationships of carbapenemase genes 
Phylogenetic trees were constructed using the Neighbor-Joining technique (Saitou and 
Nei 1987), where evolutionary history and taxa were taken from 500 replicates to 
prepare the bootstrap consensus tree confidence limits (Felsenstein 1985). Less than 
50% of the replicates collapse and conform to divisions of the corresponding branches. 
The developed distances were measured using the maximum composite likelihood 
(MCL) technique (Tamura, Nei and K umar 2004) and calculated in units of the number 
of base substitutions per position. The phylogenetic trees were generated using 
sequenced data of 19 nucleotides for OX A-48, 16 for V IM-1, and 30 for NDM-1 in the 
analysis. Codon sites included were first + second + third and noncoding areas. 
Indistinct and ambiguous sites were removed for each sequence pair. There were 326, 
392 and 447 sites for OX A-48, V IM-1 and NDM-1, respectively, and the data were 
analysed using molecular evolutionary genetics analysis software version 6 (MEGA6) 
(Tamura et al. 2013). Details of the phylogenetic relationships are shown in Figures 3.7, 
3.8 and 3.9.  
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Figure 3.7 Phylogenetic trees for OX A-48 positive gene with OX A-48 genes of 
known sequenced organisms  
Note: ‘O’ attached to isolate number depicts OX A-48, Red= OX A-48 carriers from Ghana, 
Green= control strain NCTC 13442 (OX A-48 +ve) Klebsiella pneumoniae strain, Uncoloured= 
established GenBank strains. Clusters of Ghanaian OX A-48 positive Klebsiella pneumoniae 
isolates are unique which have no link when compared with the cluster-grouped strains from the 
GenBank. 
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F igure 3.8 Phylogenetic trees for V IM-1 positive gene with V IM-1 genes of known 
sequenced organisms 
Note: ‘V ’ attached to isolate number depicts V IM-1, Red= V IM-1 carriers of carbapenemase 
gene from Ghana, Green= V IM-1 (NCTC 13439) Klebsiella pneumoniae control strain, 
Uncoloured= established GenBank strains. Clusters of Ghanaian V IM-1 positive Pseudomonas 
isolates are unique and have no link when compared with the cluster-grouped strains from the 
GenBank 
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F igure 3.9 Phylogenetic trees for NDM-1 positive gene with NDM-1 genes of 
known sequenced organisms  
Note: ‘N’ attached to isolate number depicts NDM-1 gene, Red= carriers of carbapenemase 
gene from Ghana, Uncoloured= established GenBank strains. Clusters of diverse isolates from 
Ghana indicating NDM-1 gene carriers are unique and have no link when compared with the 
cluster-grouped strains from the GenBank  
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3.4 Discussion 
 
Regrettably, to date not a single search study for the detection of carbapenemase 
resistance genes has been performed in Ghana, despite World Health Organisation 
awareness campaign launched in 2011 for member-countries to curb antimicrobial 
resistance (WHO 2015). This study sought to quantify the presence, prevalence and 
distribution of carbapenemase producers, and to find out the types of carbapenemase 
genes emerging among the CR isolates from four selected hospitals for the first time in 
Ghana. 
 
To date, no reference studies have been carried out on carbapenemase producers in 
Gram-negative bacteria in Ghana, even in the most recent laboratory-based nationwide 
study on antimicrobial resistance (Opintan et al. 2015). Lack of interest or opportunity 
due to logistical problems which constantly persist when carrying out molecular 
research, non-availability of common tools, reagents, control strains and primers are 
some of the difficulties that discourages researchers. Nonetheless, comparable 
molecular studies have been extensively carried out in Ghana, mostly hospital-based 
research studies on clonal lineage of serogroup B Salmonella by PCR using 
enterobacterial repetitive intergenic consensus (ERIC) technique and repetitive element 
(REP)-PCR and also a detection of mecA gene in methicillin-resistant Staphylococcus 
aureus isolates (Mills-Robertson et al. 2003, Egyir et al. 2014).  
 
This study had an overall carbapenem-resistant prevalence of 2.9% (111 of 3840) from 
total Gram-negative bacterial pathogens while 23.4% (26/111) of the CR isolates were 
PCR positive for known carbapenemase genes. It is worth noting that carbapenem 
antimicrobials are excluded from the Ghana Ministry of Health essential drug list 
(Ghana Essential Medicines List 2010) following strict adherence to antimicrobial 
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usage policy. However, the effectiveness of meropenem and its extended use for 
children was later recommended for patients in hospitals with serious infections. 
Presumably, the low-level usage of carbapenems may have contributed to this 
remarkably low prevalence rate of resistance in the country’s hospitals. The present 
overall prevalence rate of carbapenem resistance was extremely low when compared 
with a similar study in tertiary hospitals in Nigeria where, 5.5% (10/182) 
carbapenemase-producers were carrying recognised carbapenemase genes (Ogbolu and 
Webber 2014), mainly, MBL carbapenemases (OX A-48 and K PC genes among 
Enterobacteriaceae group were not detected).  
 
With the enforcement policy on antimicrobial usage without prescription in the country, 
this present study reported much higher carbapenem resistance with the disc diffusion 
susceptibility testing than expected. The highest carbapenem resistance was 100% to 
both meropenem and doripenem in five different CR isolates (Klebsiella pneumoniae, 
Enterobacter cloacae, Cronobacter sakazakii, Shigella sonnei and Sphingomonas 
paucimobilis) and 90.3% only to imipenem for Acinetobacter baumannii isolates. 
Resistance to the three carbapenems (imipenem, meropenem and doripenem), 85.7% for 
Pseudomonas putida and 82.3% for Pseudomonas aeruginosa isolates were observed. 
Within the CR isolates studied, only Escherichia coli CR isolates that showed the 
lowest prevalence in the phenotypic resistance, 75% for doripenem, 66.7% for 
meropenem and 58.3% for imipenem. Similarly, previous studies on carbapenem 
resistance in two separate areas showed substantially decreased rates, 9.3% (Akinduti et 
al. 2012) and 40.0% (Motayo et al. (2013) carried out within the boundaries of 
unregulated usage of antimicrobials in Nigeria.  
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In MIC E-test assays, 56.8% of CR isolates showed complete resistance to imipenem, 
meropenem and ertapenem at ≥32 µ g/ml, of which 24.3% were found in Pseudomonas 
aeruginosa isolates and 18.9% in Acinetobacter baumannii isolates. Ertapenem 
resistance of 2.7% was for carriers of carbapenemase-producing genes in 
Enterobacteriaceae isolates but all were susceptible in vitro to meropenem.  The 
findings confirmed the Anderson et al. (2007) observation that in vitro ertapenem 
resistant strains may remain susceptible to other carbapenems (Anderson et al. 2007). 
However, for non-fermenting strains coded with carbapenemase genes, 14.4% 
ertapenem resistance was found to be susceptible in vitro than to imipenem in this 
study. 
 
In this present study, sensitivity and specificity of phenotype based tests (MHT and 
BADST) showed no corresponding results with the molecular assay (PCR-based) 
employed (see Table 3.6). Determination was calculated using the formulas (Section 
2.6.3) in Chapter 2 designed by Pasteran et al. (2010) to evaluate the reliability of MHT 
and BADST when compared with the PCR-based results obtained for carbapenemase 
resistance genes (Table 3.5). Thus, the MHT method performed poorly with the 
calculation for Class B MBL-containing isolates. However, a 100% sensitivity score for 
serine type (OX A-48) was confirmed by PCR assay. There was only MHT positivity for 
two OX A-48-producing Klebsiella pneumoniae isolates and one NDM-1-producing 
Acinetobacter baumannii (metallo-β-lactamase type). Though, no K PC-1-producing 
isolate was detected to evaluate sensitivity of MHT technique. Sensitivity for NDM-1 
was only 6.3%. This is consistent with previous studies by Nordmann, Naas and Poirel 
(2011) and Doyle et al. (2012) who confirmed low sensitivity rates of less than 12% for 
MBL detection, partly due to false-positivity as a result of ESBLs co-existing with porin 
loss in association of pAmpC mimicking carbapenemase activity. Previous studies by 
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Galani et al. (2008) and Hara et al. (2013) also confirmed MHT was unable to detect 
weak V IM and NDM carbapenemase genes, however, the majority of V IM-1 and 
NDM-1-producing genes were detectable in Pseudomonas aeruginosa and 
Acinetobacter baumannii CR isolates, respectively (Galani et al. 2008, Hara et al. 
(2013). Due to differences within the continent of Africa, high prevalence rates of 
carbapenemase activity have been reported in some African countries when the MHT 
method was used, 33.5% in Nigeria (Y usuf et al. 2012) and 22.4% Uganda (Okoche et 
al. 2015) compared with low prevalence of 2.8% observed during an outbreak situation 
in a Moroccan hospital (El Wartiti et al. 2012). Currently, the MHT technique is 
considered a first line phenotype-based test for investigating carbapenemase producers 
where six to eight organisms can be evaluated simultaneously on a 90 mm Mueller-
Hinton agar plate. In low income countries, the method may be used as initial test for 
phenotypic screening of OX A-48-like activity in suspected Klebsiella pneumoniae CR 
isolates as confirmed in this study before more specific method can be employed for 
detection of carbapenemase activity.  
 
The positivity, sensitivity and specificity of boronic acid-based inhibition testing 
showed limited correlation with the PCR assay results. Pasteran et al. (2009) and 
Tsakris et al. (2009) described the boronic acid test as the most specific and sensitive 
(with meropenem and imipenem discs) for detection of K PC in Klebsiella pneumoniae 
isolates, only when the corresponding organisms existed without the presence of AmpC 
β-lactamase enzyme (Pastern et al. 2009, Tsakris et al. 2009). The inconsistency could 
have come from the presence of metallo-β-lactamases in strains harbouring AmpC genes 
(ACC, CIT, DHA, EBC, FOX  and MOX ) which according to Hara et al. (2013) are 
largely undetectable by MHT and BADST techniques. Helmy and Wasfi (2014) 
described the overall sensitivity and specificity of 65% and 74% respectively for 
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boronic acid tests which is considered relatively low for detection of AmpC β-
lactamases in isolates from urinary tract infections. However, to improve phenotypic 
detection rate of AmpC enzymes, Helmy and Wasfi (2014) suggested the use of AmpC 
disc test and inhibitor-based test with the use of cloxacillin while Woodford et al. 
(2014) recommended temocillin MIC test for OX A-48-like enzymes. Another method 
which could have phenotypically helped in detection of Class A  and B MBL enzymes 
was the use of Carba NP (Dortet, Poirel, Nordmann 2012b), though, prior to this study 
the test reagents were not available for use to improve the rates of detection.  
 
In all, the study detected most of the CR bacterial resistance to carbapenems from 
wound 47/111 (42.3%) and urine 31/111 (27.9%) samples. Though, the encoding genes 
were unevenly distributed among seven pathogens, Acinetobacter baumannii and 
Pseudomonas aeruginosa isolates were in the majority (Figure 3.5). The magnitude of 
resistance to carbapenems among Gram-negative bacteria including Pseudomonas 
aeruginosa and Acinetobacter species is increasing in numbers worldwide and studies 
have shown several acquired infections from these organisms in recent times 
(Saranathan et al. 2014, Mathlouthi et al. 2015). 
 
In this study, only 21.6% of the CR isolates were confirmed as Class B carbapenemases 
(NDM-1 and V IM-1 genes) from non-fermenting organisms, Pseudomonas aeruginosa 
and Acinetobacter baumannii in Ghanaian hospitals. Interestingly, in the age group 
categories a trend was observed for both the CR isolates and carbapenemase-encoding 
genes. The age group from 3 days to 9 years were found to be harbouring relatively high 
numbers of NDM-1 encoding gene in Acinetobacter baumannii isolates, mainly in 
females while in the male counterparts two age groups were observed with a greater 
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prevalence; 3 days to 9 years and 50 to 59 with higher prevalence of V IM-1-encoding 
genes in Pseudomonas aeruginosa isolates (Figure 3.5). Accordingly, the distribution of 
carbapenemase producing organisms based on sex, the females recorded significant rise 
for NDM-1 gene in Acinetobacter baumannii when compared with the males having 
reduced number in Pseudomonas aeruginosa each for NDM-1 and V IM-1 genes, 
respectively. However, much higher values were observed in recent study, 26.9% in 
males and 23.3% for females based on sex distribution assessment of MBLs in Nigeria 
(Y usuf et al. 2013).  
 
Furthermore, a European surveillance study reported carbapenem resistance of 23.4% in 
Pseudomonas aeruginosa and 20.4% in Acinetobacter species (Zarb 2012), while in an 
earlier worldwide study by Sacha et al. (2008) found a multitude of class B 
carbapenemases in only Pseudomonas aeruginosa isolates. In contrast, Class B gene 
prevalences of 9.9% and 4.5% were significantly higher for NDM-1 and V IM-1 
according to this study, from wound swabs, while only 3.6% and 1.8% was observed 
from urinary specimens for both genes, respectively. Of all the clinical specimens, 
wound, urine, sputum, aspirates and stool pathogens showed a considerable amount of 
carbapenemase activity in both phenotype- and genotype-based investigations, while no 
carbapenemase presence was detected in isolates from cerebrospinal fluid, ear, catheter 
tip, vaginal and eye samples. Though, other studies reported different pathogens from 
urine where considerably higher numbers of Class B genes were detected, 27% in 
France (Nordmann et al. 2009), 91.7% in India (Deshpande et al. (2010) and in Nigeria 
55% was observed only in Pseudomonas aeruginosa isolates raising the threat of these 
resistance genes (Y usuf et al. 2013). More recent studies have also shown Class B genes 
(mainly V IM and IMP) have a similar prominence, 33% of Pseudomonas aeruginosa 
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harboured blaV IM gene in Iranian hospital (Aghamiri et al. 2014) while 36% of 
Acinetobacter baumannii carried blaIMP-1 gene in India (Saranathana et al. 2014).  
 
The first ever OX A-48 producing strains to be detected in Ghanaian hospitals were from 
Effia-Nkwanta Regional hospital in the Western region and AngloGold Ashanti Mines 
hospital in the Ashanti region of Ghana according to this study. OX A-48 gene was first 
detected in Turkey in 2004 and had since spread to Middle East and beyond (Carrër et 
al. (2010) including European countries such as Belgium (Cuzon et al, 2008), France 
(Cuzon et al, 2011) and the Netherlands (K alpoe et al, 2011). This study observed 
OX A-48 encoding genes in two Klebsiella pneumoniae isolates from a female patient 
aged 37 years and a 45 year old male patient with wound and sputum infections 
respectively. A  study carried out in Senegal identified the emerging danger of OX A-48 
genes in their hospitals and community attributed to movement of the same major 
OX A-48 encoding plasmid spreading across the borders of A frica and the Middle East 
(Moquet et al. 2011). Notably, none of the CR isolates from Ghana, Pseudomonas 
aeruginosa and Acinetobacter baumannii which showed imipenem resistance were 
positive for OX A-48 encoding gene.  
 
Interestingly, no IMP-1 and K PC-1 genes were detected from Ghanaian CR strains. 
Detection of IMP-1 producing genes in Africa have been described as rare since its 
presence have been exclusively and predominantly observed in China, J apan, and 
Australia (Pitout, Nordmann and Poirel 2015). A study by Lee et al. (2014) suggested 
that success of blaK PC spread depended on certain clones of plasmids particularly 
suited to Klebsiella pneumoniae isolates than in other Gram-negative bacterial 
pathogens. The occurrence was demonstrated to ascertain the peculiar characteristics on 
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ancestral plasmids that existed among the ST258 strains following transposition and 
insertion of K PC gene. Nonetheless, Klebsiella pneumoniae isolates in K orea with 
similar multidrug resistant types from Italy and the USA were observed as good 
vehicles for K PC-encoding genes (Lee et al. 2014). Another review on molecular 
epidemiology of K PC-producing genes reported that extensive recovery were detected 
only in Klebsiella pneumoniae (Munoz-Price et al. 2013) and findings have also been 
confirmed in a recent study describing Klebsiella pneumoniae as the most influential 
species, in its ability to cause antimicrobial resistance and swiftly disseminate (Pitout, 
Nordmann and Poirel 2015). In this present study, there were only 3 Klebsiella 
pneumoniae CR isolates in which 2 were found to be positive for OX A-48 gene. 
 
Prior to this study, there was strong expectation for K PC-1 gene detection from the 
collection of Gram-negative bacterial pathogens following the revelation expressed by 
Chen, Anderson and Paterson (2012) that K PC-encoding genes in particular, were 
highly mobile, diverse and K PC-producing strains may spread within hospitals as well 
as in the community environment (Chen, Anderson and Paterson 2012). Apart from 
being the first to be detected almost two decades ago, its spread has been long expected 
across Africa and Australia. The dissemination has been extremely slow due to location 
differences, limited travels and also with contrasting epidemiological patterns in these 
regions (Chen, Anderson and Paterson 2012). These assertions have been confirmed in 
an earlier review, which attributed the spread largely through importation of K PC 
resistance genes through frequent international travels and those seeking medical 
attention abroad. Importation of carrier isolates has been critical in the dissemination of 
K PCs after its recovery in 1996 across USA and the world at large (Munoz-Price et al. 
2013).  
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Importation of resistance genes has been observed in a few countries in North and South 
Africa where tourists and migrants travel from abroad for excursions and also seek 
special medical attention. These countries yearly experienced a number of visits from 
abroad in the form of tourism and other recreational activities. In this regard, the impact 
of K PC spread in such countries in Africa has not risen to appreciable heights reflected 
in the importation pattern, especially in South Africa (Brink et al. 2012), Egypt 
(Metwally et al. 2013) and Tanzania (Mushi et al. 2014).  
 
Ghana’s position on the continent of Africa, south of the Sahara, attracted limited 
number of people traveling in groups for international tourism and foreigners coming in 
from abroad to seek medical attention. Notwithstanding, other risk factors such as 
unregulated, frequent exposure to antimicrobials most especially selective use of 
carbapenems may have existed in the country. In this present study, regardless of the 
low number of Klebsiella pneumoniae CR isolates obtained, equally important Gram-
negative bacterial pathogens including non-fermenters, Acinetobacter baumannii and 
Pseudomonas species could have acquired K PC-1 resistance genes. However, no single 
detectable strain was harbouring the K PC-1 gene. Several of these K PCs have been 
reported within this Gram-negative population in other countries (V illegas et al. 2007, 
Sacha et al. 2009, Robledo et al. 2011).  
 
According to Manenzhe et al. (2014) detection of carbapenemase resistance genes has 
been poorly reported in Africa. Studies compiled from numerous articles both published 
and non-published from databases across Africa revealed prevalence levels of 
carbapenemase producers in hospitals ranged from 9% to 60% in sub-Saharan Africa 
with no surveillance data assessment from Ghana and 2.3% to 67.7% in North Africa 
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(Manenzhe et al. 2014). Compared with surveillance studies outside Africa, several 
rates of carbapenemase producers have been reported ranging from less than 1% for 
more than twenty countries in Europe including Germany (Poirel et al. 2011a, Ehrhard 
et al. 2014) and Spain (Miro et al. 2013), 1.3% in Italy, 17% in Cyprus, with much 
higher levels recorded in Greece 43.5% (Poirel et al. 2011a). China has prevalence rate 
of 33.3% with mainly NDM-1-producing CRE (Qin et al. 2014). 
 
The significance of ESBL-types of β-lactamases and differential expression of porins 
served as a pacesetter for carbapenem resistance in many Gram-negative bacterial 
pathogens. In achieving resistance, two major mechanisms are responsible; horizontal 
transfer of plasmid-borne genes and mutation or disruption due to modification of 
existing genes within the organism. Additionally, non-enzymatic factors such as efflux 
pump systems seemed to have combinatorial interactions with plasmid β-lactamases to 
effect high-level of resistance (Peleg and Hooper 2010, Robledo, Aquino and V azquez 
2011). This is in agreement with this present study, where all the CR isolates were 
found to express β-lactamase activity.  
 
The use of SDS-PAGE indicated different expression of porins for all CR isolates 
investigated. Predominantly, reduction of OMPs was detected largely among the 
Pseudomonas aeruginosa and Acinetobacter baumannii isolates which formed the 
majority of the CR isolates. The SDS-PAGE analysis in comparison with the high-level 
β-lactamase activity results by nitrocefin assay, reduced susceptibility by disc diffusion 
method and various levels of carbapenem MICs may have significantly affected the 
detection of large number of carbapenemase non-PCR positives. Notably, three 
Enterobacter cloacae isolates were among the few Enterobacteriaceae isolates including 
each strain of Cronobacter sakazakii and Sphingomonas paucimobilis also expressed 
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presence of β-lactamase activity, high-level carbapenem MICs and reduced porin levels 
in this study. High numbers of carbapenemase negative isolates, according to PCR 
assay in this present study have β-lactam hydrolysing activity and that may be due to the 
presence of an unknown carbapenemase, an AmpC or a coincidental non-
carbapenemase β-lactamase. The findings are in agreement with Thomson (2010) that 
false positive results are possibly due to AmpC producers, commonly with reduced 
susceptibility to imipenem than with other carbapenems (Thomson 2010). 
 
The analysis of the outer membrane proteins (OMPs) on SDS-PAGE of all the CR 
isolates were specifically compared with Pseudomonas aeruginosa control strains with 
or without OprD (~44 kDa) expression which affects the susceptibility to carbapenems. 
In this study, OMPs of the Pseudomonas aeruginosa isolates produced decreased 
amounts of OprD or the porin was completely lost, except the 5.9% (3 out of 51) with 
high-level of porin. The majority of the isolates which had loss of porins were among 
the presumptive carbapenemase non-PCR positives. It is worth mentioning here that the 
effect of OprD reduction or loss could be one of the mechanisms that explain the ease 
with which Pseudomonas aeruginosa is known to become resistant. High-level 
production of β-lactamase activity by nitrocefin assays were prevalent in all the CR 
isolates studied. The effect and presence of these non-plasmid determinant enzymes 
may contribute significantly to carbapenem resistance coupled with the loss of OprD 
gene (Mathlouthi et al 2015). Essentially, in most MDR Pseudomonas aeruginosa 
isolates chromosomally encode resistance mechanisms in association with 
hyperexpression of AmpC, overproduction of the MexAB efflux system or both without 
harbouring carbapenemase resistance gene which could inactivate the OprD gene. The 
effect of these resistance mechanisms and with the presence of β-lactamase enzymes 
may have resulted in the high number of carbapenemase non-PCR positives. According 
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to Y ang et al. (2012) porins play a significant role in increasing Gram-negative bacterial 
resistance to carbapenem antimicrobials, importantly, presence of ESBL  or AmpC type 
enzymes is an essential element for resistance among Enterobacteriaceae group and 
non-fermenting Pseudomonas species (Y ang et al. 2012). This recognition was also 
observed in CR isolates in this present study. Thus, all the 7 V IM-1-producing 
Pseudomonas aeruginosa isolates were carriers of TEM-1 and SHV -1 enzymes, 6 
carbapenemase non-PCR positives out of 7 Pseudomonas putida isolates including the 
only V IM-1-positive isolate had reduced OprD or loss of porin by the SDS-PAGE 
assessment in this study. Pirnay et al. (2002) emphasised that the major determinant of 
resistance to imipenem particularly, in Pseudomonas aeruginosa isolates in the absence 
of MBL could be due to mutational change of the oprD gene (Pirnay et al. 2002). It is 
worth noting that most Pseudomonas aeruginosa carbapenemase non-PCR positives, 
including other CR isolates, showed decreased production of oprD gene which could be 
mutation-driven resistance. This phenomenon was observed on the electrophoretic 
patterns of the SDS-PAGE analysis with a reduction or loss of outer membrane porin D.  
 
A  recent study by Fusté et al. (2013), also on multidrug-resistant Pseudomonas 
aeruginosa isolates, revealed a similar reduction of the OprD, the main uptake of 
carbapenems (Fusté et al. (2013), while in another study in a Brazilian hospital by 
Cavalcanti et al. (2015) markedly reduced expression of OprD was observed in MBL-
negative Pseudomonas isolates. This is in agreement with this present study, which has 
demonstrated that OprD loss and V IM-1 production could be one of the possible 
mechanisms emerging in MBL negative-PCR Pseudomonas aeruginosa isolates from 
Ghanaian hospitals. 
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For Acinetobacter baumannii isolates, 96.8% (30 out of 31) expressed loss of OprF in 
Acinetobacter baumannii isolates which included the NDM-1-positive producers. One 
carbapenemase non-PCR positive isolate with high-level expression of porin in this 
present study was observed and the mechanism of resistance remains unclear. It should 
be mentioned that the selectivity of the outer membrane permeability barrier is different 
for organisms such as Acinetobacter species or Pseudomonas aeruginosa compared 
with those in the Enterobacteriaceae group. The OmpAb of ~40 kDa, an outer 
membrane protein of Acinetobacter baumannii accounts for approximately 30-40% of 
the total OMPs (J yothisri, Deepak and Rajeswari 1999) as compared with that of 
Pseudomonas aeruginosa. Li, Plésiat and Nikaido (2015) emphasised that these 
organisms do not produce the classical Escherichia coli-type trimeric porins that 
provide an increased influx of small drugs. The main nonspecific porin in these 
organisms is a homology of Escherichia coli OmpA, it functions by adding structural 
fitness usually connected to the outer membrane underlying peptidoglycan (Li, Plésiat 
and Nikaido 2015). Acinetobacter baumannii has a close homology to Escherichia coli 
OmpA and Pseudomonas aeruginosa OprF, which is the major outer membrane protein 
(Sugawara and Nikaido 2012). Of all the Acinetobacter baumannii isolates analysed, the 
major and significant band on SDS-PAGE was ~35 kDa. The results strongly suggest 
that the outer membrane of Acinetobacter baumannii contains reduced amounts of low-
permeability porins, a situation similar to the OprF of Pseudomonas aeruginosa. 
 
Other membrane proteins were analysed and also compared with the Pseudomonas 
aeruginosa control strains since the porins are closely related to the absence or presence 
of OmpA, OmpAb, OmpC and OmpF porins which have similar resistance to β-lactams 
and other antimicrobials. In this study, SDS-PAGE analysis for Escherichia coli, 
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Enterobacter aerogenes, Klebsiella pneuomoniae and others in the Enterobacteriaceae 
group had OmpC and OmpF absent or markedly reduced at band 35 kDa and 37 kDa, 
respectively compared with control strains. The presence of OmpA in most of the 
Enterobacteriaceae group, for instance, in Enterobacter aerogenes, is the major source 
of stabilization within the bacterial membrane, which leads to a reduction in the 
expression of OmpC and OmpF porins and eventually a reduced susceptibility to β-
lactams and other antimicrobials (Dupont et al. 2004, Amaral et al. 2014). Previous 
studies explained that the level of expression of OmpC and OmpF porins may not 
necessarily control the permeability of the outer membrane to nitrogen and glucose 
uptake under nutrient restriction, but may also be due to differentially control by the 
concentration of certain antimicrobials within the environment (Randall and Woodward 
2002, Castillo-K eller, V uong and Misra 2006). These studies are in agreement with this 
present study analysis which accounted for the high number of carbapenemase non-PCR 
positives. 
 
Sequence data from carbapenemase producers were used to generate each phylogenetic 
trees for OX A-48, V IM-1 and NDM-1 positive genes with the respective isolates and 
control strains used in the study compared with GenBank established strains to establish 
reliability of phylogenetic relationship. Unfortunately, two of the PCR-positive 
carbapenemase genes, V IM-1 positive Pseudomonas putida (CR number 12) and NDM-
1 positive Acinetobacter baumannii (CR number 27), including the positive NDM-1 
control strains failed to yield substantial sequenced data to be added for their genetic 
relationships.  
 
The phylogenetic trees showed an unevenly high level of heterogeneity among the CR 
isolates detected harbouring carbapenemase encoding genes, probably due to resistance 
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pattern differences to carbapenems, type of specimen, genus and species types. These 
features were observed from the three phylogenetic trees in this study. Clusters were 
distinctive from the controls used and those in the GenBank, signalling further studies 
may reveal a novel variant or variants from each carbapenemase-producing gene 
detected from Ghana.  
 
The phylogenetic distribution of the two OX A-48 gene-positive Klebsiella pneumoniae 
isolates is interesting, the organisms were from different regional hospitals, different 
sexes, specimens and age differences, nonetheless, the two OX A-48 encoding genes 
were closely related. This accession has been confirmed in a study where OX A-48 
carbapenemase-positive isolates with a variant type was found to be different from 
ST101 detected in Tunisia (Cuzon et al. 2011) where the same variant was previously 
reported in an outbreak in Spain (Pitart et al. 2011).  
 
Of the 8 positive V IM-1 encoding genes, all were found to be imipenem-resistant, 7 
Pseudomonas aeruginosa isolates and a strain of Pseudomonas putida by both disc 
diffusion and E-test method. Five Pseudomonas aeruginosa isolates were from wounds, 
2 from urine, and the only Pseudomonas putida was from a sputum specimen. This 
Pseudomonas putida isolate could not produce sequenced data for the phylogenetic tree 
due to limited nucleotide generation during sequencing. Of the Pseudomonas 
aeruginosa isolates, the phylogenetic tree exhibited close relatedness, while 2 accessed 
numbers from the GenBank (FR695890 and FR695888) described as harbouring partial 
V IM-2 genes which were clonally related to 6 V IM-1-positive genes in the Ghanaian 
isolates except one which showed close relatedness to a couple of the accessed numbers 
from the GenBank (K P337988, K P681695 and K P771862). Comparatively, 66% and 
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89% sequence homology indicated the overall close relatedness of the positive V IM-1 
carbapenemase genes detected in this study. 
 
There was partial relatedness to one V IM-1 positive Pseudomonas aeruginosa isolate 
with a V IM-2 Nocardia farcinica isolate (K M194591) and an allele of V IM-41 
Pseudomonas aeruginosa (K P771862) in subclass B1 metallo-β-lactamase from 
GenBank. V IM-1 gene similarities can be deceptive as genes are often carried on 
plasmids associated with class I integrons and plasmids are easily transferred between 
Pseudomonas aeruginosa isolates (Aghamiri et al. 2014). A  previous study by Sanchez-
Romero et al. (2012) also suggested some sort of linkages of common ESBL genes with 
a V IM-1 gene that occurred in clonal distribution of V IM-1-producing Klebsiella 
pneumoniae isolates and may be the cause of clustering together confirming the 
closeness of V IM-1-positive Pseudomonas aeruginosa isolates in the phylogenetic tree 
in this study (Figure 3.7).  
 
Similarly, sequence types of NDM-1 genes mainly from Acinetobacter baumannii 
isolates were different from the majority of GenBank accessed numbers used for the 
phylogenetic tree. Nonetheless, two sequenced types were closely related to 
international clones, 89N Shigella sonnei was linked to Citrobacter freundii 
(K P770032) and 108N Acinetobacter baumannii to both Escherichia coli (K P770023) 
and Enterobacter cloacae (K P770026) as observed in Figure 3.8. These close 
relationships may be due to the association of the NDM-1 gene shared in common with 
different ESBL  genes suggested in a previous study carried out in Morocco involving 
NDM-1-producing Klebsiella pneumoniae isolates (Poirel et al. 2011a). 
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This study raises concerns with the high levels of ESBLs which may have influenced 
the presence of carbapenem resistance determinants among the clinical CR isolates 
investigated. A lthough, both the phenotypic and genotypic methods yielded results 
comparable to other studies abroad. As a first time study, modified Hodge test and 
boronic-acid disc synergy method have shown inconsistencies or weaknesses in 
determination of carbapenemase activity in carbapenem-resistant Enterobacteriaceae 
group, Pseudomonas and Acinetobacter species. Relatively low sensitivity and 
specificity results from phenotype based assays clearly needed much improved and 
more diverse testing assays: examples, Carba NP, AmpC disc test, inhibitor-based test 
with the use of cloxacillin and temocillin MIC testing for determination of all classes of 
β-lactamases. PCR-based assays have shown reliability by characterising the prevailing 
types of carbapenemase-encoding genes, highlighting the prevalence and distribution 
levels among the different CR isolates, which otherwise 23 carbapenemase producers 
would have gone undetected by phenotypic tests used in this study.  
 
In the SDS-PAGE analysis, there were substantial numbers of unrelated porin 
expression among the CR isolates investigated. However, banding patterns of porins 
were assessed or evaluated with in-house MBL positive and negative Pseudomonas 
aeruginosa control strains because they formed the majority of the CR isolates, and its 
OprF is synonymous to OmpA and OmpC or OmpF in Acinetobacter baumannii and 
those in the Enterobacteriaceae group, respectively. In particular, OmpC/F or 
OmpK 35/37 expression was deficient which could be due to mutation and the presence 
of a large collection of non-fermenters highly resistant to cephalosporins and 
carbapenems studied mainly Pseudomonas aeruginosa and Acinetobacter baumannii 
isolates. These organisms have mutational complexities, structural differences, 
diminishing permeability or altered porin expressions compared with Escherichia coli 
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and Klebsiella pneumoniae isolates which were relatively few in numbers in this study. 
Furthermore, Acinetobacter baumannii and Pseudomonas aeruginosa isolates were in 
the majority being the carriers of carbapenemase genes; NDM-1, and V IM-1, while 
OX A-48 gene was only found in Klebsiella pneumoniae isolates by PCR assays, first to 
be identified in Ghana.  
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Chapter four 
 
4. Plasmid analysis of carbapenem-resistant Gram-negative 
bacteria 
 
4.1 Background and Aims 
 
The increased use of β-lactam antimicrobials in the late 1980s has resulted in increased 
bacterial resistance identified in many Enterobacteriaceae species with the acquisition of 
ESBL encoding genes and more recently in the expression of mobile plasmid-encoded 
metallo-β-lactamase genes (Arya 2011, Fallah et al. 2011). These resistance genes have 
been observed in many clinical isolates, especially in non-fermenting organisms such as 
Pseudomonas and Acinetobacter species which have been prominent in harbouring high 
levels of multiple resistance mechanisms to first-line antimicrobials in addition to 
carbapenems (Peleg and Hooper 2010, Saranathan et al. 2014). There are five common 
acquired MBL-types designated as GIM, SIM, SPM, IMP and V IM. These resistance 
genes occur frequently in Gram-negative bacterial strains and a more recently identified 
type is NDM-1, classified as class B in Ambler’s molecular classification (Queenan and 
Bush 2007). Of the MBL-types, V IM and IMP are widespread and commonly found in 
non-fermenting Gram-negative bacteria, Pseudomonas aeruginosa and Acinetobacter 
isolates (Ellington et al. 2007, Peleg and Hooper 2010).  
 
Since the discovery of the NDM-1 gene in 2008 its moveable plasmids have spread 
rapidly into the population of different Gram-negative bacterial pathogens (Struelens et 
al. 2010). At present, over six different NDM variants have been reported in Gram-
negative bacterial isolates. A lternatively, over expression of OX A β-lactamases (Class 
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D β-lactamases) have been detected including all variants in Acinetobacter baumannii 
CR isolates (Chen et al. 2011, Cornaglia, Giamarellou and Rossolini 2011, Fallah et al. 
2011, Saranathan et al. 2014). As discussed in Chapter 3, chromosomally determined 
DNA characterisation revealed the prevalence of three carbapenemase producing genes; 
NDM-1, V IM-1 and OX A-48 in six different carbapenem-resistant isolates. In this 
Chapter, the presence of common plasmid-encoding β-lactamases was investigated in 
order to establish the prevalence and distribution among the carbapenem-resistant 
isolates from Ghana. The aim of the study was to perform plasmid analysis by 
conjugation and curing experiments in order to ascertain the effect of plasmid-borne β-
lactamases in CR isolates. In addition, to determine the presence of common ESBL β-
lactamases (TEM-1, SHV -1) associated with carbapenemases to establish the 
prevalence and distribution among the carbapenem-resistant isolates.  
The specific objectives were to: 
ñ Perform plasmid DNA extractions and estimate the nucleic acid content using 
Nano NanoDrop®  ND-1000 spectrophotometer  
ñ Determine the prevalence and distribution of common ESBL-gene types (TEM-
1 and SHV -1) and carbapenemase genes among the study isolates  
ñ Determine the presence of plasmid-mediated carbapenem resistance genes and 
to elucidate their role in plasmid resistance by conjugation and curing 
experiments  
ñ Carry out susceptibility testing of plasmid-cured isolates to carbapenem 
antimicrobials to establish the resistance profiles  
ñ Establish plasmid band sizes of cured CR isolates with restriction enzyme 
digestion on gel electrophoresis  
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4.2 Method summary 
Plasmid DNA isolation of 111 CR isolates was performed and nucleic acid content 
estimated using a NanoDrop®  ND-1000 spectrophotometer to establish plasmid DNA 
concentrations in each carbapenem-resistant isolate. Amplified plasmid DNA products 
were analysed on agarose gel electrophoresis to establish the locations of the plasmid 
resistance genes. Acquisition and elimination of plasmid-borne carbapenem resistance 
genes were performed by conjugation and curing experiments using CR isolates as 
donor and Top 10 Escherichia coli cells as recipient. Susceptibility testing was 
performed on all cured CR isolates to establish the level of resistance by both disc 
diffusion and E-test assays to show plasmid-associated loss of resistance. Finally, to 
establish the differences or similarities in the fingerprints of the encoded plasmids 
generated by digestion with or without restriction endonucleases to compare the 
respective cured CR isolates of the 26 carbapenemase-positive gene carriers 
chromosomally detected and described in Chapter 2 to establish the presence of 
plasmid-borne resistance genes. The full description is in Chapter two of this study.  
 
4.3 R esults 
 
4.3.1 Plasmid DNA concentration analysis 
The extraction procedure described in Chapter 2 (Section 2.8.1) was used to determine 
the concentrations of the nucleic acid content of all plasmid DNA samples including 
Escherichia coli (ATCC 25922) negative control strain and two positive control strains, 
Klebsiella pneumoniae NDM-1 (NCTC 13443) and Pseudomonas aeruginosa V IM-1 
(NCTC 13437) for this study. The NanoDrop®  ND-1000 spectrophotometer was used 
to determine the estimated nucleic acid content of each plasmid DNA sample. V alues 
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ranging from 1.8 ng/l to 48.5 ng/l were determined in the samples. For positive 
carbapenemase producing strains, values ranging from 2.3 to 20.4 ng/l were found of 
which the highest was in the Klebsiella pneumoniae isolate and the lowest observed in 
one of the Pseudomonas aeruginosa isolates. The highest value of 48.5 ng/l was 
obtained from the carbapenemase non-producing Acinetobacter baumannii isolate 
found in the urine of a female patient aged 29 years. Details of the plasmid DNA 
concentrations are shown in Table 4.1.  
 
4.3.2 Plasmid DNA analysis by gel electrophoresis 
Gel electrophoresis analysis of the plasmid DNA samples revealed that all the 111 CR 
isolates were harbouring one or multiple plasmids with sizes ranging averagely between 
10 kb and ~95 kb when compared with the known 100 kb DNA molecular marker. The 
gel electrophoretic analysis of the Plasmid DNA reaction products revealed that the 
number of band lanes averagely ranged from 1 to 7. A  representative gel showing one or 
more band locations of plasmid-borne carbapenemase resistance from different types of 
CR isolates used can be seen in Figure 4.1. 
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T able 4.1 Quantification of plasmid DNA in carbapenem-resistant isolates using 
the Nano-Drop Spectrophotometer (ND-1000) 
Cn Conc. 
in 
ng/l 
Cn Conc. 
in 
ng/l 
Cn Conc. 
in 
ng/l 
Cn conc. 
in 
ng/l 
Cn Conc. 
in 
ng/l 
Cn Conc. 
in 
ng/l 
S1 6.1 S21 4.7 S41 7.7 S61 8.8 S81 3.6 S101 7.5 
S2 12.8* S22 7.7 S42 5.2* S62 20.0* S82 5.2 S102 6.3* 
S3 18.7 S23 3.4 S43 7.5* S63 5.8 S83 10.2 S103 15.5 
S4 5.7 S24 4.1 S44 4.3 S64 17.6* S84 8.9* S104 10.2 
S5 6.6* S25 9.9 S45 10.0 S65 8.5 S85 8.9 S105 15.9* 
S6 2.4* S26 6.3 S46 4.2* S66 8.2 S86 5.1 S106 7.6 
S7 2.3* S27 8.9* S47 5.2* S67 7.9 S87 9.0 S107 12.4 
S8 12.8 S28 8.2 S48 6.4 S68 13.0 S88 26.5 S108 9.9* 
S9 11.2 S29 4.7 S49 5.9 S69 9.1 S89 8.5* S109 8.3 
S10 4.7 S30 6.6 S50 5.0* S70 13.7 S90 4.8 S110 14.4 
S11 6.0 S31 3.9 S51 10.3 S71 7.6 S91 14.9 S111 11.9 
S12 5.8* S32 3.3 S52 3.8 S72 11.8* S92 5.2 NDM-1 19.3 
S13 4.8 S33 10.9 S53 5.2 S73 11.7 S93 7.6 V IM-1 10.6 
S14 3.7 S34 3.9 S54 7.1 S74 7.0* S94 5.4 EC-ve 12.6 
S15 4.0 S35 7.7 S55 19.5 S75 48.5 S95 18.3   
S16 9.9 S36 6.7 S56 5.9 S76 18.1* S96 9.4   
S17 16.6 S37 1.8 S57 9.0 S77 8.6 S97 7.5   
S18 11.5 S38 7.1 S58 23.1 S78 13.0 S98 20.4*   
S19 19.7* S39 3.2* S59 2.4 S79 4.0 S99 7.3   
S20 7.7 S40 2.2 S60 2.9* S80 4.5 S100 6.5*   
* Carbapenemase-positive gene carriers  
Note: Cn= code number, S= sample, NDM-1= New Delhi metallo-β-lactamase-1 Klebsiella 
pneumoniae (NCTC 13443), V IM-1= V erona integron-encoded metallo-β-lactamase-1 
Pseudomonas aeruginosa (NCTC 13437), EC-ve= Escherichia coli (ATCC 25922) negative 
control 
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Figure 4.1 Plasmid DNA profiling on agarose gel electrophoresis 
Note: M= 100 kb DNA marker, Nc= negative control Escherichia coli ATCC 25922, Tc= Top 
10 Escherichia coli competent cell, lane: 1 to 6= plasmid DNA samples, Bk= Blank sample. 
 
4.3.3 Plasmid transfer analysis 
Conjugation experiments were performed for both carbapenemase non- and positive- 
producers (donor cells) mating-out into Escherichia coli Top 10 competent cells 
(recipient cell) using the technique described in Chapter 2 (Section 2.8.4). Either double 
or multiple bands were observed in all the plasmid DNA extracts. For the 26 
carbapenemase positive-producers and the cured isolates, carriers of multiple plasmids 
were observed while carbapenemase non-producers showed either single or multiple 
plasmids, indicating the presence of unknown plasmids among the CR isolates. PCR 
amplicons from plasmid DNA were visualised on agarose gels. This was performed to 
demonstrate the presence of common ESBL-type β-lactamase encoding genes (TEM-1 
and SHV -1) and carbapenemase encoding genes (K PC-1, NDM-1, V IM-1, IMP-1 and 
OX A-48) using plasmid DNA. In total, TEM-1 ESBL demonstrated 100% prevalence in 
plasmids from all the CR isolates while only 3.6% (4/111) were without the SHV -1 
ESBL (sample code numbered: 11, 67, 70 and 89). Details of the sample numbers, type 
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of isolate and source of specimens of the CR isolates are listed in Appendix 1. The 
prevalence and distribution of common ESBL type β-lactamases investigated and 
plasmid-borne carbapenemase gene carriers detected and the type of CR isolates are 
shown in Tables 4.2 and 4.3. 
 
T able 4.2 Beta-lactamase genes amplified from plasmid DNA identified in 
carbapenem-resistant isolates  
Ambler 
C lass 
β-lactamase type 
tested 
T ypes found in isolates (n) %  
A TEMs, SHV s TEMs (111) 100, SHV s (107) 96.4 
SME-1, K PC-1 SME-1 (0) 0.0, K PC-1 (0) 0.0 
B IMP-1, V IM-1, Ccr-A, 
NDM-1 
IMP-1 (0) 0.0, V IM-1 (8) 7.2, Ccr-A (0) 
0.0, NDM-1 (16) 14.4 
C  None None 
D OX A-48 OX A-48 (2) 1.8 
 
Note: n= number of CR isolate 
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T able 4.3 Distribution of carbapenemase genes carried on plasmids in 
carbapenem-resistant Gram-negative isolates  
 
β-lactamase type CR isolates 
n=111 (%) 
Ps.a A.b E.c Ps.p K .p En.c C.z P.s S.s S.p 
51 31 12 7 3 3 1 1 1 1 
TEM-1 111 (100) 51 31 12 7 3 3 1 1 1 1 
SHV -1 107 (96.4) 50 31 11 7 3 3 1 1 0 0 
NDM-1 16 (14.4) 2 8 3 1 0 0 0 1 1 0 
V IM-1 8 (7.2) 7 0 0 1 0 0 0 0 0 0 
OX A-48 2 (1.8) 0 0 0 0 2 0 0 0 0 0 
 
Note: n= total number of CR isolate, Ps.a= Pseudomonas aeruginosa, A .b= Acinetobacter 
baumannii, E.c= Escherichia coli, Ps.p=  Pseudomonas putida, K .p=  Klebsiella pneumoniae, 
En.c= Enterobacter cloacae, C.z= Cronobacter zakasakii, P.s= Providencia stuartii, S.s= 
Shigella sonnei, S.p= Sphingomonas paucimobilis 
 
In the samples tested, 96.4% (107/111) of the CR isolates co-harboured both TEM-1 
and SHV -1 genes. However, three of the carbapenemase non-PCR positives' harboured 
the TEM-1 gene alone. The three isolates included Sphingomonas paucimobilis (isolate 
11), Escherichia coli (isolate 67) and Pseudomonas aeruginosa (isolate 70) and one 
carbapenemase-positive gene carrier, Shigella sonnei (isolate 89). Bands for K PC-1 and 
IMP-1 were not identified in the plasmid DNA samples with the primer sequences used. 
A ll of the 26 carbapenemase-positive gene carrying isolates harboured both the ESBL  
genes (TEM-1 and SHV -1) except the Shigella sonnei strain which harboured only the 
TEM-1 ESBL gene. Representative samples of group A & B and C & D (Figures 4.2a 
& 4.2b) are shown for comparison, comprising plasmid DNA analysis for both 
carbapenemase-positive gene carriers and carbapenemase deficient isolates on agarose 
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gel electrophoresis. Figure 4.3 shows the presence of two β-lactamases (TEM-1 and 
SHV -1) carried on plasmids on agarose gel electrophoresis, where TEM-type ESBL  
genes were identified in all samples (1 to 11) while SHV -type ESBL gene was 
identified in all samples except in sample number 11. 
      M             2                5                 6            7                 12 
10kp 
60kp 
100kp 
A 
 
 
0.5kp 
    1kp 
  621bp 
  438bp 
      M             2                5                6              7                 12 
B 
 
Figure 4.2a Amplified carbapenemase genes from plasmids  
Note: M= marker ladder, NC= NDM-1 positive (NCTC 13443) control strain. (A , plasmid on 
gel), five plasmid DNA extracts each (2, 5, 6, 7, and 12) showing different band patterns. In (B, 
PCR product on gel) corresponding plasmid DNA extracts each amplified with known positive 
carbapenemase gene primers showing; lanes 2 and 5 for NDM-1 gene (621bp); lanes, 6, 7 and 
12 for V IM-1 gene (438bp), respectively.  
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F igure 4.2b Amplified carbapenemase genes from plasmids  
Note: M= marker ladder, NC= NDM-1 positive (NCTC 13443) control strain. In (C plasmid on 
gel), five plasmid DNA extracts (23, 24, 25, 26, and 27) showing different plasmid band 
patterns. In (D, PCR product on gel), corresponding plasmid DNA extracts amplified with 
known positive carbapenemase gene primers showing only lane 27 is encoded with NDM-1 
gene (621bp).  
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F igure 4.3 Plasmid profiling of two β-lactamase genes on gel electrophoresis 
Note: M= 10K b DNA marker, B= Blank, S= SHV -type ESBL  gene (Klebsiella pneumoniae 
NCTC 165032 positive control), 1-11= CR sample numbers, T= TEM-type ESBL  gene 
(Escherichia coli NCTC 13351 positive control), C= negative ESBL  (Escherichia coli 
ATCC 25922) control strain. In (A) gel showing TEM-type ESBL  gene is showing in all the CR 
isolate numbers from 1 to 11 while in (B) gel SHV -type ESBL  gene is showing in all except CR 
isolate number 11.  
 
 
4.3.4 R esistance pattern of cured plasmid-isolates to carbapenems 
The 26 cured carbapenemase-positive isolates were tested using disc diffusion 
susceptibility to imipenem, meropenem and doripenem agents. The resistance patterns 
were compared with the original CR isolates tested earlier (see Appendix 2) in which 15 
out of the 26 cured isolates were reduced to intermediate resistance or remained 
resistant to one carbapenem (Table 4.4a). Ten cured isolates were susceptible and only 
one cured isolate retained the same level of resistance to one or two carbapenems used. 
 
     M    B   T    1    2     3     4     5    6     7    8     9   10   11  S   C           
     1kb 
0.8kb    
  10kb 
 
       0.86kb
   A 
 
       M    1    2    3   4     5    6    7    8    9   10  11  T   S    B   C 
   10kb 
    1kb 
 0.8kb  
   0.93kb 
B 
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Further inhibition analysis revealed that 8 of the cured carbapenemase-positive gene 
carriers exhibited complete susceptibility to all the carbapenems. These isolates were 
from 4 Pseudomonas aeruginosa, 2 Acinetobacter baumannii and 1 Escherichia coli 
and Shigella sonnei isolates. However, 3 of the cured isolates, Klebsiella pneumoniae, 
Pseudomonas putida and Providencia stuartii remained resistant to all the carbapenems 
tested.  
 
Comparatively, significant numbers of the original carbapenemase non-PCR positives 
exhibited substantially increased levels of susceptibility 44/111 (39.6%), and 34/111 
(30.6%) displayed intermediate resistance to one or two carbapenems tested when 
compared with cured isolates encoded with carbapenemase genes. A  representative 
example of an original (uncured) CR isolate compared with the corresponding cured 
variant of the same isolate was tested together (Figure 4.4). The cured isolate showed 
complete susceptibility to both imipenem and meropenem discs.  
 
F igure 4.4 Comparison between resistance pattern of an uncured plasmid-borne 
isolate and corresponding cured susceptibility testing 
Note: Uncured {A= imipenem, intermediate resistance; B= meropenem, total resistance} ; Cured 
{A and B showing complete susceptibility to imipenem and meropenem respectively}  
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4.3.5 R esistance profile of cured isolates by the E -test assay 
The E-test resistance patterns of all the cured isolates tested for both carbapenemase 
non-PCR positives and carbapenemase-positive gene carriers showing various MIC 
levels are listed in Table 4.4a. The differences observed in the disc diffusion resistance 
patterns were consistent with those observed in the MIC assay results. The original CR 
isolates were found to have relatively high MIC values (see Appendix 2 and Table 
4.4a). The MIC levels were reduced more towards imipenem and meropenem than 
ertapenem, where some maintained the same high-level of resistance as evidenced in the 
original MIC values (Table 4.4a). It can be seen that the MICs of the cured isolates were 
either reduced by 2- or 4-fold, the majority of the carbapenemase non-PCR positives 
were found to be harbouring TEM-1 and SHV -1 genes (Table 4.4b).  
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T able 4.4a Plasmid profiling of carbapenem-resistant isolates before conjugation and cured experiments 
 
Isolate 
code 
 
Name of 
isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after 
cured 
After cured 
(size range 
in 
 ~ kb) 
 
Original Cured Imi Mer E rt Imi Mer E rt 
1 P. aeruginosa R In >32 >32 >32 32 16 >32 4 3 60 
2* E. coli R In >32 >32 >32 16 8 16 9 3 70 to 85 
3 P. aeruginosa R S 4 16 >32 4 16 32 5 4 55 
4 A. baumannii R R >32 >32 >32 >32 >32 >32 8 7   55 
5* E. coli R S 2 3 16 0.12 0.5 2 7 3 60 to 95 
6* P. aeruginosa R In >32 >32 >32 16 16 8 4 2 75 to 85 
7* P. aeruginosa R In >32 >32 >32 8 8 16 7 6 45 to 75 
8 A. baumannii R In >32 >32 >32 16 16 16 8 6 45 to 80 
9 C. sakazakii R S >32 >32 >32 4 4 16 7 5 40 to 70 
10 P. aeruginosa R S >32 >32 >32 4 8 8 8 5 45 to ≥100 
11 S. paucimobilis R S >32 >32 >32 2 4 4 9 5 45 to ≥100 
12* P. putida R S >32 >32 >32 4 4 8 5 5 - 
13 P. aeruginosa R S 16 >32 >32 2 8 16 6 5 ≥100 
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Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
 ~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
14 P. aeruginosa R S 8 4 >32 1 1 4 9 7 45 to ≥100 
15 P. aeruginosa R S >32 12 >32 4 2 8 9 7 45 to ≥100 
16 P. aeruginosa R S 16 4 >32 2 0.5 16 9 6 90 to ≥100 
17 P. aeruginosa R In >32 >32 >32 32 16 16 6 5 ≥100 
18 E. coli R In 16 >32 >32 4 8 32 6 6 - 
19* K. pneumoniae R S 16 8 >32 2 1 16 6 5 60 
20 A. baumannii R In >32 >32 >32 16 16 32 9 6 70 to ≥100 
21 P. aeruginosa R S 2 16 >32 0.5 2 8 8 4 30 to 75 
22 A. baumannii R In >32 16 >32 16 16 32 9 6 35 to 95 
23 E. coli R S >32 >32 >32 4 4 16 9 6 30 to 95 
24 P. aeruginosa R S >32 >32 >32 12 16 32 7 5 20 to 70 
25 P. aeruginosa R S >32 >32 >32 8 8 16 7 5 30 to 70 
26 P. aeruginosa R S >32 >32 >32 4 16 32 7 3 30 to 70 
27* A. baumannii R S 6 >32 >32 2 8 16 9 4 30 to 95 
28 P. aeruginosa R In >32 >32 >32 32 16 16 6 5 95 
29 A. baumannii R In >32 >32 >32 8 16 32 9 5 35 to ≥100 
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Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
   ~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
30 A. baumannii R S >32 16 >32 8 8 32 7 4 30 to 75 
31 Ps aeruginosa R S 4 16 >32 2 2 16 7 4 30 to 70 
32 P. aeruginosa R S >32 >32 >32 4 4 16 9 3 20 to 95 
33 En. cloacae R S 32 >32 >32 4 4 16 9 4 30 to 95 
34 A. baumannii R S 8 16 >32 2 2 16 9 5 30 to 95 
35 E. coli I S 0.38 0.50 0.50 0.38 0.50 0.50 9 4 40 to 95 
36 A. baumannii R In >32 >32 >32 8 16 32 6 3 30 to 60 
37 P. aeruginosa R In 16 >32 >32 4 32 32 9 3 30 to 95 
38 A. baumannii R In >32 >32 >32 16 16 32 7 4 30 to 75 
39* P. aeruginosa R In >32 >32 >32 16 16 32 7 3 30 to 75 
40 P. aeruginosa R In >32 >32 >32 32 8 32 8 4 30 to 80 
41 P. aeruginosa R In >32 >32 >32 16 32 >32 7 3 30 to 70 
42* A. baumannii R In >32 >32 >32 16 16 32 9 4 30 to 95 
43* A. baumannii R In >32 >32 >32 16 8 32 9 4 30 to 95 
44 P. putida R S >32 >32 >32 4 4 16 8 4 20 to 80 
45 A. baumannii R In >32 >32 >32 16 8 32 9 4 30 to 95 
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Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
46* A. buamannii R In >32 >32 >32 32 16 32 9 4 30 to 95 
47* P. aeruginosa R In >32 >32 >32 8 8 32 9 4 30 to 95 
48 P. aeruginosa R S >32 >32 >32 8 16 16 7 5 30 to 70 
49 A. baumannii R In >32 >32 >32 16 16 16 9 4 30 to 95 
50* A. baumannii I S 4 16 >32 2 4 8 9 4 30 to 95 
51 A. baumannii R In >32 >32 >32 16 16 32 9 5 50 to 95 
52 P. aeruginosa R S 12 12 >32 2 2 16 8 3 40 to 80 
53 E. coli R S 16 >32 >32 2 8 16 9 4 30 to 95 
54 P. aeruginosa R S 4 >32 >32 2 4 16 7 5 40 to 70 
55 K. pneumoniae R S 8 16 >32 2 2 8 7 4 10 to 75 
56 A. baumannii R In 16 >32 >32 8 32 32 7 1 20 to ≥100 
57 P. aeruginosa R S 4 >32 >32 2 4 8 9 4 40 to 95 
58 P. aeruginosa I S 8 4 >32 0.5 2 16 9 3 25 to 90 
59 P. aeruginosa R S 6 3 >32 2 1 16 9 3 25 to 90 
60* P. aeruginosa R In >32 >32 >32 16 8 32 7 3 30 to 70 
61 P. aeruginosa R In >32 16 >32 16 8 32 9 3 25 to 90 
Continuation from page 154  
156 
 
 
Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
62* P. aeruginosa R In >32 8 >32 16 8 32 9 3 30 to 95 
63 P. aeruginosa R In 16 >32 >32 8 32 32 8 6 30 to 85 
64* A. baumannii R In 8 >32 >32 8 16 32 9 4 30 to ≥100 
65 P. aeruginosa R In >32 >32 >32 32 16 32 9 3 10 to ≥100 
66 P. aeruginosa R In >32 >32 >32 16 16 32 8 2 30 to 75 
67 E. coli I S 2 0.125 16 0.5 0.125 4 8 2 30 to 75 
68 E. coli I S 4 0.19 4 1 0.12 16 9 1 25 to 90 
69 A. baumannii R S 16 32 >32 2 8 16 9 3 30 to 95 
70 P. aeruginosa I S 4 0.50 >32 2 0.50 4 7 2 10 to 70 
71 P. aeruginosa R S 16 8 >32 4 2 16 8 4 30 to ≥100 
72* A. baumannii R In >32 >32 >32 8 32 32 9 5 30 to ≥100 
73 A. baumannii R In >32 16 >32 8 16 16 9 6 30 to ≥100 
74* P. aeruginosa R In >32 >32 >32 16 16 32 9 5 30 to ≥100 
75 A. baumannii R R >32 >32 >32 >32 >32 >32 8 5 40 to 75 
76* P. stuartii I S 4 0.25 8 1 0.25 8 9 3 20 to ≥100 
77 A. baumannii R In >32 >32 >32 16 16 32 9 4 30 to 95 
Continuation from page 155  
157 
 
 
Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
78 P. putida R S >32 >32 >32 8 8 16 5 3 20 to 50 
79 P. aeruginosa R R >32 >32 >32 >32 >32 >32 8 6 50 to 80 
80 P. aeruginosa R S 8 16 >32 2 4 16 9 4 20 to 90 
81 P. aeruginosa R S 0.38 6 16 0.12 2 8 9 3 30 to 95 
82 A. baumannii R In 32 >32 >32 16 8 16 7 4 30 to 70 
83 P. putida R S 0.38 16 32 0.38 4 16 6 3 20 to 60 
84* P. aeruginosa R S 8 4 16 2 2 8 8 5 30 to ≥100 
85 E. coli I S 0.38 0.25 4 0.38 0.25 2 8 2 30 to 80 
86 P. aeruginosa R R >32 >32 >32 >32 >32 >32 8 4 30 to 75 
87 P. aeruginosa R S >32 32 >32 8 8 16 9 3 30 to 95 
88 P. putida R In >32 >32 >32 16 16 32 8 4 20 to ≥100 
89* S. sonnei R S 1.5 4 32 1.5 2 16 8 3 30 to 80 
90 P. putida R S >32 >32 >32 4 4 8 5 2 10 to 50 
91 En. cloacae R R >32 >32 >32 >32 >32 >32 8 4 20 to 75 
92 P. putida R In >32 >32 >32 16 32 32 5 3 20 to 50 
93 E. coli R In >32 >32 >32 >32 >32 >32 9 6 25 to 95 
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Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
94 A. baumannii R S 6 12 >32 2 4 4 9 4 30 to 95 
95 En. cloacae R In 32 >32 >32 16 32 32 5 2 15 to 50 
96 P. aeruginosa R S 16 8 32 4 4 16 8 4 30 to 80 
97 E. coli R In 16 >32 >32 8 32 16 9 3 30 to 95 
98* K. pneumoniae R S 16 8 >32 4 4 16 9 3 30 to 95 
99 P. aeruginosa R R >32 >32 >32 >32 >32 >32 9 4 30 to 95 
100* P. aeruginosa R In >32 >32 >32 16 8 32 8 3 30 to 75 
101 P. aeruginosa R In 8 8 >32 2 4 16 8 2 30 to 80 
102* A. baumannii R In >32 >32 >32 16 8 32 9 4 30 to 95 
103 A. baumannii R S 1 4 32 1 2 16 8 3 30 to 75 
104 P. aeruginosa R In 16 >32 >32 16 16 32 8 4 30 to75 
105* E. coli R S 0.75 2 32 0.50 2 4 8 4 15 to 75 
106 A. baumannii R In >32 >32 >32 8 16 16 9 3 10 to ≥100 
107 A. baumannii R S 16 >32 >32 4 16 16 8 3 25 to ≥100 
108* A. baumannii R R >32 >32 >32 >32 >32 >32 8 3 30 to ≥100  
109 P. aeruginosa R In >32 >32 >32 16 16 16 9 6 15 to ≥100 
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Isolate 
code 
 
Name of isolate 
 
Sensitivity testing 
MIC  (µ g/ml) Plasmid DNA 
Original Cured Original 
number of 
bands 
Band loss 
after cured 
After cured 
(size range in 
~ kb) 
Original Cured Imi Mer E rt Imi Mer E rt 
110 P. aeruginosa R In >32 >32 >32 16 8 32 6 2 25 to 60 
111 P. aeruginosa R S 16 >32 >32 4 4 16 9 3 30 to ≥100 
Control E. coli Top 10 S S 0.125 0.12 0.50 0.125 0.12 0.50 - - - 
Control E. coli (ATCC 
25922 isolate) 
S S 0.12 0.125 0.50 0.12 0.125 0.50 - - - 
 
*Positive carbapenemase-producers. Note: Imi= imipenem, Mer= meropenem, Ert= etapenem, R= resistant, S= sensitive, In= intermediate, -= No band 
seen 
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T able 4.4b Plasmid profiling of carbapenemase non-PCR  positives and minimum 
inhibitory concentrations with common β-lactamase genes 
Isolate 
number 
Name 
Carbapenem-
resistant isolate 
Type of 
ESBL  
Carbapenemase non-PCR positives 
MIC (µ g/ml) before 
curing 
MIC (µ g/ml) after curing 
TEM SHV  Imp Mer Ert Imp Mer Ert 
1 P. aeruginosa + + >32 >32 >32 32 16 >32 
3 P. aeruginosa + + 4 16 >32 4 16 32 
4 A. baumannii + + >32 >32 >32 >32 >32 >32 
8 A. baumannii + + >32 >32 >32 16 16 16 
9 C. sakazakii + + >32 >32 >32 4 4 16 
10 P. aeruginosa + + >32 >32 >32 4 8 8 
11 S. paucimobilis + - >32 >32 >32 2 4 4 
13 P. aeruginosa + + 16 >32 >32 2 8 16 
14 P. aeruginosa + + 8 4 >32 1 1 4 
15 P. aeruginosa + + >32 12 >32 4 2 8 
17 P. aeruginosa + + 16 4 >32 2 0.5 16 
18 E. coli + + >32 >32 >32 32 16 16 
20 A. baumannii + + 16 >32 >32 4 8 32 
21 P. aeruginosa + + 2 16 >32 0.5 2 8 
22 A. baumannii + + >32 16 >32 16 16 32 
23 E. coli + + >32 >32 >32 4 4 16 
24 P. aeruginosa + + >32 >32 >32 12 16 32 
25 P. aeruginosa + + >32 >32 >32 8 8 16 
26 P. aeruginosa + + >32 >32 >32 4 16 32 
28 P. aeruginosa + + >32 >32 >32 32 16 16 
29 A. baumannii + + >32 >32 >32 8 16 32 
30 A. baumannii + + >32 16 >32 8 8 32 
31 P. aeruginosa + + 4 16 >32 2 2 16 
32 P. aeruginosa + + >32 >32 >32 4 4 16 
33 En. cloacae + + 32 >32 >32 4 4 16 
34 A. baumannii + + 8 16 >32 2 2 16 
35 E. coli + - 0.38 0.50 0.50 0.38 0.50 0.50 
36 A. baumannii + + >32 >32 >32 8 16 32 
37 P. aeruginosa + + 16 >32 >32 4 32 32 
38 A. baumannii + + >32 >32 >32 16 16 32 
40 P. aeruginosa + + >32 >32 >32 32 8 32 
41 P. aeruginosa + + >32 >32 >32 16 32 >32 
44 P. putida + + >32 >32 >32 4 4 16 
45 A. baumannii + + >32 >32 >32 16 8 32 
48 P. aeruginosa + + >32 >32 >32 8 16 16 
49 A. baumannii + + >32 >32 >32 16 16 16 
51 A. baumannii + + >32 >32 >32 16 16 32 
52 P. aeruginosa + + 12 12 >32 2 2 16 
53 E. coli + + 16 >32 >32 2 8 16 
54 P. aeruginosa + + 4 >32 >32 2 4 16 
55 K. pneumoniae + + 8 16 >32 2 2 8 
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Isolate 
number 
Name 
Carbapenem-
resistant isolate 
Type of 
ESBL  
Carbapenemase non-PCR positives 
MIC (µ g/ml) before 
curing 
MIC (µ g/ml) after curing 
TEM SHV  Imp Mer Ert Imp Mer Ert 
56 A. baumannii + + 16 >32 >32 8 32 32 
57 P. aeruginosa + + 4 >32 >32 2 4 8 
58 P. aeruginosa + + 8 4 >32 0.5 2 16 
59 P. aeruginosa + + 6 3 >32 2 1 16 
61 P. aeruginosa + + >32 16 >32 16 8 32 
63 P. aeruginosa + + 16 >32 >32 8 32 32 
65 P. aeruginosa + + >32 >32 >32 32 16 32 
66 P. aeruginosa + + >32 >32 >32 16 16 32 
67 E. coli + - 2 0.125 16 0.5 0.125 4 
68 E. coli + + 4 0.19 4 1 0.12 16 
69 A. baumannii + + 16 32 >32 2 8 16 
70 P. aeruginosa + - 4 0.50 >32 2 0.50 4 
71 P. aeruginosa + + 16 8 >32 4 2 16 
73 A. baumannii + + >32 16 >32 8 16 16 
75 A. baumannii + + >32 >32 >32 >32 >32 >32 
77 A. baumannii + + >32 >32 >32 16 16 32 
78 P. putida + + >32 >32 >32 8 8 16 
79 P. aeruginosa + + >32 >32 >32 >32 >32 >32 
80 P. aeruginosa + + 8 16 >32 2 4 16 
81 P. aeruginosa + + 0.38 6 16 0.12 2 8 
82 A. baumannii + + 32 >32 >32 16 8 16 
83 P. putida + + 0.38 16 32 0.38 4 16 
85 E. coli + + 0.38 0.25 4 0.38 0.25 2 
86 P. aeruginosa + + >32 >32 >32 >32 >32 >32 
87 P. aeruginosa + + >32 32 >32 8 8 16 
88 P. putida + + >32 >32 >32 16 16 32 
90 P. putida + + >32 >32 >32 4 4 8 
91 En. cloacae + + >32 >32 >32 >32 >32 >32 
92 P. putida + + >32 >32 >32 16 32 32 
93 E. coli + + >32 >32 >32 >32 >32 >32 
94 A. baumannii + + 6 12 >32 2 4 4 
95 En. cloacae + + 32 >32 >32 16 32 32 
96 P. aeruginosa + + 16 8 32 4 4 16 
97 E. coli + + 16 >32 >32 8 32 16 
99 P. aeruginosa + + >32 >32 >32 >32 >32 >32 
101 P. aeruginosa + + 8 8 >32 2 4 16 
103 A. baumannii + + 1 4 32 1 2 16 
104 P. aeruginosa + + 16 >32 >32 16 16 32 
106 A. baumannii + + >32 >32 >32 8 16 16 
107 A. baumannii + + 16 >32 >32 4 16 16 
109 P. aeruginosa + + >32 >32 >32 16 16 16 
110 P. aeruginosa + + >32 >32 >32 16 8 32 
111 P. aeruginosa + + 16 >32 >32 4 4 16 
Control E. coli Top 10 - - 0.125 0.12 0.50 0.125 0.12 0.50 
 
Note: Imi= imipenem, Mer= meropenem, Ert= ertapenem, += positive, -= negative 
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4.3.6 Plasmid DNA restriction pattern of cured carbapenemase-positive gene 
carriers 
Analysis of both undigested and restriction enzyme (EcoRI and HindIII) digested 
plasmids of the cured 26 PCR-positive CR isolates were analysed by agarose gel 
electrophoresis in order to study plasmid resistance gene patterns. The restriction 
patterns were found to be non-identical in almost all of the cured PCR-positive CR 
isolates with their corresponding differences in band sizes ranging from 3 to > 6 bands, 
indicating that the isolates were harbouring diverse types of plasmids. However, profiles 
of a few cured CR isolates encoded with NDM-1 and V IM-1 genes respectively showed 
unclear similarities when carefully examined. The indication here is that dependent 
upon the type of gene (NDM-1 or V IM-1), those few CR isolates may have common 
shared genes but remain genetically unrelated. A  representative restriction analysis of 
plasmid-cured isolates of the carbapenemase-positive gene carriers from the Top 10 
Escherichia coli competent cells depicting different plasmid band sizes are shown in 
Figure 4.5 and 4.6. Gel (A) was without restriction enzymes digestion, showing 
relatively low number of band lanes with no significant relatedness or similarities, while 
in gel (B) with digested endonucleases (EcoRI and HindIII) displaying different β-
lactamase genes in the cured CR isolates with increased number of band lanes (Figure 
4.5). 
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F igure 4.5 Undigested and digested restriction enzyme profiling from cured 
carbapenemase-positive gene carriers 
Note: M= DNA marker; lanes, 1 to 8= plasmid-cured carbapenemase-positive producers; EH= 
EcoRI- HindIII-digested marker; NC= Escherichia coli Top 10 recipient cells. Gel A: 
(undigested) profile; lane 1 through to 8 representing CR numbers (27, 39, 42, 43, 46, 47, 50 
and 60) are showing different band patterns of the cured carbapenemase-positive producers. Gel 
B (digested) profile; corresponding to the same respective cured carbapenemase producers in 
(gel A) showing diverse plasmid band patterns, suggesting that they harbour different plasmids  
 
 
 
Figure 4.6 Profiling of restriction enzyme digestion from cured carbapenemase-
positive gene carriers  
 
Note: M= DNA ladder marker; Lanes, 100, 102 105 and 108= plasmid-cured carbapenemase 
producers; EcR= EcoRI-digested; HI= HindIII-digested; B= blank; UE= undigested Escherichia 
coli Top 10 recipient cells; DE= digested Escherichia coli Top 10 recipient cells; DP= digested 
Pseudomonas aeruginosa (ATCC 27852) control strain. In this gel, all the plasmid-cured 
carbapenemase producers are showing diversity in band patterns (see also appendix 5). 
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4.4 Discussion 
 
Plasmids are sometimes considered as non-essential elements found in normal bacterial 
growth. However, the spread of plasmids and acquired antimicrobial resistance genes 
are a major clinical challenge (Pitout and Laupland 2008). TEM and SHV  families are 
commonly detected from Enterobacteriaceae species in Africa, while CTX -M ESBL 
types are predominantly found in East Asia and Europe (Dhillon and Clark 2012).  
 
Since the discovery of TEM and SHV  types in the 1980s, the enzymes have been 
widely reported in Egypt (Borg et al. 2006), South Africa (Bamford et al. 2011), and 
recently in Ghana (Opintan et al. 2015). Expressions of these common ESBLs have 
been also detected in common non-fermenting organisms, Pseudomonas aeruginosa 
and Acinetobacter baumannii (J acoby and Munoz-Price 2005, Meyer et al. 2010, 
Heizmann et al. 2013). Infections caused by multidrug-resistant Gram-negative bacteria, 
including Pseudomonas aeruginosa and Acinetobacter baumannii isolates, have been 
found to co-harbour ESBLs, AmpC-type β-lactamases and plasmid-encoded 
carbapenemase resistance genes (K anj and K anafani 2011, Armand-Lefè vre et al. 2013, 
Carattoli 2013). The presence of these resistance genes poses diagnostic and therapeutic 
challenges. Early recognition or detection of these resistance genes makes them more 
preventable and their spread into susceptible pathogens to cause severe infections in 
many sensitive areas such as ICUs and transplantation units in many health-care 
facilities can be controlled.  
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The aim of this study was to perform plasmid analysis on CR isolates from Ghanaian 
hospitals to ascertain the presence, prevalence and distribution of plasmid-borne β-
lactamases including carbapenemase resistance genes. The main findings have shown 
high-levels of common ESBLs probably due to frequent exposure to drugs such as 
penicillins and third generation cephalosporins. Similar resistance mechanisms have 
been observed in other studies in which the loss of porin expression or ESBL  enzymes 
in association with ampC β-lactamases and expression of common efflux pumps play a 
role in the acquisition of carbapenemase resistance in Gram-negative bacterial 
pathogens (Armand-Lefè vre et al. 2013, Meletis 2016).  
 
In this study, high-levels of the common traditional enzymes, TEM- and SHV -ESBL 
types were detected in Pseudomonas aeruginosa and Acinetobacter baumannii isolates, 
which may have contributed to the resistance of carbapenem antimicrobials. Several 
studies have reported that bacterial production of ESBL enzymes serve as the first-step 
in the development of bacterial resistance. Genetically, blaTEM and blaSHV  types are 
derived from a simple point mutation and largely linked to cross infection in health-care 
facilities because of persistent exposure to β-lactams without the use of carbapenems 
and cephamycins (Shah et al. 2004, V arkey, Balaji and Abraham 2014).  
 
Plasmids act as intermediaries in the dissemination of mobile elements, aiding 
antimicrobial resistance especially among Gram-negative bacterial pathogens (Raj 
2012), and movements of these resistance genes have been the focus of intense study in 
global antimicrobial resistance (Nordmann, Naas and Poirel 2011, Pitout, Nordmann 
and Poirel 2015). Plasmid profiling revealed that carbapenemase genes co-existed with 
the TEM-1 and SHV -1 β-lactamase enzymes which also may have compounded the 
resistance to carbapenems. The effect of the β-lactamase enzymes was evidently 
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observed in all the cured CR isolates by the reduction in susceptibility testing to one or 
two of the carbapenems when compared with the original CR isolates tested. This 
notable behaviour confirms the mobile resistance genes were located on plasmids 
including TEM- and SHV -type genes and this finding is in agreement with the Raj 
(2012) study that found a single plasmid that when lost during curing experiments at an 
elevated temperature of 45ºC, plasmid-borne resistance was eliminated (Raj 2012). In 
contrast, in another curing experiment conducted by Saranathan et al. (2014) the loss of 
three or more plasmids did not eliminate multidrug resistance in two cured 
Acinetobacter baumannii isolates. The resistance pattern of the two isolates remained 
the same when tested with ceftriaxone and carbapenems after acridine orange was used 
in the curing process (Saranathan et al. 2014). A lthough, curing agent (acridine orange) 
was not used in this present study, the findings here seemed to suggest that there were 
inherent chromosomal resistance possibly in association with plasmid-borne multidrug 
resistance genes that augment the resistance in Acinetobacter baumannii isolates. It is 
now well understood that ESBL encoding genes that co-exist in poly-microbial 
infections may easily disseminate into other genera or within species of the same strain 
causing outbreaks in hospitals or in community settings (Dhillon and Clark 2012). The 
risks of outbreaks in such environments cannot be overemphasised; strains harbouring 
these resistance genes may disseminate, especially in ICUs, during mechanical 
ventilation, emergency surgery and during urinary catheterisations (Enoch, Birkett and 
Ludlam 2007, Meletis et al. 2012).  
 
There are other β-lactamases such as CTX -M and AmpC-types that have clinical 
relevance and present a threat to growing number of Gram-negative bacterial resistance 
observed in severe infections in recent times (Naas et al. 2011, Ma et al. 2015). 
Frequent urinary pathogens, usually from urethral catheterisation have been identified 
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as having high-levels of multidrug resistance largely driven by plasmid β-lactamase 
enzymes (Motayo et al. 2013). These two enzymes, CTX -M and AmpC-type β-
lactamases were not determined due to unavailability of control strains during the study. 
However, these two β-lactamase enzymes in combination with non-enzymatic 
mechanisms (e.g. efflux pump systems) have been found in most Gram-negative 
bacterial pathogens and may be contributing to the increasing array of resistance to 
carbapenems. A  recent study in India, found a prevalence of 84% for blaCTX -M-15 
among ESBL isolates, either alone or co-harbouring blaNDM-1-producing gene 
(K hajuria et al. 2014). Previous studies have reported TEM-1 and CTX -M-15 as the 
most frequently encountered ESBL enzymes detected in the NDM-1-possessing 
Enterobacteriaceae in India (Lascols et al. 2011, K han and Nordmann 2012), Africa 
(Poirel et al. 2011b) and Norway (Samuelsen et al. 2011). Interestingly in this study, 
7.2% of plasmid NDM-1 resistance among Acinetobacter baumannii isolates, in which 
blaTEM-1 and blaSHV -1 co-existed as additional enzymes probably contributing to CR 
Gram-negative bacterial resistance, is reported for the first time. 
 
In this present study, plasmid profiling has shown that resistance genes were carried on 
plasmids. On average, the original plasmid-bands of seven were reduced to four or three 
after the curing experiments. However, the majority of the profiles obtained from 
diverse species of CR pathogens studied, including the cured carbapenemase-positive 
gene carriers, showed different patterns of band sizes from plasmids. The indication was 
that most of the CR isolates were carrying different unknown plasmids from their 
various hospitals where they were isolated. In susceptibility testing by the disc diffusion 
method, all cured isolates showed a significant reduction in MIC to either one or two 
carbapenems tested. MIC assays performed against carbapenems (imipenem, 
meropenem and ertapenem) were observed to have 2- or 4-fold reductions in MIC 
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values, except in one of the cured carbapenemase-producing Acinetobacter baumannii 
isolates and eight (7.2%) of the cured carbapenemase non-PCR positives that 
maintained the same MIC levels of >32 µ g/ml as previously tested in the original state. 
The results of the MIC assays were suggestive of chromosomal mediated resistance, 
ineffective curing or that there were no relevant plasmids for this isolate. Additionally, 
there could be some mimicking effects of non-plasmid mediated resistance and/or 
AmpC-type of β-lactamases that co-existed with the cabapenemase resistance genes. 
Other studies have suggested that the presence and alteration of specific outer 
membrane proteins may significantly contribute to carbapenemase resistance (Landman, 
Bratu, Quale 2009, Mataseje et al. 2011).  
 
Other important findings include the observation that no two plasmid-borne 
carbapenemase-producing genes were detected in a single CR isolate, and the absence 
of blaK PC-1 and blaIMP-1 genes in all the plasmid DNA samples. These two 
carbapenemase resistance genes, due to their limited spread, are scarcely experienced in 
most studies conducted in Africa (Manenzhe et al. 2014). This phenomenon across the 
African continent is in agreement with the present study.  
 
In this study, restriction enzyme digestion profiling of the cured carbapenemase-positive 
gene carriers exhibited different plasmid-mediated resistance genes except in a few CR 
isolates depending on the species. Notably, there are isolates commonly encountered 
from the reservoir of intestinal flora which were among the CR isolates studied, 
especially, the cured carbapenemase-positive gene carriers: Providencia stuartii, 
Klebsiella pneumoniae, Escherichia coli and Shigella sonnei isolates. These organisms 
may easily acquire plasmid-borne resistance genes from different sources of specimen 
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within the four different regional hospital centres and may pose challenges in the 
evaluation of band size similarities. This study was able to identify a small number of 
cured CR isolates that have some unclear identity on the agarose gel electrophoresis. 
The band patterns were commonly linked to blaNDM-1- and blaV IM-1-encoded genes 
rather than to the OX A-48 gene with slight differences in the band sizes of the digested 
plasmid-mediated DNA occurring in Acinetobacter baumannii and Pseudomonas 
aeruginosa isolates. This finding is in agreement with a study conducted by Rasheed et 
al. (2008) in which two different multidrug-resistant Gram-negative bacterial pathogens 
harbouring a common plasmid from two different care-receivers in the same hospital 
were found at identical band sizes. This indication showed that there was some evidence 
of horizontal dissemination of plasmid-borne carbapenemase resistance genes between 
the two clinically important pathogens by restriction digestion (Rasheed et al. 2008). 
 
Globally, plasmid analysis has increased awareness of the various types of plasmids in 
most outbreak situations circulating within a particular region or area (Tato et al. 2010). 
Plasmids investigations are crucial in clinically relevant pathogens usually by PCR-
based assays and sought to reveal differences or similarities on agarose gel 
electrophoresis during an outbreak situation to assist in the development of an 
immediate treatment action plan. Currently, the spread of carbapenemase resistance 
genes are largely linked to horizontal transfer of an array of plasmid-borne β-lactamase 
genes. Several epidemiology studies, for instance, have recognised a high diversity of 
plasmid resistance genes linked to the blaNDM genes, particularly, IncA/C types 
mainly spreading into the Enterobacteriaceae group (Poirel et al. 2011a, Carattoli et al. 
2012). Others such as IncFII, IncH, IncL/M and IncN types have also been found linked 
to the appearance of blaNDM, often in association with clinically important 
antimicrobial resistance genes notably, CMY -type β-lactamases for cephalosporin 
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resistance, qnrA for quinolone resistance, and rmtA and rmtC also responsible 
resistance genes to aminoglycosides (Pitout, Nordmann and Poirel 2015). The capture 
of blaV IM-1 has been commonly detected in integrons harbouring aadA and aacA4 
cassettes, usually such plasmids were found in the population of Pseudomonas or 
Enterobacteriaceae which are widely disseminated in Europe (Tato et al. 2010). In 
contrast, several laboratory-based studies have reported that the detection of the V IM-2 
gene is limited to plasmid-mediated Pseudomonas aeruginosa isolates: 100% (57/57) in 
K enya (Pitout et al. 2008), 100% (30/30) in Tunisia (K tari et al. 2011), 73% (11/15) in 
South Africa (Jacobson et al. 2012) and 58% (7/12) in the Ivory Coast (J eannot et al. 
2013). On a different note, OX A-48-producing isolates have been recognised to have 
only one type of plasmid-borne OX A-48a at a range size of 62 kb which belongs to the 
IncL/M group and currently found in many geographical locations which are different 
from those observed with the blaNDM genes (Poirel, Bonnin and Nordmann 2012). 
 
There were several limitations to this plasmid study analysis, some plasmid-encoded 
genes of interest could not be determined because of the non-availability of resources 
and materials. Firstly, lack of experimental reagents and various primer-sets to extend 
the investigations to plasmid-mediated CTX -M and AmpC β-lactamase genes, including 
relevant antimicrobial resistance genes of significance in the health care delivery system 
such as: qnrS and qnrB for fluoroquinolone resistance and RmtA and RmtC for 
aminoglycoside resistance genes. Other detailed investigations into aminoglycoside-
modifying enzymes (AMEs) for aminoglycoside resistance gene cassettes such as  
acetyltransferases AAC (3)-Ia (aacC1), nucleotidyl transferases ANT (2'')-Ia (aadB), 
ANT(3")-Ia (aadA1) and phosphotransferases APH (3')-V ia (aphA6), conferring 
gentamicin resistance in Acinetobacter baumannii isolates have been critically 
evaluated (Aliakbarzade et al. 2014). These resistance genes are on plasmids, otherwise, 
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further investigations may have revealed associations with carbapenemase-producing 
genes since ciprofloxacin and gentamicin or both used in combination have been 
frequently used to manage highly resistant Gram-negative bacterial infections in 
Ghanaian hospitals (Opintan et al. 2015). Secondly, standard control strains on plasmids 
such as pCTX -M, pAmpCs and pAMEs were unavailable during the conjugation 
experiments. These control strains may have served as markers for obtaining reasonable 
band lanes to match with the unknown plasmid-borne resistance genes for more 
comprehensive comparison of the various plasmid bands on gels.  
 
The results generated from this study, suggest that genes encoding for most the 
plasmids were unknown at different band locations. Further studies are needed in the 
transfer experiments in order to identify various resistance genes which may 
incapacitate carbapenem antimicrobials. An area of interest is the mechanism of spread 
of resistance genes than growth and division of the initial transconjugant cells. By 
simple conjugation method, the number of transconjugant cells over time intervals that 
would retain the resistance genes could be identified. The findings may assist 
determination of conjugation frequency rate and also put in place control measures of 
any possible outbreak of CR isolates that may occur in hospitals.  
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In this study, common plasmid resistance genes and some unknown resistance genes 
may have contributed to resistance of carbapenemases in both carbapenemase non-PCR 
positives and carbapenemase-positive gene carriers. The curing method by using high 
temperature was simple and successfully eliminated most plasmids with reduced 
susceptibility to the carbapenems tested. The diversity of the CR isolates investigated 
was broad, those in association with carbapenemase resistance genes showed substantial 
prevalence of unknown plasmid-borne patterns with a high-level of ESBL enzymes. 
The findings of the transfer experiments had also shown that if strict measures are not 
taken to curb infection, rapid spreading of resistance genes may spread from carriers to 
commensal organisms living in a poly-microbial environment (e.g. the gastrointestinal 
tract) by conjugation. In order to curb the spread of infections, clinicians would be 
advised to separate infected patient from contact with uninfected persons in the hospital. 
The presence of these resistance genes is attributable not to clonal spread, but rather, 
may aide the dissemination of plasmids among genetically diverse isolates that are 
found in the hospital facilities. 
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Chapter five 
 
5. Genetic relatedness of carbapenem-resistant isolates from Ghana 
using E R IC-PCR  technique 
 
5.1 Background  
 
The enterobacterial repetitive intergenic consensus (ERIC) technique is a molecular 
method that has been added to the methods used for the epidemiological analysis and 
genotyping of bacterial species. The application of ERIC offers a greater potential for 
the study of the development of bacterial interspersed repetitive arrangements because 
sequences are lengthier without targeting a specific region of the genome. In addition, it 
offers detailed information to enable the comparative analysis in a wider range of 
bacterial species (Wilson and Sharp 2006, Stefańska, Rzewuska and Binek 2008).  
 
It is noteworthy that the ERIC technique has been used in different areas of research 
including veterinary microbiology (Guimarães et al. 2011), food microbiology (Munoz 
et al. 2011) and in particular, various clinical areas dealing with human infections 
within the hospital environment (Rai et al. 2014, Durmaz et al. 2015). Indeed, ERIC-
PCR can be used to study human pathogens, in both Gram-positive and -negative 
bacterial isolates in order to determine their genetic diversity, and occasionally extended 
to bacterial pathogens in the animal kingdom. Further, genomic DNA fingerprints from 
ERIC-PCR have proved to be useful for the investigation of other organisms apart from 
those in the Enterobacteriacae family such as Aeromonas species (Szcuka and 
K aznowski 2004), Staphylococcus aureus (Sabat et al. 2006) and Haemophilus parasuis 
(Wei et al. 2011). More recently, the application of ERIC-PCR has been used to 
investigate opportunistic pathogens, Pseudomonas aeruginosa and Acinetobacter 
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baumannii isolates capable of causing outbreaks in hospitals worldwide (Urban, Segal-
Maurer and Rahal 2003, Nigro, Post and Hall 2011, Siqueira et al. 2013, Freeman et al. 
2015). Notably, isolates from Pseudomonas and Acinetobacter can easily acquire 
multiple resistance to a panel of antimicrobials including carbapenems, share common 
genes, transfer resistant traits both intra and interspecies, and the encoded genes they 
carry are extremely mobile, particularly in Pseudomonas aeruginosa (Armand-Lefevre 
et al. 2013, Meletis 2016). Good reproducibility and applicability in the determination 
of closed relatedness have been reported in several studies on a variety of pathogens, 
which share the same homogeneities. For most Gram-negative bacterial strains, 
diversity/similarity among pathogens have traditionally been determined using 
antimicrobial resistance patterns, basic microbiological methods or genotyping methods 
such as by gene expression using microarray technology, multilocus sequence typing 
(MLST), pulsed field gel electrophoresis (PFGE) and Enterobacterial repetitive 
intergenic consensus (ERIC). Irrespective of the species they belong to, the ERIC 
technique has been used to study Enterobacter sakazakii (Y e et al. 2009), Pseudomonas 
aeruginosa (Stehling, Leite and Silveira 2010, K idd et al. 2011) and Acinetobacter 
baumannii isolates (V iana et al., 2011).  
 
Results presented in Chapters 3 and 4 have identified the presence of three types of 
carbapenemase genes (NDM-1, V IM-1 and OX A-48) that were associated with the 
common plasmid-borne ESBL β-lactamases (TEM-1 and SHV -1) and unknown 
resistance genes of importance in the profiling analysis of plasmids which have not yet 
been identified. In most cases, the ERIC assay has generated DNA patterns, which 
enable the differentiation of plasmid-borne resistance genes found in pathogenic 
organisms. Several studies have shown remarkable successes using ERIC-PCR assay to 
distinguish bacterial strains among diverse species (X ia et al. 2012, Ramazanzadeh, 
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Zamani and Zamani 2013, Martins et al. 2014, Filgona, Banerjee and Anupurba 2015, 
Abdalhamid et al. 2016). To date, there are no reports on the investigation of the 
presence of β-lactamase determinants in CR isolates and their clonal relatedness or 
variabilities in Ghana. This study aimed to broadly determine the genetic relatedness or 
variability in both carbapenemase non-PCR positive and PCR-positive isolates by 
species, and separately assess clonal similarities same for all the PCR-positive species 
using fingerprint patterns generated by ERIC-PCR amplifications.  
 
The specific objectives were to: 
ñ Perform genomic DNA typing of carbapenem-resistant isolates using ERIC-
PCR assay technique 
ñ Determine the various genetic diversities of all CR isolates with regard to the 
presence of the common ESBL β-lactamases and carbapenemase resistance 
genes acquired in the four regional hospitals 
ñ Determine clonal similarities of CR isolates in relation to the bacterial species 
and source of specimens 
ñ Detect the genetic relatedness of all PCR-positive species linked with the 
resistance genes identified. 
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5.2 Method summary 
Genomic DNA samples of all CR isolates were amplified using the ERIC-PCR assay 
technique to construct the dendrograms. Positions of the band lanes on each agarose gel 
electrophoresis were normalised using the standard 1 kb DNA molecular marker. The 
location of each given band was located as one and no band as zero. The nearest band 
patterns of each bacterial species were used to analyse the similarity or variability 
matrix calculated by the number of base differences. Dendrograms of ERIC-PCR 
fingerprint patterns were assembled for both PCR carbapenemase negatives and 
carbapenemase positive gene carriers together and separately for all carbapenemase 
positive gene carriers based on each species using Gel ComparII image analysis 
software (version 6.6.11, Applied Maths, K ortrijk, Belgium), and applied the 
unweighted pair group method with arithmetic mean (UPGMA) cluster method. The 
full description is in Chapter two of this study.  
 
5.3 R esults 
In this study, the ERIC molecular setup described in Chapter 2 section 2.9 was used. A ll 
genomic DNA samples and their relevant controls were successfully amplified using the 
PCR method. The presence of DNA banding patterns representing known or unknown 
resistance genes in all of the CR isolates, including 10 different Gram-negative bacterial 
pathogens comprising: Pseudomonas, Acinetobacter, Klebsiella, Enterobacter, 
Providencia, Shigella, Cronobacter, Sphingomonas species and Escherichia coli were 
analysed. Gel electrophoretic patterns revealed high level of variation in which a 
majority of the fingerprints resulted in single or multiple DNA yields with 1 to 8 bands 
ranging from 50 to 800 bp. Band patterns of 93 complex dissimilarities were visually 
distinguished from the 111 CR isolates studied, while the remaining 18 showed band 
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similarities in pairs: sample number 1 & 14, 12 & 18, 26 & 36, 33 & 35, 38 & 39, 41 & 
45, 42 & 43, 58 & 59 and 94 & 97. Figure 5.1 shows a representative band patterns in 
which sample number 58 exhibits band relatedness to sample 59 by visual inspection. 
Other band patterns of CR isolates and control strains by ERIC-PCR profiling are 
shown on agarose gel electrophoresis (see Appendix 6). 
  
 
M     55     56    57     58    59     60     61    62     63    64    65    66     67    68    69    70 
 0.1kb 
 0.6kb 
  1kb 
 
F igure 5.1 R epresentative example of E R IC  fingerprints of different carbapenem-
resistant isolates on agarose gel electrophoresis 
Note: M= DNA 1 kb marker, 55 through to 70= CR isolate number listed in Appendix 1. By 
visual inspection sample numbers 58 & 59 are showing close relatedness on the gel. 
 
The dendrogram data from the computer-designed analysis for both carbapenemase 
non-PCR positives and PCR-positive CR isolates were evaluated together to analyse the 
genetic diversity or close relatedness. 
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Group A: P. aeruginosa CR isolates with control strains 
 K ey                  Organism                           Location          
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Group B: P. putida CR isolates 
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Group C: A. baumannii CR isolates 
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Group D: E. coli CR isolates with control strains 
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Group F: En. cloacae CR isolates 
 
Figure 5.2 Dendrogram generated from E R IC-PCR  genomic DNA products for 
both carbapenemase non-PCR  positives and carbapenemase-positive gene carriers 
Note: K ey= isolate number or control strain/type number and CR= carbapenem-resistant. 
Regarding the type of isolate, resistance gene, hospital location and source of specimen, the 
following groupings based on type of species: Group A (P. aeruginosa) 60 & 74 (V IM-1 
positive) and 1 & 3; Group B (P. putida) 83 & 88; Group C (A. baumannii) 34 & 36, 42 & 43 
(NDM-1 positive), 38 & 75 and 67 & 85; and Group F (En. cloacae) 33 & 95 are showing close 
relatedness in cluster-pairs.  
 
K ey                               Organism                        Location                   
Source 
K ey                    Organism                                   Location                 
K ey                    Organism                                 Location             
Source 
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T able 5.1 Genetic relatedness for both carbapenemase non-PCR  positives and carbapenemase-positive gene carriers 
 
Sample 
code 
number
a
 
 
Name of 
carbapenem- 
resistant isolate 
Regional hospitals  
Type of 
specimen 
ESBL  β-lactamase genes Carbapenemase genes 
 
K BTH 
 
ENRH 
 
AGMH 
 
HRH 
 
TEM 
 
SHV  
 
NDM 
 
V IM 
 
OX A 
60* & 74* P. aeruginosa + - - - Urine + + - + - 
1 & 3 P. aeruginosa + - - - Wound + + - - - 
83 & 88 P. putida + - - - Urine + + - - - 
34 & 36 A. baumannii + - - - Aspirate + + - - - 
42* & 43* A. baumannii + - - - Wound + + + - - 
38 & 75 A. baumannii + - - - Urine + + - - - 
67 & 85 E. coli +  - - - Urine + -
b
 & + - - - 
33 & 95 En. cloacae + - - - Urine + + - - - 
 
a
 Cluster-paired sample numbers 
*Positive carbapenemase-positive gene carriers 
-
b
 SHV  negative gene for isolate number 67 
 
Note:  += found in both, -= not found in both  
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For easier comparison and recognition, Table 5.1 is showing similarity details analysed 
from Figure 5.2. There was great dissimilarity among all the CR isolates, except for 6 of 
the Acinetobacter baumannii, 4 Pseudomonas aeruginosa, 2 each of Pseudomonas 
putida, Escherichia coli and Enterobacter cloacae isolates which demonstrated cluster-
pair similarities, respectively. One cluster-pair each of Acinetobacter and Pseudomonas 
aeruginosa isolates were identified to carry NDM-1 gene (number 42 & 43 from wound 
samples) and V IM-1 gene (number 60 & 74 from urine samples), while the other 
cluster-pairs were carbapenemase non-PCR positive carriers (numbers: 1 & 3, 83 & 88, 
34 & 36, 38 & 75, 67 & 85 and 33 & 95) with different ages; 58 & 31, 4 & 44, 13 & 55, 
35 & 29, 1
1
/52 & 33 and 4 & 30 years, respectively. Interestingly, the close relatedness 
among the bacterial species were commonly observed from male patients (see Appendix 
1) from a regional hospital (K orle Bu Teaching hospital, Greater Accra). Overall ERIC 
data obtained from diverse clinical specimens indicate that the majority of the CR 
isolates were not horizontally transmitted within the hospital, since few have shown 
similarities. 
 
High genetic dissimilarity was also observed among the 26 PCR-positive 
carbapenemase carriers with few distinguishable patterns based on species of CR 
isolates (Figure 5.3). However, 2 cluster-pairs of Acinetobacter baumannii and cluster-
pair Pseudomonas aeruginosa isolates were harbouring NDM-1 and V IM-1 genes, 
respectively. 
 
 
183 
 
 
 
1
0
0
5
0
102
27
72
108
50
64
46
42
43
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
A. baumannii (NDM-1 positive)
Accra
Accra
Accra
Accra
Accra
Accra
Accra
Accra
Accra
Wound
Wound
Wound
Urine
Urine
Wound
Wound
Wound
Wound
 
Group A: A. baumannii NDM-1 positive gene carriers 
 
 
1
0
0
5
0
02
105
05
E . coli Top 10 Competent cell
E  coli ATCC  25922 control strain
E . coli (NDM-1 positive)
E . coli (NDM-1 positive)
E . coli (NDM-1 positive)
Accra
Accra
Accra
Wound
Urine
Wound
 
Group B: E. coli NDM-1 positive gene carriers with control strains 
 
 
1
0
0
8
0
6
0
4
0
2
0
06
NCTC 13437 
07
60
74
100
62
 ATCC 27852
39
P. aeruginosa (VIM-1 positive)
P. aeruginosa VIM (+ve) control
P. aeruginosa (VIM-1 positive)
P. aeruginosa (VIM-1 positive)
P. aeruginosa (VIM-1 positive)
P. aeruginosa (VIM-1 positive)
P. aeruginosa (VIM-1 positive)
P. aeruginosa (CR  -ve)
P. aeruginosa (VIM-1 positive)
Accra
Accra
Accra
Accra
Obuasi
Accra
Accra
Wound
Wound
Urine
Urine
Wound
Wound
Wound
 
Group C: P. aeruginosa V IM1-1 positive gene carriers with control strains 
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F igure 5.3 Dendrogram generated from E R IC-PCR  genomic DNA products for 
carbapenemase-positive gene carriers  
 
Note: K ey= isolate number or control strain/type number. Regarding the groupings based on 
type of species, type of resistance gene, hospital location and source of specimen, the following 
groupings based on type of species: Group A (A. baumannii NDM-1 positive) 102 & 27, 42 & 
43 and 50 & 44 in urine and wound respectively; Group B (E. coli NDM-1 positive) 02 & 105 
in wound and urine respectively; Group C (P. aeruginosa V IM-1 positive) 60 & 74 are showing 
close relatedness in cluster-pairs 
 
 
For easier comparison, Table 5.2 illustrates the actual relatedness analysed from Figure 
5.3. Strikingly, the only cluster-pair of OX A-48 carrying Klebsiella pneumoniae isolates 
were genetically related from male patients, however, they were observed to have come 
from different age groupings, specimens and hospitals in this study.  
 
 
 
K ey                 Organism                                    Location                 
Source 
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T able 5.2 Genetic relatedness among the carbapenemase-positive gene carriers 
 
Sample 
code 
number
a
 
 
Name of 
carbapenem- 
resistant isolate 
Regional hospitals  
Type of 
specimen 
ESBL  β-lactamase 
genes 
Carbapenemase genes 
 
K BTH 
 
ENRH 
 
AGMH 
 
HRH 
 
TEM 
 
SHV  
 
NDM 
 
V IM 
 
OX A 
102 & 27 A. baumannii + - - - Wound + + + - - 
42 & 43 A. baumannii + - - - Wound + + + - - 
50 & 64* A. baumannii + - - - Urine & 
Wound 
+ + + - - 
02 & 105* E. coli + - - - Wound & 
Urine 
+ + + - - 
60 & 74 P. aeruginosa + - - - Urine + + - + - 
 
a
 Cluster-paired sample numbers 
* Closely related but different specimens respectively 
Note: += found in both, -= not found in both 
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5.4 Discussion 
Recently, molecular characterisation based on ERIC fingerprinting has become a new 
area of interest for the analysis of bacterial similarity or variability found in ecological 
niches. In this context, ERIC-PCR is described as a simple, reliable, reproducible, cost-
effective and discriminatory genotyping method appropriate for use in rapidly clustering 
genetically related microbial pathogens responsible for both hospital and community 
acquired infections (Wilson and Sharp 2006, Sabat et al. 2013, Durmaz et al. 2015). 
Other potential genotyping applications include: detection of strain diversity, gene 
mapping, epidemiology studies and taxonomic similarities (Guimarães et al. 2011). 
 
The aim of the present study was to analyse the genetic relatedness or variability among 
CR isolates from Ghana. The study analysis has shown a high degree of genetic 
diversity among the CR isolates using the ERIC-PCR technique. ERIC-PCR 
fingerprints have proved the existence and expression of MBL-types namely; NDM-1- 
and V IM-1-type of genes following genomic DNA optimisation of both carbapenemase 
non-PCR positives and carbapenemase positive gene carriers. A  study by Abdalhamid 
et al. (2016) described the expression of the two genes as highly transmissible on 
mobile elements that can easily spread from one patient to another in a health-care 
environment (Abdalhamid et al. 2016).  
 
The difference in genetic diversity that existed between carbapenemase non-PCR 
positives and carbapenemase-positive producers was observed in the non-fermenting 
isolates including those in the Enterobacteriaceae group. ERIC-PCR typing showed 
distinguishable fingerprints for the 111 CR isolates. In assessing the patterns of all 
fingerprints, 83.8% (93/111) were observed to have substantial variability among the 10 
diverse CR isolates recovered from the four hospitals. However, a small number of the 
187 
 
non-fermenting, Acinetobacter baumannii and Pseudomonas aeruginosa isolates were 
observed to have close relatedness. Of significance to this study, the ERIC-PCR 
profiling has shown the diversity that existed among the various species of pathogens 
within the CR isolates. Notably, in the carbapenemase-positive gene carriers, the only 
two cluster-pairs NDM-1 positive Acinetobacter baumannii and cluster-pair V IM-1 
positive Pseudomonas aeruginosa isolates were only detected from the K orle Bu 
Teaching Hospital (K BTH) in the Greater Accra region (Table 5.1 and 5.2) and none of 
these cluster relations were detected in the three other regional hospitals studied.  
 
The presence of these MBL-types of resistance genes, coupled with ESBL production 
and the unknown number of other resistance genes encoded in Acinetobacter baumannii 
isolate is of major concern in a hospital environment (Bassetti, Ginocchio and Mikulska 
2011). The two isolates, Pseudomonas aeruginosa and Acinetobacter baumannii have 
been described as environmental and opportunistic pathogens naturally adaptable in 
hospitals to cause serious infections, with mortality rates ranging from 18% to 61% 
(Nordmann and Poirel 2014). Conversely, clonal transfer of resistance genes are 
commonly associated with these non-fermenting isolates in several studies worldwide 
(Stehling, Leite and Silveira 2010, K aase et al. 2011, Armand-Lefè vre et al. 2013, 
Diene and Rolain 2014, Mathlouthi et al. 2015). 
 
The virulent characteristics of Acinetobacter baumannii and Pseudomonas species are 
known to cause serious infections, and have the propensity to colonise most health-care 
facilities and also the capacity to harbour antimicrobial determinant genes. Most 
vulnerable patients such as the elderly in ICUs, and children and babies admitted in 
NICU may be prone to infections caused by these organisms (Hewitt et al. 2013, 
Berezin, Solórzano and the Latin America Working Group on Bacterial Resistance 
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2014). An evidence based study carried out in the paediatric and NICU wards recovered  
emerging carriers of OX A-type carbapenemase genes in Pseudomonas and 
Acinetobacter species (Siqueira et al. 2013), while both species have been found as 
carriers of the MBL-type genes, commonly in Acinetobacter isolates (Bush and Jacoby 
2010, Roca et al. 2012).  
 
Berezin, Solórzano and the Latin America Working Group on Bacterial Resistance 
(2014) described the infections of Pseudomonas and Acinetobacter species as most 
critical when additionally associated with resistance genes for fluoroquinolones, 
tetracyclines, sulphonamides, and aminoglycosides encoded on the same moveable 
genetic elements (Berezin, Solórzano and the Latin America Working Group on 
Bacterial Resistance 2014). The presence of ESBL  enzymes in these non-fermenting 
isolates is their common risk factors for carbapenemase resistance. Further, ESBL  
production becomes problematic when in association with carbapenemase resistance 
genes, usually identified with a reduced susceptibility to third-generation 
cephalosporins and quinolones, whereas on the contrary, in the Enterobacteriaceae 
group moderate susceptibility is observed in the same antimicrobial drug classes when 
phenotypically assessed (Armand-Lefè vre et al. 2013, Meletis 2016).  
 
In the present study, a computer-generated profiling of ERIC-PCR revealed that 14.4% 
(16/111) of both the carbapenemase non-PCR positive and carbapenemase-positive 
isolates which displayed multiple band patterns comprising; 9 (8.1%) isolates of 
Acinetobacter baumannii, 4 (3.6%) Pseudomonas aeruginosa, 2 (1.8%) each of 
Pseudomonas putida, Escherichia coli and Enterobacter cloacae respectively showed 
cluster patterns. These few species were indicating a related origin of dissemination, 
especially those from the Pseudomonas and Acinetobacter baumannii species in this 
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study. A  similar study conducted by Siqueira et al. (2013) found that small pocket 
groupings of Pseudomonas and Acinetobacter encoded with carbapenemase resistance 
genes were detected showing clonal similarities by the ERIC-PCR amplification 
technique in a Brazilian hospital (Siqueira et al. 2013). Of note, these findings were 
comparable to those in this present study, in which close relatedness were found 3 
cluster-pair patterns of Acinetobacter baumannii isolates recovered from aspirate, 
wound and urine, and 2 cluster-pair Pseudomonas aeruginosa isolates from urine and 
wound specimens. Interestingly, the relatedness was identified in the same hospital, 
K orle Bu Teaching Hospital in the Greater Accra region. The significance of the 
findings attest to the fact that the hospital is the largest hospital in the study receives the 
largest number of patients and serves as the largest tertiary and referral centre in the 
whole country. However, close relatedness of ERIC-PCR fingerprints was unexpectedly 
observed between the 2 PCR-positive OX A-48 Klebsiella pneumoniae isolates since 
both were recovered from different hospitals; AGMH and ENRH, while the sample sites 
were also different; sputum and wound, respectively. 
 
The findings presented here suggest high genetic diversity existed among the CR 
isolates may have harboured other unknown resistance genes that can potentially cause 
cross-transmission, together with the small number of positive NDM-1 Acinetobacter  
and V IM-1 Pseudomonas aeruginosa isolates identified as closely related in cluster-pair 
patterns by ERIC-PCR fingerprints. However, these resistance gene are emerging and 
may require further infection control measures to be implemented in the care facility. 
The significance of the genetic relatedness of the few cluster-pairs identified by ERIC-
PCR has given an indication of the relatedness of carbapenemase genes in 
dissemination. Besides the common ESBLs (TEM-1 and SHV -1) detected, various 
banding patterns may be associated with other antimicrobial resistance genes. It is 
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noteworthy and of concern, that large numbers of non-PCR carbapenemase-positive 
Acinetobacter and Pseudomonas isolates may possibly be associated with non-
carbapenemase-related resistance features or unknown resistance genes that can also 
disseminate into different bacterial isolates within the same health-care facility. Further 
studies on non-carbapenemase-related resistance need to be systematically carried out.  
 
The multiple plasmid bands in these nosocomial non-fermenting pathogens were 
observed in this study, which have the capacity to harbour many resistance genes, make 
them a clinical concern as well as major public health threat. The multi-resistant nature 
of these bacterial pathogens to commercially available antimicrobials subsequently 
renders their treatment extremely challenging. Of clinical significance is the emergence 
of plasmid-encoded AmpC cephalosporinases. These AmpC enzymes are resistance 
determining attributes' to carbapenems that may be prevalent in those detected as 
carbapenemase non-PCR positive Acinetobacter baumannii and Pseudomonas 
aeruginosa isolates. The production of AmpC enzymes may be implicated in both 
carbapenemase-positive producers and carbapenemase non-PCR positives and may have 
the ability to spread to other clinically relevant pathogens in the same hospital setting.  
 
In summary, ERIC-PCR fingerprints have shown a great diversity among the species of 
Gram-negative bacterial pathogens and specimen collection sites in this study. There 
was a small number of cluster-pairs from both carbapenemase non-PCR positives and 
carbapenemase-positive gene carriers that exhibited close genetic relatedness, 
particularly in Acinetobacter baumannii and Pseudomonas aeruginosa isolates. The 
presence of the carbapenemase genes in clinical isolates from Ghana is revealed for the 
first time. Therefore, necessary steps should be taken to contain the spread of resistance 
genes, most especially frequent transfers of patients to affected areas or wards within 
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the hospitals should be avoided. These study findings underpin the need to 
implementing serious and preventive measures to control resistance-gene dissemination 
into the Ghanaian population. The emerging worldwide threat of drug resistance 
requires that all countries make all effort to understand the trends of resistance patterns 
at a local and national level. A lthough current efforts can prevent the emergence of new 
resistance patterns they may not reverse existing patterns in the Ghanaian population.  
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Chapter six 
 
6. Overall discussion, conclusion and future work 
 
6.1 General discussion 
This study aimed to apply various phenotype- and genotype-based techniques to 
identify and characterise carbapenemase resistance in Gram-negative bacterial 
pathogens in Ghana. A  diverse number of carbapenemase resistance genes have been 
reported worldwide including many African countries. In Ghana, no known extensive 
studies have been carried out and published on carbapenemase resistance genes using 
clinical isolates. 
 
It is noteworthy that the first V IM-2 gene found in Pseudomonas aeruginosa was 
isolated in Norway from a Ghanaian patient (Samuelsen et al. 2009), but since then 
there has been no follow-up studies to ascertain the presence and existence of the V IM-
2 resistance gene in the Ghanaian population (Manenzhe et al. 2014). Indeed, since the 
detection of the V IM-2 gene in 2009, no molecular studies have been carried out on 
carbapenem resistance mechanisms in the country. To the knowledge of the author, this 
present study is the only research study that has explored the carbapenemase 
determining genes in clinical isolates. Thus, the presence of the V IM-2 gene had 
confirmed that the occurrence of V IM-types may have existed long ago among some 
species of Pseudomonas in the Ghanaian population. 
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The primary approach was to apply basic phenotypic tests and genotyping techniques 
available in Ghana that would easily detect and characterise the presence of 
carbapenemase resistance genes for the first time in the country. The emphasis was that 
Ghana as a developing country is faced with numerous constraints and resources 
deficiencies for investigating important health-related studies. In this regard, engaging 
in more sophisticated and laborious techniques may require collaborative support from a 
funding agency or the Ghana Government. Long delays of securing funding support and 
lack of sponsorship from funding agencies are some of the cumulative setbacks for 
carrying out meaningful and extensive studies in Ghana. The resources available were 
only to support conventional methods of culture and susceptibility testing, inexpensive 
phenotype-based tests that could easily be applied and the use of basic genotypic assay 
such as PCR technique. Importation difficulties, cumbersome procedures and unstable 
currency exchange rate systems are major challenges, compounded with unusual delays 
at the ports on receipt of purchased chemicals, reagents and consumables. Sometimes 
importation items are rendered unreliable, when reagents that require freezing at an 
ambient temperature of -20 ºC at the ports are usually kept under poor conditions due to 
frequent electricity power outages.  
 
In Ghana, carbapenems are not used in the management of patients with serious 
bacterial infections except meropenem, which is strongly recommended because the 
usage of the drug could be extended to cover children over the age three, and strictly 
given to patients whose laboratory reports show complete resistance to third or fourth 
generation cephalosporins and quinolones (Ghana Essential Medicines L ist 2010). High 
resistance observed in the disc diffusion and the MIC investigations are clearly in 
agreement with the assertion that the detection of carbapenemases may not necessarily 
be exclusively due to carbapenems but may be caused by a combination of additional 
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resistance mechanisms (Baroud et al. 2013). In this present study, over 76.6% (85/111) 
of the CR isolates were found to be carbapenemase non-PCR positives which needed 
further investigation. In Africa, the presence of different carbapenemase resistance 
genes have recently been reported in Morocco (Barguigua et al. 2013), Egypt (Fouad et 
al. 2013), Ivory Coast (J eannot et al. 2013), Nigeria (Olaitan et al. 2013), and South 
Africa (Govind et al. 2013).  
 
The findings following the phenotype-based assays, the molecular characterisation, 
outer membrane protein profiling, plasmid profiling and ERIC-PCR analysis of the CR 
isolates, suggested that the hospital environments may act as a reservoir of resistance 
determining genes. Of particular relevance are those CR species namely: Acinetobacter 
baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, 
Pseudomonas putida, Providencia stuartii and Shigella sonnei that harbour the various 
resistance genes. The majority of the resistance genes were found in non-fermenting 
Acinetobacter baumannii and Pseudomonas aeruginosa isolates identified from 
different clinical specimens obtained from four geographically and demographically 
unrelated regional hospitals in Ghana. These two species were significantly from 
wound, urine, sputum and aspirate specimens, however, no CR isolates were cultured 
from blood samples. Thus, poor environmental conditions in health-care facilities may 
have contributed to their presence and at the same time may act as a reservoir for the 
carbapenemase resistance determining genes. This is because these species are 
ubiquitous environmental organisms that are often found in the hospital setting. 
Presently, there is no epidemiological record to ascertain this fact since this present 
study is the first to reveal the prevalence and distribution of carbapenemase genes in the 
country's hospitals.  
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In the present study, phenotype-based tests only revealed CR resistance patterns to 
carbapenems and few numbers were detected as having carbapenemase activity. Most 
previous studies conducted on bacterial resistances were based on phenotypic analysis 
without applying molecular techniques. Studies conducted on antimicrobial resistance 
in a few Ghanaian hospitals saw a rise of bacterial resistance without detectable 
resistance to carbapenems (Newman et al. 2011, Feglo et al. 2013). In most African 
countries, and in particular in Ghana, identification of bacterial resistance strains is 
routinely performed as an investigative tool in order to offer researchers vital 
information on the spread of hospital infections. The high-level of antimicrobial 
resistance has existed for several decades, especially on the continent of Africa due to 
non-compliance of drug use (WHO 2014). The emergence and occurrence of multidrug 
resistance has been attributed to the lack of antimicrobial drug controls. According to 
Habte-Gabr (2010) and WHO (2014) the problems of resistance could only be managed 
properly by: education of the public, training prescribers of antimicrobials, improved 
access to diagnostic laboratories, constant surveys to detect the emergence of resistance 
and the existence of a policy to regulate the use of antimicrobial agents (Habte-Gabr 
2010, WHO 2014).  
 
Indeed, several changes in investigative methodologies by different groups of experts 
have been made in order to standardise the procedures, and to take into account the 
inherent factors that constantly affect the suitability of susceptibility testing. These 
factors include the rates of mutations occurring in most bacterial species, reproducibility 
and cultivable growth medium that can support the majority of bacterial growth. 
Notably, the use of disc diffusion susceptibility testing alone could not have revealed 
the major findings following the phenotype-based tests performed for carbapenemase 
activity. The application of susceptibility testing techniques narrows the scope of 
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determination and identification of serious infection situations involving ESBLs, 
AmpC, and metallo-β-lactamase enzymes in Gram-negative bacilli. Apart from these 
phenotype-based methods, PCR-based techniques are preferred for the determination of 
the distribution, prevalence, plasmid analysis and clonal relationship of multidrug 
resistance most especially the trend of carbapenemase-producing isolates. In some parts 
of Africa, investigators lack the expertise and technical competency in using molecular 
techniques regularly in their research studies. A  recent study conducted by Opintan et 
al. (2015) reported that the levels of antimicrobial resistances are of concern because of 
the unregulated use of antimicrobials by Ghanaians as a result of which various 
antimicrobial resistances are conferred. The study also detected different multidrug-
resistant isolates, including Gram-negative bacilli with ESBL-producing strains in a 
nationwide laboratory-based survey. However, no attempt was made to explore the 
presence of carbapenemase resistance determining genes with phenotype- and 
genotype-based assays (Opintan et al. 2015). In this present study, the most common of 
these assay techniques employed were to establish the distribution and prevalence of 
carbapenemase genes in clinical isolates from Ghana were reliable and reproducible.  
 
The inconsistency of MHT results were evident when this method was employed in this 
study, where only two isolates of Klebsiella pneumoniae and one Acinetobacter 
baumannii were detected as positive for OX A-48 and NDM-1 genes when compared 
with the twenty-six positive isolates assayed by PCR amplification. However, it was 
observed that the MHT was more reliable for the detection of isolates harbouring an 
OX A-48 gene than the BADST method. It was observed that MHT had a lower 
sensitivity for NDM-1 gene detection, while BADST was found to be unreliable for 
phenotyping isolates harbouring NDM-1, V IM-1 and OX A-48 determining genes. In 
contrast, the boronic acid-disc synergy test which was employed as another phenotype-
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based method was inconclusive for the determination of carbapenemase activity since 
none of the positive results were detected by PCR assay. This could be a consequence 
of primer sequences that amplify specific regions of the DNA in the test isolates. 
Therefore, it was possible that the CR isolates were not false-positive results from the 
BADST, but false-negative results from the PCR-based assay. Indeed, the findings 
obtained from the phenotype-based tests were not comparable to the PCR amplification 
technique. In this study, Paterans et al. (2010) and Doyle et al. (2012) observed that 
MHT and BADST are efficient and more reliable for the detection of carbapenemase 
enzymes in the Enterobacteriaceae group (Paterans et al. 2010, Doyle et al. 2012). 
These findings are in agreement with those in this study, where the majority of the 
positive carbapenemase producers detected were mostly non-fermenting isolates. 
Additionally, availability of the chromogenic culture medium, ChromID CARBA 
(BioMérieux, France) with sensitivity and specificity of 97.4% and 99.7% respectively, 
for carbepenemase producers from the Enterobacteriaceae group (Cantón et al. 2012) 
could have improved detection rates during the study investigations. 
 
PCR amplification revealed diverse species that are carriers of NDM-1, OX A-48 and 
V IM-1 resistance genes mainly in isolates of Acinetobacter baumannii, Klebsiella 
pneumoniae and Pseudomonas species, respectively, with no K PC-1 and IMP-1 gene 
detections. Search on databases has confirmed the finding that genes encoding K PC-1 
and IMP-1 are more frequently found in North America, Europe and Asia than Africa 
(Manenzhe et al. 2014).  
 
The V IM-1 gene was found in Pseudomonas aeruginosa and Pseudomonas putida, and 
OX A-48 in Klebsiella pneumoniae isolates. Of serious concern was the class B type of 
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MBLs detected among the Acinetobacter baumannii isolates and Pseudomonas species 
detected in different clinical specimens from four demographically unrelated regional 
hospitals. Their presence in this study suggests that the occurrence of carbapenemase 
genes have already emerged in the Ghanaian population which needs regular monitoring 
and implementation of a policy to detect routinely most of the carbapenemase activity 
phenotypically in hospital laboratories with occasional surveillance studies supported 
with molecular detections. 
 
There was strong expectation for K PC-1 gene detection prior to this present study since 
it was known worldwide, although, none was detected in any of the CR isolates. An 
earlier review revealed that the spread of K PC-1 resistance genes is one of the leading 
causes of hospital acquired infections and it is also the most prevalent circulating gene 
worldwide (Nordmann, Naas and Poirel 2011). In a subsequent review by Munoz-Price 
et al. (2013) it was claimed that the K PC types were the most common encoding genes 
found in the countries of Europe, Asia and the Americas after its discovery over 16 
years ago with little or few records of spread in Africa (Munoz-Price et al. 2013). The 
K PC-1 gene is scarcely found in African countries. K PCs are detectable in 
Acinetobacter and Pseudomonas species in parts of the northern regions of South 
America, the Caribbean and Central America. Evidently, none of the non-fermenter 
isolates in this study were encoded with K PC carbapenemases, which could be 
attributed to continental differences and locations. Most countries have reported a threat 
of two different types of genes co-inhibiting a positive K PC-1 organism. Several studies 
report the emergence of these genes in isolates of carbapenemase-producing Klebsiella 
pneumoniae, co-harbouring two carbapenemase genes: V IM-19 and K PC-2 co-producer 
isolate from Greece (Pournaras et al. 2010), NDM-1 and OX A-181 producer K. 
pneumoniae in Oman (Dortet et al. 2012), NDM-1 and OX A-232 producer K. 
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pneumoniae in the USA (Doi et al. 2014) and recently, K. pneumoniae harbouring 
NDM-1 and OX A-48 reported from Saudi Arabia (Zowawi et al. 2014). Fortunately, no 
double detectable carbapenemase genes in a single CR isolate from Ghanaian hospitals 
were identified in this present study. 
 
Interestingly, no IMP-1 gene was detected which may attest to the fact that imipenem is 
excluded as an essential antimicrobial for clinical management of patients according to 
the Ghana’s Essential Medicines L ist and National Drug Policy (Ghana’s Essential 
Medicines List 2010). However, among the MBLs, the V IM-1 gene was only detected 
in the CR Pseudomonas species with no IMP-1 gene found. Chen et al. (2009) reported 
that the IMP gene alone does not confer increased carbapenem resistance in 
Enterobacteriaceae, however, they contend that care has to be taken on its spread when 
the drug is used on patients tested of having reduced susceptibility, and warned that the 
results of investigations into carbapenemase activity should be treated with caution 
(Chen et al. 2009). 
 
The carbapenemases detected in this study were found to co-exist with TEM-1- and 
SHV -1-encoding genes, which indicate that there could be variants or other types of β-
lactamases in existence that could not be detected. Further investigation is needed since 
most of the CR isolates studied are potential pathogens that can cause nosocomial 
infections, and harbour other undetermined plasmid-borne antimicrobial resistance 
determinant-genes. The presence of these genes may aid the persistence and survival of 
these species in the hospital environment.  
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In the plasmid-cured CR isolates tested, the observation that MIC levels to the 
carbapenems were moderately reduced by E-test assay is of major concern. The low 
levels of MICs indicate that there were some alternative mechanisms of resistance 
contributing to carbapenem resistance. Results from previous studies suggest the 
possible mechanisms for the incorporation of the AmpC genes and the alteration of 
porins that decrease the entry of carbapenem agents into the cell, as exhibited in most 
imipenem-resistant Klebsiella pneumoniae isolates (Miriagou et al. 2010, El Wartiti et 
al. 2012) or the alteration of the efflux pump systems encountered especially in 
Acinetobacter and Pseudomonas species.  
 
The impact of improper use of antimicrobials have been reported in previous studies 
carried out in Nigeria (Okonko et al. 2009), Tanzania (Moyo et al. 2010) and recently, 
in Ghana (Opintan et al. 2015). In these studies, only traditional methods for detection 
of bacterial resistance were employed. Currently, pulsed-field gel electrophoresis 
(PFGE), and random amplification of polymorphic DNA (RAPD) are extensively used 
by most clinical laboratories worldwide (Sabat et al. 2013) for the determination of 
bacterial resistance profiles.  
 
In this study, enterobacterial repetitive intergenic consensus (ERIC) by PCR 
amplification of genomic DNA products revealed an array of diversity among the 
different CR isolates studied. However, small number of closely related isolates existed 
within a pair each from the Acinetobacter baumannii and Pseudomonas aeruginosa 
isolates. The simplicity and reproducibility of the ERIC-PCR technique is paramount in 
that it makes it adaptable in less endowed countries in Africa, including Ghana to 
investigate outbreak of infections in hospitals. Indeed, none of the traditional methods 
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alone may have revealed the diversity of strains in the diverse Gram-negative bacterial 
species studied. For future surveillance studies involving genetic characterisation, 
keeping epidemiologic records and monitoring isolates capable of demonstrating clonal 
transmission of bacteria in hospital environments, ERIC-PCR fingerprints may help the 
profiling of genetic variability or relatedness in any outbreak situations in Ghana. 
 
ERIC-PCR has been used to study genetic diversity or relatedness of various bacterial 
species present in clinical samples. One limitation of ERIC sequences is when 
compared with genomic sequences. Comparatively, genomic sequences are extremely 
dependent on the GenBank DNA database for easy evaluation of genome assembly 
depending on each microbial species. Thus, isolates are easily identified by genetic 
features individually assessed using BLAST to determine their location, origin within 
the genome (chromosomal or plasmid borne) and function based on homology. In 
contrast, band patterns of the ERIC fingerprints are currently assessed by software 
license for evaluation. In spite of good reproducibility, genotyping and without having 
prior knowledge of target genome sequences of the Gram-negative bacterial pathogens, 
however, there were few limitations encountered when using ERIC-PCR technique. 
Carbapenemase producing and multi-resistant Gram-negative bacterial pathogens that 
are known to be associated with wound and urine have been investigated using ERIC-
PCR. Isolates of Acinetobacter baumannii and Pseudomonas species were isolated in 
large numbers in all the four regional hospitals under non-outbreak conditions. Despite 
the differences in the source of specimens, ages and sexes, high genetic diversity was 
observed among the CR isolates by ERIC-PCR analysis. Of concern are the relatively 
small number of ubiquitous isolates Acinetobacter baumannii and Pseudomonas 
aeruginosa showing similarities in the same hospital, K orle Bu Teaching hospital in the 
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Greater Accra region. These may pose a serious threat to public health in the care 
facility. 
 
The major limitations of this study are that investigations were carried out at the 
University of Ghana, Medical Microbiology laboratory attached to the K orle Bu 
Teaching hospital laboratory where collections of suspected CR isolates were frequently 
recovered, identified and monitored in their numbers. Large numbers of CR isolates 
were therefore obtained as a result of constant flow of specimens on regular basis for 
isolation and susceptibility testing. As a major tertiary and referral centre of the country 
a larger number of samples can be examined when compared with the other 3 regional 
hospitals that received limited samples daily and have accounted for fewer CR isolates. 
In addition, irregular patient attendance and low bed capacity coupled with limited 
resources to carry out comprehensive laboratory analysis on clinical samples may have 
greatly contributed to the low numbers in CR isolates. This discrepancy has limited the 
numbers of samples for the ERIC-PCR analysis from three of the four hospitals studied. 
As a result, substantial number of carbapenemase resistance genes was found at the 
K orle Bu Teaching Hospital.  
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6.2 Conclusion 
 
In all, carbapenem resistances were relatively low with high numbers of ESBL carriage 
coupled with small number of PCR-positive carbapenemase gene detections. Porin loss 
was one of the possible major mechanisms. The CR isolates were diverse and showed 
limited relatedness in this study. CR isolates encoded with carbapenemase resistance 
genes in the four regional hospitals in Ghana following the use of common phenotype-
based methods and PCR optimisation assays have been characterised. This is the first 
report of the occurrence of three significant carbapenemase genes; NDM-1, V IM-1 and 
OX A-48 in Ghanaian hospitals. These findings have provided an insight of the 
emerging resistance genes belonging to the Ambler Class B, two MBL-types; NDM-1 
and V IM-1 and one non-MBL-type, OX A-48 in the Class D group.  
 
Potentially, the emergence of these three resistance genes is of relevance and a threat to 
the medical community. It is therefore essential that early detection by “quick-to-
perform” tests must be used in order to identify the presence of carbapenemase activity 
in real time so that the severity of infections caused by these bacterial pathogens can be 
minimised by putting into place preventative measures. The possibility of plasmid-
borne carbapenemase genes and uncertain multidrug resistant isolates of Acinetobacter, 
Pseudomonas and Klebsiella including other nosocomial Gram-negative bacterial 
pathogens could be tested and identified using PCR amplification assays. ERIC-PCR 
optimisation assays may serve as a suitable genotyping tool for the assessment of 
genetic diversity or close relatedness of isolates that are found in clinical settings. 
 
The findings reported here have broadly highlighted the emergence of carbapenemase 
resistance genes found in Ghanaian healthcare settings. However, further nationwide 
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study on a larger scale to determine the common variants of the carbapenemase genes 
detected in this study is required in order to ascertain their presence in the Ghanaian 
population for the purposes of future epidemiological records.  
 
Finally, the present study may also contribute to the debate about which techniques in 
the Ghanaian context can be deployed for an inexpensive nationwide study of 
carbapenemase determining genes during outbreaks. Frequent investigations should be 
conducted to detect the CR pathogens present in susceptible environments within the 
hospital. It is strongly recommended that the use of specific test-kits to complement 
resistance patterns obtained from disc diffusion and E-test assays as screening tests for 
all clinical isolates resistant to carbapenems is adopted. Results from these test-kits, in 
effect may help care-givers to institute early interventions such as reviewing the 
antimicrobial treatment policy and plan patient isolation. The use of ChromID CARBA 
medium and Carba NP test can be introduced as the first screening method to identify 
weakly detectable carbapenemases and also to provide the basic information before the 
application of molecular assay by PCR or be used in combination in any research 
studies. 
 
6.3 Future work 
 
The detection of a large number of carbapenemase non-PCR positives has shown that 
resistance patterns significantly varied among the clinical isolates studied. 
Carbapenemases are emerging in Acinetobacter and Pseudomonas species (Mataseje et 
al. 2012), which indicate that these isolates may spread within the hospital environment 
and to follow the trend of ESBLs into the community population.  
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For meaningful future work, awareness drive and active advocacy may resolve some of 
the major goals since little is known in Ghana about the epidemiology and strains 
encoding carbapenemase resistance genes in the health-care delivery system. The 
importance of these resistance genes is the great risk they pose to all who work as 
health-care personnel and the Ghanaian population at large. The study findings can be 
used by the medical community, largely to the medical doctors, epidemiologists, 
microbiologists, researcher scientists and other health-care providers to inform practice. 
Serious infections cannot be ruled out in strains encoded with these resistance genes. 
 
The first task would be on awareness creation to showcase the study findings to the 
Heads of Clinical Departments in their monthly meetings in form of presentations, to 
explain the relevance and importance of the carbapenemase resistance genes in the 
hospital environments. Emphasis would be placed on how to prevent the spread of the 
genes in the intensive care units (ICUs), cardiothoracic units (CTUs) and surgical 
theatres. Multicentre screening in these sensitive areas (ICUs and CTUs) would be the 
first target within the hospital setting. 
 
Other audiences that deal with health-related problems such as the Ministry of Health, 
Ghana College of Physicians and Surgeons Council, Ghana Association of Biomedical 
Scientists, Ghana Registered Nurses and Midwives Association, Parliamentary Select 
Committee for Health and the Office of the World Health Organisation would be 
briefed on the study findings in support of funds for a nationwide surveillance study. A  
nationwide study would establish the actual level of prevalence of the isolates encoded 
with carbapenemase resistance genes in the country. Of note, all the 10 regional 
hospitals in Ghana would be involved and networked in order to have a constant flow of 
information for implementing the necessary objectives, a quick supply of reagents and 
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data collection. Target groups that may be involved in the nationwide study detection 
(microbiologists, biomedical scientists and research assistants) would be given intensive 
training on modern techniques of identifying carbapenemase production in a simplified 
detection outline in a form of flow-chart diagram. A ll suspected CR isolates would be 
phenotypically identified and positive isolates stored and sent for genotype typing to be 
collectively carried out at the collaborative institution, the Noguchi Memorial Institute 
for Medical Research, University of Ghana. 
 
Specifically, consultants, doctors and other health-care providers would be advised to be 
vigilant and strictly stick to basic strategies to decrease person-to-person transmission of 
infections, including limitation of medical device use, contact precautions, hand 
hygiene, patient and staff contact, healthcare personnel education, antimicrobial 
stewardship, laboratory notification strategies, and introduction of active screening for 
CR isolates in every hospital. 
 
The overall results of the study would be disseminated to the medical community and 
policy-makers; the Ministry of Health and the Government of Ghana. The outcome 
would give the nation a better understanding of the true prevalence of all types of 
carbapenem-resistant isolates encoded with resistance genes. As a threat to public 
health, strategies in regard to transmission of infections by the carrier isolates would be 
significantly controlled in Ghana.  
 
With massive improvement of laboratory resources through research funding, other 
unanswered area of study could be tackled independently. For instance, a total of 80.2% 
(89/111) of the CR isolates recovered were made up of these two non-fermenting 
pathogens, while only 17.1% (19/111) were encoded w
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carbapenemases, leaving a number of unanswered questions. The reasons for the large 
number of negative results require further investigations.  
 
This study is in agreement with the suggestion made by Perez and van Duin (2013) that 
various methods are to be used when investigating carbapenemase activity in a clinical 
laboratory. Thus, in the context of this study, future work could include the use of 
different testing assays, depending on the availability of the testing reagents, reliability 
and reproducibility of the methods that clearly detect all carbapenemase and other β-
lactamase genes. Further work could be conducted on the high numbers of non-
carbapenemase producers by using the Carba NP test described by Nordmann, Poirel 
and Dortet (2012) for rapid determination of carbapenemase-producing isolates that 
harbour weakly detectable genes that could not be detected by PCR assay.  
 
Other determining genes in association with carbapenemase genes, usually with the 
OX A-type β-lactamases, could be investigated in detail with no prior knowledge of the 
underlying resistance traits that encode each CR isolate. Non-susceptibility of 
carbapenems in combination with the production of ESBLs or intrinsic types, CTX -M 
and plasmid-borne AmpC-type β-lactamases with additional loss of porin proteins poses 
detection difficulties. For instance, mutational loss or reduced expression of OprD 
raising the MIC levels higher than the normal breakpoints are major contributors to 
carbapenems resistance. There should be special emphasis on the growing number of 
new allele variants found among the host of clinically relevant β-lactamases. With the 
requisite reference control strains, future work could include the CTX -M-15 gene in 
particular which is found to be associated with incompatibility group FII plasmids. 
Broad host-range replicon plasmids such as IncL/M, IncN and IncI1 have also been 
shown to be involved in the dissemination and spread of CTX -M genes. The resistance 
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had been reported from the co-production of CTX -M-15 with OX A-48 and other 
carbapenemases (V IM-1 and NDM-1) increases the emergence and development of 
multidrug resistant pathogens (Bakthavatchalam, Anandan and V eeraraghavan 2016). 
Further studies could be carried out to establish the true number of positive 
carbapenemases from the high numbers of carbapenemase non-PCR positives obtained 
in this present study. 
 
Future work on OMPs would be subjected to a panel of control strains. Isolates of the 
same species would have its specific control strain for easier analysis on SDS-PAGE. 
Thus, actual expression of OMPs could be properly analysed on the basis of its control 
strain. For example, uptake of antimicrobials into the periplasmic region of the cell is 
greatly affected by diminishing or increased permeability of the outer membrane in each 
individual bacterial species. Based on resistance to imipenem and meropenem, the outer 
membrane of Pseudomonas aeruginosa control strains were regulated and analysed 
using the presence or absence of OprD on SDS-PAGE.  
 
The finding that the NDM-1 gene was the most prevalent among CR isolates could be 
investigated further using long-fragment real-time quantitative PCR (LF-qPCR) to 
determine the in vitro transcription of NDM-1 in order to determine the full length of 
the NDM-1 gene and also find any unknown variants. This innovation was described in 
a study by Huang et al. (2014) can rapidly detect NDM-1 gene when long fragment 
quantitative PCR technique is used (Huang et al. 2014), which can then be extended to 
other carbapenemase gene detection studies. 
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Genomic DNA fingerprints generated by using ERIC-PCR amplification could be 
performed to evaluate the genetic diversity of CR isolates of both clinical and 
environmental samples. This could be a comparative study to establish the possibility of 
similar bacterial isolates having close relatedness in the transmission of resistance genes 
into the Ghanaian population. For future epidemiologic studies, it is suggested that 
some form of real-time characterisation of various carbapenemase variants by PCR 
amplification, could be included in future Public Reference Laboratory investigations in 
the country to rapidly identify the carbapenemase variant-types for record keeping and 
to support further outbreak investigations in our hospitals. 
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Appendices 
 
Appendix 1 V itek automated microbial identification results of carbapenem-
resistant isolates from Ghana  
T ype of 
specimen 
Isolate code Sex Age 
(Y ear) 
Name of isolate 
Wound 1 M  58 P. aeruginosa 
Wound 2 F 26 E. coli 
Wound 3 M 31 P. aeruginosa 
Wound 4 F 25 A. baumannii 
Wound 5 F 41 E. coli 
Wound 6 F 7 P. aeruginosa 
Wound 7 F 2½ P. aeruginosa 
Sputum 8 M 91 A. baumannii 
Wound 9 F 22 C. sakazakii 
Wound 10 M 57 P. aeruginosa 
Urine 11 M 26 S. paucimobilis 
Sputum 12 F 23 P. putida 
Urine 13 F 30 P. aeruginosa 
Urine 14 F 22 P. aeruginosa 
CSF 15 M 19 P. aeruginosa 
Sputum 16 M 44 P. aeruginosa 
Sputum 17 M 30 P. aeruginosa 
Urine 18 F 57 E. coli 
Wound 19 F 37 K. pneumoniae 
Urine 20 F 2months A. baumannii 
Ear 21 F 28 P. aeruginosa 
Wound 22 F 4months A. baumannii 
Wound 23 F 16 E. coli 
Wound 24 M 79 P. aeruginosa 
Sputum 25 F 32 P. aeruginosa 
Urine 26 M 13 P. aeruginosa 
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T ype of 
specimen 
Isolate code Sex Age 
(Y ear) 
Name of isolate 
Wound 27 F 75 A. baumannii 
Urine 28 M 16 P. aeruginosa 
Wound 29 F 24 A. baumannii 
Urine 30 M 78 A. baumannii 
Wound 31 M 2 P. aeruginosa 
CSF 32 F 6 P. aeruginosa 
Urine 33 M 4 En. cloacae 
Aspirate 34 M 13 A. baumannii 
Wound 35  F 30 E. coli 
Aspirate 36 M 55 A. baumannii 
Urine 37 M 58 P. aeruginosa 
Urine 38 M 35 A. baumannii 
Wound 39 M 56 P. aeruginosa 
Aspirate 40 F 36 P. aeruginosa 
Urine 41 F 63 P. aeruginosa 
Wound 42 M 1 A. baumannii 
Wound 43 M 19 A. baumannii 
Wound 44 M 22 P. putida 
Urine 45 F 63 A. baumannii 
Wound 46 F 3days A. buamannii 
Wound 47 M 1 P. aeruginosa 
Urine 48 M 58 P. aeruginosa 
Urine 49 F 36 A. baumannii 
Urine 50 M 60 A. baumannii 
Urine 51 F 33 A. baumannii 
Wound 52 M 74 P. aeruginosa 
Urine 53 M 24 E. coli 
Urine 54 M 84 P. aeruginosa 
Urine 55 F 69 K. pneumoniae 
Urine 56 F 19 A. baumannii 
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T ype of 
specimen 
Isolate code Sex Age 
(Y ear) 
Name of isolate 
Wound 57 M 15days P. aeruginosa 
Urine 58 M 3 P. aeruginosa 
Urine 59 M 38 P. aeruginosa 
Urine 60 M 58 P. aeruginosa 
Wound 61 M 3months P. aeruginosa 
Wound 62 F 70 P. aeruginosa 
Urine 63 M 74 P. aeruginosa 
Wound 64 F 7days A. baumannii 
Urine 65 F 60 P. aeruginosa 
Wound 66 M 53 P. aeruginosa 
Urine 67 M 13months E. coli 
Urine 68 F 2 E. coli 
Urine 69 F 29 A. baumannii 
Wound 70 M 22 P. aeruginosa 
Wound 71 F 2 P. aeruginosa 
Wound 72 F 5months A. baumannii 
Urine 73 F 32 A. baumannii 
Urine 74 M 60 P. aeruginosa 
Urine 75 F 29 A. baumannii 
Wound 76 F 42 P. stuartii 
Wound 77 M 76 A. baumannii 
Ear 78 M 6 P. putida 
Catheter tip 79 M 73 P. aeruginosa 
Wound 80 F 1 P. aeruginosa 
Wound 81 M 70 P. aeruginosa 
Urine 82 F 88 A. baumannii 
Urine 83 F 4 P. putida 
Urine 84 F 1½ P. aeruginosa 
Urine 85 F 33 E. coli 
Wound 86 M 3 P. aeruginosa 
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T ype of 
specimen 
Isolate code Sex Age 
(Y ear) 
Name of isolate 
Wound 87 F 5 P. aeruginosa 
Urine 88 F 44 P. putida 
Stool 89 M 60 S. sonnei 
Ear 90 M 21 P. putida 
Wound 91 F 17 En. cloacae 
Ear 92 M 65 P. putida 
HV S 93 F 46 E. coli 
Wound 94 F 6 A. baumannii 
Urine 95 F 30 En. cloacae 
Wound 96 F 70 P. aeruginosa 
Wound 97 F 50 E. coli 
Sputum 98 M 45 K. pneumoniae 
Sputum 99 M 30 P. aeruginosa 
Wound 100 F 86 P. aeruginosa 
Aspirate 101 F 12 P. aeruginosa 
Wound 102 F 3days A. baumannii 
Aspirate  103 M 27 A. baumannii 
Wound 104 M 23 P. aeruginosa 
Urine 105 M 3months E. coli 
Wound 106 F 9months A. baumannii 
Urine 107 F 19 A. baumannii 
Urine 108 F 33 A. baumannii 
Urine   109 F 40 P. aeruginosa 
Eye 110 M 5days P. aeruginosa 
Wound 111 M 5 P. aeruginosa 
 
Note: M= male, F= female  
 
 
 
 
Continuation from page 270  
272 
 
Appendix 2 Phenotype-based identification of carbapenem-resistant isolates 
 
No 
Sensitivity 
testing 
ESBL  testing MIC Levels M
H
T 
BADST 
I
m
p 
M
e 
r 
D
o 
r 
Cpd+ 
clv 
Cpd Ratio Px Ip Mp Er Mp Mp+
Apb 
Ratio 
1 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
2 R R R 0 0 0 12 >32 >32 >32 - 10 11 1 
3 S R R  0 0 0 >256 4 16 >32 - 6 6 0 
4 R R R  8 9 1 >256 >32 >32 >32 + 6 6 0 
5 R R R  0 0 0 >256 2 3 16 - 18 18 0 
6 R R R  0 0 0 >256 >32 >32 >32 - 6 6 1 
7 R R R  0 0 0 >256 >32 >32 >32 - 17 18 1 
8 R R R  8 8 0 >256 >32 >32 >32 + 8 6 2 
9 R R R  8 8 0 >256 >32 >32 >32 - 17 18 1 
10 R R R  0 0 0 >256 >32 >32 >32 - 6 7 1 
11 R R R  0 0 0 >256 >32 >32 >32  6 7 1 
12 R R R  0 0 0 >256 >32 >32 >32 - 6 6 0 
13 R R R  10 10 0 8 16 >32 >32 - 11 12 1 
14 R R R  0 0 0 >256 8 4 >32 + 11 13 2 
15 R R R  0 0 0 >256 >32 12 >32 - 8 10 2 
16 R R R  0 0 0 >256 16 4 >32 - 20 20 0 
17 R R R  0 0 0 >256 >32 >32 >32 + 6 6 0 
18 R R R  10 10 0 12 16 >32 >32 - 12 12 0 
19 R R R  0 0 0 >256 16 8 >32 + 14 14 0 
20 R R R 0 0 0 16 >32 >32 >32 - 6 6 0 
21 I R R 0 0 0 >256 2 16 >32 - 12 14 2 
22 R R R 0 0 0 >256 >32 16 >32 + 6 6 0 
23 R R R 0 0 0 >256 >32 >32 >32 - 6 7 1 
24 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
25 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
26 I R R 0 0 0 >256 >32 >32 >32 - 6 8 2 
27 I R R 9 6 3 >256 6 >32 >32 - 6 8 2 
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28 R R R 0 0 0 >256 >32 >32 >32 - 6 7 1 
29 R R R 0 0 0 >256 >32 >32 >32 + 6 8 2 
30 R R R 0 0 0 24 >32 16 >32 + 6 7 1 
31 S R R 12 11 1 >256 4 16 >32 - 6 6 0 
32 R R R 0 0 0 >256 >32 >32 >32 - 7 8 1 
33 R R R 0 0 0 >256 32 >32 >32 - 25 31 6 
34 R R R 0 0 0 32 8 16 >32 + 6 8 2 
35 I I I 0 0 0 >256 0.3
8 
0.5
0 
0.5
0 
- 20 21 1 
36 R R R 0 0 0 >256 >32 >32 >32 + 6 6 0 
37 R R R 0 0 0 >256 16 >32 >32 - 6 6 0 
38 R R R 0 0 0 12 >32 >32 >32 - 6 7 1 
39 R R R 0 0 0 >256 >32 >32 >32 - 6 8 2 
40 R R R 0 0 0 >256 >32 >32 >32 + 6 6 0 
41 R R R 0 0 0 32 >32 >32 >32 - 6 7 1 
42 R R R 0 0 0 >256 >32 >32 >32 - 6 7 1 
43 R R R 8 6 2 >256 >32 >32 >32 - 6 8 2 
44 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
45 R R R 0 0 0 12 >32 >32 >32 - 6 8 2 
46 R R R 0 0 0 >256 >32 >32 >32 - 6 9 3 
47 R R R 0 0 0 >256 >32 >32 >32 - 8 8 0 
48 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
49 R R R 13 13 0 >256 >32 >32 >32 + 6 7 1 
50 I I R 0 0 0 >256 4 16 >32 - 6 7 1 
51 R R R 12 13 1 >256 >32 >32 >32 + 6 8 2 
52 R R R 0 0 0 >256 12 12 >32 - 12 13 1 
53 R R R  10 10 0 12 16 >32 >32 - 6 7 1 
54 S R R 0 0 0 >256 4 >32 >32 - 6 6 0 
55 R R R 0 0 0 >256 8 16 >32 + 15 15 0 
56 R R R 6 9 3 >256 16 >32 >32 - 6 7 1 
57 R R R 7 8 1 >256 4 >32 >32 - 13 15 2 
58 R I R 0 0 0 >256 8 4 >32 - 11 13 2 
59 R R R 0 0 0 >256 6 3 >32 - 11 12 1 
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60 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
61 R R R 0 0 0 >256 >32 16 >32 - 6 6 0 
62 R R R 0 0 0 >256 >32 8 >32 - 6 6 0 
63 R R R 0 0 0 >256 16 >32 >32 - 6 8 2 
64 I R R 0 0 0 >256 8 >32 >32 - 6 8 2 
65 R R R  0 0 0 >256 >32 >32 >32 - 6 6 0 
66 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
67 S I I 0 0 0 128 2 0.1
25 
16 - 22 22 0 
68 S I I 0 0 0 >256 4 0.1
9 
4 - 22 22 0 
69 R R R 15 15 0 >256 16 32 >32 + 6 8 2 
70 S I I 0 0 0 >256 4 0.5
0 
>32 - 29 29 0 
71 R R R 0 0 0 >256 16 8 >32 - 10 11 1 
72 I R R 9 6 3 >256 >32 >32 >32 - 6 8 2 
73 R R R 0 0 0 >256 >32 16 >32 + 6 8 2 
74 R R R 0 0 0 >256 >32 >32 >32 - 6 8 2 
75 R R R 0 0 0 >256 >32 >32 >32 - 15 15 0 
76 R I R 0 0 0 >256 4 0.2
5 
8 - 21 22 1 
77 R R R 0 0 0 >256 >32 >32 >32 - 8 8 0 
78 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
79 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
80 R R R 0 0 0 >256 8 16 >32 - 6 7 1 
81 S R S 0 0 0 >256 0.3
8 
6 16 - 13 15 2 
82 R R R 10 10 0 >256 32 >32 >32 - 6 7 1 
83 S R R 0 0 0 >256 0.3
8 
16 32 - 6 6 0 
84 R R R 0 0 0 >256 8 4 16 - 6 7 1 
85 I I I 0 0 0 >256 0.3
8 
0.2
5 
4 - 21 22 1 
86 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
87 R R R 0 0 0 >256 >32 32 >32 - 6 8 2 
88 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
89 R R R 0 0 0 >256 1.5 4 32 - 15 16 1 
90 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
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91 R R R 0 0 0 >256 >32 >32 >32 - 24 31 7 
92 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
93 R R R 0 0 0 >256 >32 >32 >32 - 6 7 1 
94 R R R 0 0 0 >256 6 12 >32 - 9 9 0 
95 R R R 0 0 0 >256 32 >32 >32 - 24 30 6 
96 R R R 0 0 0 >256 16 8 32 - 9 10 1 
97 R R R  9 9 0 12 16 >32 >32 - 6 7 1 
98 R R R  0 0 0 >256 16 8 >32 + 15 15 0 
99 I R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
100 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
101 R R R 0 0 0 >256 8 8 >32 + 10 10 0 
102 R R R 0 0 0 >256 >32 >32 >32 - 6 6     0 
103 I R I 0 0 0 >256 1 4 32 - 15 16 1 
104 R R R 0 0 0 >256 16 >32 >32 - 6 6 0 
105 R R R 0 0 0 >256 0.7
5 
2 32 - 17 17 0 
106 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
107 R R R 7 6 1 >256 16 >32 >32 + 6 6 0 
108 R R R 0 0 0 >256 >32 >32 >32 + 6 6 0 
109 R R R 0 0 0 >256 >32 >32 >32 + 6 6 0 
110 R R R 0 0 0 >256 >32 >32 >32 - 6 6 0 
111 R R R 0 0 0 >256 16 >32 >32 - 6 6 0 
+vc R R R 0 0 0 >250 4 >32 >32 + 9 15 6 
-vc S S S 34 34 0 0.50 0.1
25 
0.0
12 
0.0
12 
- 36 36 0 
Note: S= sensitive, I= intermediate, R= resistant, +vc= positive carbapenemase Klebsiella 
pneumoniae (NCTC 13438) control strain, -vc= negative carbapenemase Escherichia coli 
(ATCC 25922) control strain, Imp= imipenem disc, Mer= meropenem disc, Dor= doripenem 
disc, Cpd= cefpodoxime, Cpd+clv= cefpodoxime + clavulanic acid, Px= cefpodoxime E-test 
strip, Ip= imipenem E-test strip, Mp= meropenem E-test strip, Er= ertapenem E-test strip, 
MHT= modified Hodge test, MIC= minimum inhibitory concentration, BADST= boronic acid 
disc synergy test, Apb= aminophenylboronic acid hydrochloride.  
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Appendix 3 R epresentative outer membrane proteins of control strains and 
carbapenem-resistant isolates on SDS-PAGE   
 
 
Note: M= Protein marker in kDa; C1= control SHU 2048 V IM positive Pseudomonas 
aeruginosa strain; C2= control SHU 2054 MBL negative Pseudomonas aeruginosa strain; 85-
111 represent sample numbers; OprM/J  (48/49kDa)= major intrinsic multidrug efflux 
proteins; OprD (44kDa)= specific for β-lactam imipenem resistance; OprF (35kDa)=  
major porin for structural stabilisation of peptidoglycan; OprH/G (22/23kDa)= 
polycationic antimicrobial uptake and putatively in iron uptake  
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Appendix 4 Carbapenem MIC levels and major porins in carbapenem-resistant 
isolates  
Isolate Code Name of isolate A  B C  Major porins 
OprD
a
 OprF
b
 
1 P. aeruginosa + - - H M 
4 A. baumannii  + - - - - 
6* P. aeruginosa + - - R - 
7* P. aeruginosa + - - - - 
8 A. baumannii  + - - - - 
9 C. sakazakii + - - - - 
10 P. aeruginosa + - - - - 
11 S. paucimobilis + - - - - 
12* P. putida + - - - - 
16 P. aeruginosa + - - R M 
20 A. baumannii  + - - - - 
23 E. coli + - - - - 
24 P. aeruginosa + - - - R 
25 P. aeruginosa + - - - R 
26 P. aeruginosa + - - - - 
29 A. baumannii  + - - - - 
32 P. aeruginosa + - - - R 
33 En. cloacae + - - - - 
36 A. baumannii  + - - - - 
37 P. aeruginosa + - - R - 
38 A. baumannii  + - - - - 
39* P. aeruginosa + - - - - 
40 P. aeruginosa + - - R R 
41 P. aeruginosa + - - R - 
42* A. baumannii + - - R - 
43* A. baumannii  + - - - - 
44 P. putida + - - - - 
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Isolate Code Name of isolate A  B C  Major porins 
OprD
a
 OprF
b
 
45 A. baumannii  + - - - - 
46* A. baumannii  + - - - - 
47* P. aeruginosa + - - - - 
48 P. aeruginosa + - - - - 
49 A. baumannii  + - - - - 
51 A. baumannii  + - - - - 
53 E. coli + - - - - 
56 A. baumannii  + - - M M 
60* P. aeruginosa + - - R - 
61 P. aeruginosa + - - - - 
62* P. aeruginosa + - - R - 
63 P. aeruginosa + - - - - 
64* A. baumannii  + - - - - 
65 P. aeruginosa + - - - - 
72* A. baumannii  + - - - - 
74* P. aeruginosa + - - - M 
75 A. baumannii  + - - - - 
77 A. baumannii  + - - - - 
78 P. putida + - - - - 
79 P. aeruginosa + - - - M 
82 A. baumannii  + - - R - 
86 P. aeruginosa + - - - H 
87 P. aeruginosa + - - - M 
88 P. putida + - - - - 
90 P. putida + - - - - 
91 En. cloacae + - - - R 
92 P. putida + - - - - 
93 E. coli + - - - R 
95 En. cloacae + - - R R 
97 E. coli + - - - - 
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Isolate Code Name of isolate A  B C  Major porins 
OprD
a
 OprF
b
 
100* P. aeruginosa + - - - R 
102* A. baumannii  + - - - - 
106 A. baumannii  + - - R - 
108* A. baumannii  + - - R - 
109 P. aeruginosa + - - R - 
110 P. aeruginosa + - - R H 
2* E. coli - + - R - 
13 P. aeruginosa - + - - - 
14 P. aeruginosa - + - - + 
15 P. aeruginosa - + - R R 
17 P. aeruginosa - + - - - 
18 E. coli - + - - - 
19* K. pneumoniae - + - - - 
22 A. baumannii  - + - - - 
27* A. baumannii  - + - - - 
28 P. aeruginosa - + - R H 
30 A. baumannii  - + - - - 
31 P. aeruginosa - + - R - 
34 A. baumannii  - + - - - 
50* A. baumannii  - + - - - 
52 P. aeruginosa - + - - - 
54 P. aeruginosa - + - - - 
55 K. pneumoniae - + - - - 
57 P. aeruginosa - + - - - 
58 P. aeruginosa - + - - - 
66 P. aeruginosa - + - - - 
69 E. coli - + - - - 
71 P. aeruginosa - + - R - 
73 A. baumannii  - + - - - 
80 P. aeruginosa - + - - - 
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Isolate Code Name of isolate A  B C  Major porins 
OprD
a
 OprF
b
 
84* P. aeruginosa - + - - - 
94 A. baumannii  - + - - - 
96 P. aeruginosa - + - - - 
98* K. pneumoniae - + - - - 
99 P. aeruginosa - + - M H 
101 A. baumannii  - + - - - 
104 En. cloacae - + - R - 
107 A. baumannii - + - - - 
111 P. aeruginosa - + - R H 
3 P. aeruginosa - - + R - 
5* E. coli - - + R - 
21 P. aeruginosa - - + - R 
35 E. coli - - + - - 
59 P. aeruginosa - - + M M 
67 E. coli - - + - - 
68 E. coli - - + H - 
70 P. aeruginosa - - + R - 
76* P. stuartii - - + - - 
81 P. aeruginosa - - + - H 
83 P. putida - - + M - 
85 E. coli - - + H - 
89* S. sonnei - - + - - 
103 A. baumannii  - - + R - 
105* E. coli - - + H - 
*Positive carbapenemase producers  
a 
Analysis mainly for Pseudomonas species only 
b
Analysis for all CR isolates 
 
Note: A= 3 carbapenems (imipenem, meropenem, ertapenem) E-test levels were ≥32 µ g/ml (n= 
63); B= 2 or 1 carbapenems (imipenem, meropenem, ertapenem) E-test levels were between 
≥16 and ≤4 µ g/ml (n= 33); C= 1 or 2 carbapenems (imipenem, meropenem, ertapenem) E-test 
levels were < 4 µ g/ml (n= 15), += susceptible; - = negative; H= high level of protein; M= 
moderate level of protein; R= low/reduced level of protein 
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Appendix 5 R epresentative profiles of restriction enzyme digestion from cured 
carbapenemase producers  
 
 
M  50   60   62  64   72  74   76  84  89   98 
   100 kb 
     10 kb 
     50 kb 
 
Note: M= DNA marker; Lanes, 50 through 98= plasmid-cured carbapenemase producers. In this 
gel, all the plasmid-cured carbapenemase producers are showing different band patterns 
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Appendix 6 Different band patterns obtained from carbapenem-resistant isolates on electrophoretic gels by E R IC-PCR technique 
 
 M      1        2         3       4        5        6        7       8        9       10      11      12      13     14 
 0.1kb 
 0.3kb 
    1kb 
 
 
M     21    22     23    24     25     26    27    28     29    30     31    32     33    34     35    36 
     1kb 
  0.6kb 
   0.1kb 
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 M        37        38         39        40        41        42        43       44       45 
  0.1kb 
     1kb 
  0.6kb 
   M        46         47        48          49       50         51       52        53        54 
  0.1kb 
  0.6kb 
     1kb 
 
 
M          71       72         73         74         75       76       77        78        79 
  0.1kb 
  0.6kb 
     1kb 
 
 M         80         81        82        83        84         85        86       87       88  
     1kb 
  0.6kb 
   0.1kb 
 
 
 M        89          90        91        92         93       94        95         96       97  
  0.1kb 
     1kb 
  0.6kb 
 M         98         99        100     101     102       103     104       105      106 
  0.1kb 
  0.6kb 
  0.1kb 
 
 
     M               107               108              109               110              111            
  0.1kb 
   0.6kb 
  1kb 
 
  0.1kb 
     1kb 
     0.6kb 
    M               15              16              17               18            19           20 
 
Note: M= DNA 1 kb marker, Lane numbers (1 through to 111 excluding 55 through to 70)= representative CR test samples listed in Appendix 1 
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